US20200231652A1 - Tgf-b-receptor ectodomain fusion molecules and uses thereof - Google Patents

Tgf-b-receptor ectodomain fusion molecules and uses thereof Download PDF

Info

Publication number
US20200231652A1
US20200231652A1 US15/755,595 US201615755595A US2020231652A1 US 20200231652 A1 US20200231652 A1 US 20200231652A1 US 201615755595 A US201615755595 A US 201615755595A US 2020231652 A1 US2020231652 A1 US 2020231652A1
Authority
US
United States
Prior art keywords
polypeptide construct
tgf
seq
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/755,595
Inventor
John C. Zwaagstra
Traian Sulea
Maria Jaramillo
Maureen D. O'Connor
Anne E.G. Lenferink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Priority to US15/755,595 priority Critical patent/US20200231652A1/en
Publication of US20200231652A1 publication Critical patent/US20200231652A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and their use in TGF- ⁇ superfamily ligand neutralization.
  • TGF- ⁇ is part of a superfamily of over 30 ligands that regulate several physiological processes, including cell proliferation, migration and differentiation. Perturbation of their levels and/or signaling gives rise to significant pathological effects. For instance, TGF- ⁇ and activin ligands play critical pathogenic roles in many diseases including cancer (Hawinkels & Ten Dijke, 2011; Massague et al, 2000; Rodgarkia-Dara et al, 2006). TGF- ⁇ , in particular, is considered as a critical regulator of tumor progression and is overexpressed by most tumor types.
  • TGF- ⁇ also promotes tumorigenesis by acting as a powerful suppressor of the immune response in the tumor microenvironment (Li et al, 2006). In fact, TGF- ⁇ is recognized as one of the most potent immunosuppressive factors present in the tumor microenvironment.
  • TGF- ⁇ interferes with the differentiation, proliferation and survival of many immune cell types, including dendritic cells, macrophages, NK cells, neutrophils, B-cells and T-cells; thus, it modulates both innate and adaptive immunity (Santarpia et al, 2015; Yang et al, 2010).
  • the importance of TGF-beta in the tumor microenvironment is highlighted by evidence showing that, in several tumor types (including melanoma, lung, pancreatic, colorectal, hepatic and breast), elevated levels of TGF- ⁇ ligand are correlated with disease progression and recurrence, metastasis, and mortality.
  • significant effort has been invested in devising anti-tumor therapeutic approaches that involve TGF- ⁇ inhibition (Arteaga, 2006; Mourskaia et al, 2007; Wojtowicz-Praga, 2003).
  • receptor ectodomain (ED)-based ligand traps antibodies or soluble decoy receptors (also termed receptor ectodomain (ED)-based ligand traps) to bind and sequester ligand, thereby blocking access of ligand to its normal cell surface receptors (Zwaagstra et al, 2012).
  • receptor ED-based traps are a class of therapeutic agents that are able to sequester a wide range of ligands and that can be optimized using protein engineering approaches (Economides et al, 2003; Holash et al, 2002; Jin et al, 2009).
  • T22d35 exhibited TGF- ⁇ neutralization potencies ⁇ 100-fold higher than the monovalent non-engineered T ⁇ RII ectodomain, though it did not neutralize the TGF- ⁇ 2 isoform and had a relatively short circulating half-life.
  • the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and their use in TGF- ⁇ superfamily ligand neutralization.
  • the invention relates to TGF- ⁇ superfamily receptor ectodomain-based polypeptides that are similar to typical Fc fusions in design, in that the ectodomain is fused to a dimeric antibody constant domain.
  • the Fc portion occupies the N-terminal position.
  • Fc fusions in the prior art typically provide the Fc portion at the C-terminal end of the fusion. As will be evident from the results presented herein, this difference in orientation provides a number of significant advantages.
  • the present polypeptides incorporate at least two TGF- ⁇ superfamily receptor ectodomains that are linked in tandem to the C-terminus of an antibody constant domain.
  • a polypeptide construct comprising: a first portion comprising the second constant domain (C H2 ) and/or third constant domain (C H3 ) of an antibody heavy chain, and a second portion comprising at least two TGF- ⁇ superfamily receptor ectodomains (T ⁇ SR-ED) linked in tandem; wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • polypeptide construct comprising: a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a second portion comprising at least one TGF- ⁇ superfamily receptor ectodomains (T ⁇ SR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and further wherein the first portion does not further comprise an antibody that binds to an antigen that is PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4 TGF- ⁇ superfamily receptor ectodomains
  • polypeptide construct comprising: a first portion comprising the second constant domain (C H2 ) and/or third constant domain (C H3 ) of an antibody heavy chain, and a second portion comprising at least one TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED), wherein the N-terminus of the second portion is directly fused to the C-terminus of the first portion.
  • a polypeptide construct comprising a first portion comprising the second constant domain (C H2 ) and/or third constant domain (C H3 ) of an antibody heavy chain, and a second portion comprising at least one TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and wherein the polypeptide construct neutralizes TGF- ⁇ with at least 100-fold more potency than the T ⁇ SR-ED alone.
  • the second portion comprises one, two, or multiple TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED).
  • T ⁇ SR-ED is a TGF- ⁇ receptor type II ectodomain (TI ⁇ R-II-ED).
  • the T ⁇ SR-ED comprises a sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto.
  • the second portion may comprise a sequence selected from the group consisting of SEQ ID NO:43-SEQ ID NO:51, SEQ ID NO:61-SEQ ID NO:68, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:88, and a sequence substantially identical thereto.
  • the first portion of a polypeptide construct of the present invention further comprises a C H1 , a C H1 and V H , or C H1 and scFv.
  • the antibody heavy chain is of human origin.
  • the antibody heavy chain is selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain. More preferably, the antibody heavy chain is a human IgG1.
  • the polypeptide construct shows longer in vivo half-life compared to the half-life of the second portion alone.
  • polypeptide construct of the present invention wherein the polypeptide construct is a single chain polypeptide.
  • polypeptide construct forms a dimeric polypeptide. In another embodiment, the polypeptide construct is heterodimeric.
  • polypeptide construct selected from the group consisting of any one of SEQ ID NO:91 to SEQ ID NO:120, and a sequence substantially identical thereto.
  • polypeptide construct comprising an antibody, antigen binding fragment thereof, or a targeting moiety.
  • the antibody, the antigen binding fragment, or the targeting moiety is at the N-terminus of the first portion.
  • the antigen binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb. In a preferred embodiment, the antigen binding fragment binds to any antigen, provided that it is not PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • a polypeptide construct of the present invention comprises an antibody selected from the group consisting of Cetuximab, Avastin, Herceptin, Synagis, and FC5.
  • the antibody is Cetuximab.
  • a polypeptide construct of the present invention comprises a targeting moiety, wherein the targeting moiety comprises a poly-aspartate sequence motif for bone targeting.
  • the targeting moiety comprises D10.
  • a polypeptide construct wherein the construct is a dimeric polypeptide; wherein the dimeric polypeptide comprises: a first single chain polypeptide comprising a first portion comprising the second constant domain (C H2 ) and third constant domain (C H3 ) of an antibody heavy chain, and a heavy chain variable region of a given antibody; a second portion comprising one or more TGF- ⁇ superfamily receptor ectodomains (T ⁇ SR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and a second single chain polypeptide comprising a first portion comprising the second constant domain (C H2 ) and third constant domain (C H3 ) of an antibody heavy chain, and a light chain variable region of said given antibody; a second portion comprising one or more TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED) which is the same or different from the ectodomain(s) in the first polypeptide, wherein the N
  • nucleic acid molecule encoding the polypeptide construct of the present invention.
  • vector comprising the nucleic acid molecule of claim the present invention.
  • composition comprising one or more than one independently selected polypeptide construct of the present invention and a pharmaceutically-acceptable carrier, diluent, or excipient.
  • transgenic cellular host comprising the nucleic acid molecule or a vector of the present invention.
  • the transgenic cellular host further comprising a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct.
  • a polypeptide construct according to the present invention for treatment of a medical condition, disease or disorder; wherein the medi medical condition, disease or disorder comprises, but is not limited to, cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.
  • polypeptide construct comprising:
  • the antibody constant domain can further comprise, either linked thereto or formed integrally therewith, a binding agent such as a full size antibody, a ligand or any other protein of interest.
  • a binding agent such as a full size antibody, a ligand or any other protein of interest.
  • the antibody constant domain comprises only the CH2 and/or CH3 regions, and not a full size antibody.
  • the CH2 and/or CH3 region can be altered by deleting or substituting amino acids including one or more of the cysteines that provide cross-linking when the present constructs are provided as dimeric constructs.
  • a polypeptide construct that incorporates one or more such ectodomains.
  • the constructs comprise only one ectodomain linked to the antibody constant domain
  • the construct is further characterized by at least one of the following: (1) when the constant domain further comprises a full sized antibody, that antibody does not bind effectively to PD-L1 or to an immunoregulatory antigen selected, (2) the constant domain comprises only the CH2 and/or CH3 regions, (3) the constant domain comprises an amino acid alteration relative to a wild type counterpart, such as a cysteine residue alteration; and (4) the first portion is linked to the second portion directly and without intervening amino acids.
  • the present invention provides a polypeptide construct comprising
  • the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • These polypeptide constructs can neutralize TGF- ⁇ , and with at least 100-fold more potency than the T ⁇ SR-ED alone.
  • the second portion of the polypeptide construct of the present invention may comprise one or two or more T ⁇ SR-ED.
  • the construct comprises two or more independently selected ectodomains linked in tandem and to the C-terminus of the constant domain.
  • the T ⁇ SR-ED may be selected from the group consisting of a TGF- ⁇ receptor type II ectodomain (T ⁇ RII-ED), a bone morphogenetic protein receptor type la ectodomain (BMPR-ED), an activin receptor type IIa ectodomain (ActRIIA-ED), and an activin receptor type IIb ectodomain (ActRIIb-ED).
  • the ectodomain is a TI ⁇ R-II ectodomain.
  • the first portion further may comprise a C H1 , a C H1 and V H , or a C H1 and scFv. It may constitute an Fc region, an antibody, or any ligand binding agent or moiety.
  • the polypeptide construct of the present invention may comprise a C H2 and C H3 from an antibody heavy chain that is of human or mouse origin.
  • the antibody heavy chain may be selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain.
  • the constant domain in the constructs is CH2 per se, or CH3 per se or CH2-CH3.
  • polypeptide construct described herein may show longer in vivo half-life compared to the half-life of T ⁇ SR-ED alone.
  • polypeptide construct of the present invention may be a single chain polypeptide.
  • the polypeptide construct as described herein may also form a dimeric polypeptide. This dimeric polypeptide may be heterodimeric.
  • the present invention further provides a polypeptide construct comprising
  • the N-terminus of the second portion is linked to the C-terminus of the first portion; additionally, in the construct as just described, the first portion is not derived from certain antibodies discussed infra.
  • the present invention also provides a polypeptide construct, comprising:
  • N-terminus of the second portion is linked to the C-terminus of the first portion
  • the polypeptide construct comprises an antibody Fc fragment linked at the C-terminus of each heavy chain to at least one TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED), as described above.
  • T ⁇ SR-ED TGF- ⁇ superfamily receptor ectodomain
  • the receptor ectodomain portion comprises two independently selected ectodomains that are linked in tandem, i.e., in a linear manner.
  • the ectodomains are the same in sequence, or least the same with respect to their target ligand.
  • the construct may further comprise a binding fragment or moiety at the N-terminus of the Fc; the binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb, or any other binding moiety such as a motif for bone targeting, also as described above.
  • the TGF- ⁇ receptor ectodomain does not interfere in the native function or specificity of the binding fragment.
  • the present invention also provides a nucleic acid molecule encoding the polypeptide constructs as described herein.
  • a vector comprising the nucleic acid molecule just described is also encompassed by the invention.
  • the invention also includes a transgenic cellular host comprising the nucleic acid molecule or a vector as described herein; the cellular host may further include a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct.
  • Systems used to produce the present polypeptides can be secretion systems, particularly in the case where dimerization through disulfide bridges is required, and the expression polynucleotides thus encode secretion signals that are cleaved by the host upon secretion into the culturing medium.
  • compositions comprising one or more than one independently selected polypeptide construct described herein and a pharmaceutically-acceptable carrier, diluent, or excipient are also encompassed by the present invention.
  • FIG. 1A is a schematic diagram showing TGF- ⁇ Type II receptor ectodomain (T ⁇ RII-ED)-based molecules T2m and T22d35 along with their sequences (SEQ ID NO:43 and 46, respectively).
  • Natural linker sequences (SEQ ID NO:36, 39 and 40) are underlined and depicted as dark grey lines; the sequence of the TI ⁇ R-II-ED structured domain (SEQ ID NO:35) is shown in bold, and the domain labeled and depicted in dark grey; the site of the fusion of natural linkers is depicted by a slash.
  • FIGS. 1B-D are schematic diagrams of IgG Fc-based scaffolds: an IgG Fc region ( FIG. 1B ), a V H H-IgG Fc (comprising a V H H single domain antibody fused to the N-terminus of an Fc region; FIG. 1C ), and a full-size antibody ( FIG. 1D ).
  • FIG. 2 is a schematic representation of TGF- ⁇ superfamily receptor-ectodomain-based fusion constructs of the present invention.
  • A represents constructs in which T22d35 (dark grey) is fused to the C-terminus of IgG Fc regions (IgG isoforms 1, 2, 3 or 4) with no Fab or other functional binding moiety at the N-terminus (Fc-T22d35, A)
  • D represents constructs in which T22d35 (dark grey) is fused to the C-terminus of the IgG Fc region of full-size antibodies with heavy and light chain Fabs (FSA-T22d35, D)
  • E represents constructs in which T22d35 (dark grey) is fused to the C-terminus of IgG Fc regions that have a non-Fab binding/localization moiety at the N-terminus, such as the variable region of a camelid V H H antibody (V H H-Fc-T22d35) or a deca-aspartate
  • (B), (C) and (F) and (G) represent constructs in which T2m (the TGF- ⁇ Type II receptor ectodomain, T ⁇ RII-ED—dark grey) is fused at the N-terminus of an IgG Fc (T2m-Fc, B) or the C-terminus of IgG Fc regions with no Fab or other functional binding moiety at the N-terminus (Fc-T2m, C), or the C-terminus of full-size antibodies with heavy and light chain Fabs (FSA-T2m, F), or the C-terminus of IgG Fc regions that have a non-Fab binding/localization moiety at the N-terminus, such as the variable region of a camelid V H H antibody (V H H-Fc-T2m, G) or a deca-aspartate motif for bone targeting (D10-Fc-T2m).
  • T2m the TGF- ⁇ Type II receptor ectodomain, T ⁇ RII-ED—
  • FIG. 3 presents (ProtA)-affinity column elution profiles, size exclusion (SEC) purification profiles, SDS-PAGE gels, and UPLC-SEC profiles of representatives of constructs type C and D in FIG. 2 .
  • FIG. 3A is a (ProtA)-affinity column elution profile for T22d35 fused to the Cetuximab FSA (Cet-T22d35—a representative of construct D in FIG. 2 ).
  • FIG. 3B is the size exclusion (SEC) purification profile of the Cet-T22d35.
  • FIG. 3C show 4-15% SDS-PAGE gels of ProtA-purified Cet-T22d35 under reducing (left panel) and non-reducing (right panel) conditions (CetHC-T22d35, Cetuximab heavy chain fused to T22d35; CetLC, Cetuximab light chain). Lanes 1 are the pooled Prot-A eluted fractions, while lanes 2 are the pooled SEC fractions.
  • FIG. 3D shows the UPLC-SEC profile of ProtA-purified Cet-T22d35.
  • FIG. 3E shows the (ProtA)-affinity column elution profile for hIgG1Fc ⁇ K(C)-T2m (a construct with T2m fused to an Fc region with no functional binding moiety at the N-terminus; a representative of construct D in FIG. 2 ).
  • FIG. 3F , G, H show the UPLC-SEC profile before SEC (F), the UPLC-SEC profile after SEC (G) and the SDS-PAGE (NR & R) (H) of hIgG1Fc ⁇ K(C)-T2m.
  • FIG. 4A shows graphs depicting the efficient inhibition of TGF- ⁇ 1 (top panel), TGF- ⁇ 3 (middle panel) and TGF- ⁇ 2 (bottom panel) signaling in Mv1 Lu luciferase reporter cells by Cet-T2m (a representative of construct F in FIG. 2 ) and Cet-T22d35 (a representative of construct D in FIG. 2 ), compared to the significantly lower inhibition potency of non-Fc-fused T22d35.
  • FIG. 4B shows graphs and a summary table depicting the efficient inhibition of TGF- ⁇ 1 signaling in an A549/IL-11 cell-based assay by several representatives of FSA-T22d35 constructs (Type D construct from FIG. 2 ), compared to the lower inhibition potency of Fc-T2m (Type C construct) and non-Fc-fused T22d35.
  • FIG. 4C shows graphs and a summary table depicting the efficient inhibition of TGF- ⁇ 1 signaling in an A549/IL-11 release cell-based assay by several representatives of “headless”-T2m constructs (Type C construct from FIG. 2 ), compared to the lower inhibition potency of non-Fc-fused T22d35.
  • FIG. 4D is a graph showing competitive SPR analysis of binding of Cetuximab-fusion constructs to TGF- ⁇ isoforms in solution, compared to T22d35.
  • FIG. 5A is a SDS-PAGE gel showing the inhibition of EGFR phosphorylation in A549 cells by Cetuximab-fusion constructs.
  • FIG. 5B is a graph showing Cet-T22d35 (triangles) cytotoxicity in MDA-MB-468 and HaCat cells compared to Cetuximab (circles) and T22d35 (squares).
  • FIG. 6 is a bar graph showing the apparent permeability coefficient (P app ) values, as a measure of transport of FC5-Fc, FC5-Fc-fusion constructs, T22d35, and T2m across a human brain endothelial cell barrier in vitro, relative to a non-transporting V H H control (A20.1).
  • P app apparent permeability coefficient
  • FIG. 7 demonstrates the Cet-T22d35 inhibition of EGF+TGF- ⁇ 1 induced EMT in A549 cells.
  • FIG. 7A shows pictures of cultured A549 cells showing their morphologies before treatment (left panel A) and after treatment with EGF+TGF- ⁇ 1 (right panel B).
  • FIG. 7B shows a western blot of whole cell lysates of A549 cells treated with EGF+TGF- ⁇ 1 in the presence or absence of various concentrations of Cetuximab (Cetux), Cet-T22d35 or T22d35, probed for the epithelial marker E-Cadherin, while FIG. 7C is the densitometer quantification of the E-cadherin bands in the Western blot.
  • Cetuximab Cetuximab
  • FIG. 7D shows the inhibition of EGF+TGF- ⁇ -induced EMT by Cetuximab (Cetux), Cet-T22d35, T22d35 or Cet-T22d35 plus T22d35 as measured by flow cytometry detection of the epithelial E-Cadherin (top panel) and mesenchymal N-Cadherin (bottom panel) markers.
  • FIG. 8A represents the pharmacokinetic (PK) profile of Cet-T22d35 in the serum collected from BALB/C mice that were injected with a single dose of Cet-T22d35.
  • the fusion construct appears to be cleaved in vivo; the terminal half-life of the T22d35 potion of the construct was determined to be 45.8 hours, while the terminal half-life of the Cetuximab portion of the construct was determined to be 262.5 hours.
  • FIG. 8B represents the PK profiles and data table (serum half-lives in bold) for constructs in which the lysine at the C-terminus of the Fc region was removed, i.e.
  • FIGS. 9A, 9B and 9C present graphs showing the effect of “headless” Fc-T2m constructs (representatives of construct C in FIG. 2 ) and a FSA-T2m construct (a representative of construct F in FIG. 2 ) on tumor growth and T-cell function in an immune-competent syngeneic triple negative breast cancer (4T1) model (for comparison, the effects of the 1D11 antibody and non-Fc-fused T22d35 are also shown).
  • the results demonstrate the improved efficacy on T-cell function of two headless-T2m constructs relative to the FSA-T2m construct, and relative to 1D11 and non-Fc-fused T22d35.
  • FIG. 10 shows data illustrating enhanced bone localization of two constructs containing a deca-aspartate motif for bone targeting at the N-terminus of the Fc region (D10-hIgG1Fc ⁇ K(CC)-T2m (SEQ ID NO:136) and D10-GSL-hIgG1Fc ⁇ K(CC)-T2m (SEQ ID NO:137)—representatives of construct G in FIG. 2 ).
  • FIGS. 10A and B show results from an A549/IL-11 release cell-based assay demonstrating that the addition of D10 at the N-terminus did not affect TGF- ⁇ neutralization potency.
  • FIGS. 10C and D show images demonstrating significant enhancement of the accumulation of the D10-containing constructs in bones relative to a construct without D10.
  • the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF- ⁇ superfamily receptor ectodomain fusion molecules and their use in TGF- ⁇ superfamily ligand neutralization.
  • the present invention provides polypeptide constructs, comprising
  • polypeptide constructs in which TGF- ⁇ superfamily receptor-ectodomains were fused to IgG Fc regions. Specifically, the T2m (single ectodomain) or T22d35 (double ectodomain) moieties were linked (fused) to the C-terminal end of the Fc region.
  • fusion constructs of this type have advantages relative to several other versions of receptor-ectodomain based molecules, including non-Fc fused monovalent or multivalent TGF- ⁇ receptor ectodomain constructs (such as T2m and T22d35) and constructs in which a receptor ectodomain is fused to the N-terminus of an Fc region.
  • the constructs have improved manufacturability due to the presence of the Fc region (for example, purification can be accomplished using protein A chromatography).
  • the Fc region also allows for improved circulating half-lives.
  • the present constructs have substantially higher TGF- ⁇ neutralization potencies compared to T2m and T22d35 alone or to constructs where a receptor ectodomain is fused to the N-terminus of an Fc region.
  • an advantage of the present invention is unexpected high potency TGF- ⁇ superfamily ligand neutralization, including some degree of neutralization of TGF- ⁇ 2, which was not observed for the non-Fc fused constructs T2m and T22d35.
  • constructs in accordance with embodiments of the present invention that is where the ectodomain(s) is/are fused to the C-terminus of an Fc region of an antibody, allows for preservation of the structure and function of the natural N-terminal regions/domains of an antibody; as such, antigen binding to the antibody CDR regions is not perturbed. This leads to the generation of a bifunctional construct able to interact with the target of the antibody while interacting with, and neutralizing, members of the TGF- ⁇ superfamily of ligands.
  • the invention relates not only to bifunctional constructs, but also to constructs that are monofunctional, and comprise an Fc region that consists only of the CH2 and/or CH3 regions of an antibody constant region.
  • the G1, G2 or G4 subclasses are used, and particularly G1 as well as G2.
  • These constructs are monofunctional in the sense that the constant region itself has no particular activity, other than to act as a structure through which dimers of the polypeptide constructs can form.
  • These minimal constant regions can also be altered to provide some benefit, by incorporating the corresponding hinge regions (SEQ ID NO:5-8) and optionally changing the cysteine residue composition.
  • cysteine residues involved in bridging the two Fc fragments or naturally used to bridge between the heavy and light chains of a full-length antibody can be replaced or deleted. These cysteine residues are seen in hinge sequences listed in SEQ ID NO:5-8.
  • hinge-region cysteine residues may become problematic when the Fc region lacks its N-terminal Fab fragment (i.e., is a headless Fc) as in the case of some polypeptide constructs of the present invention. This leads to untethering and exposure of these hinge-region cysteines, and in turn that may result in complex mixtures of high-order polymeric chains, which creates manufacturability issues in addition to potentially diminishing the intended biological activity and efficacy.
  • Ig immunoglobulin
  • each chain fold When an antibody is correctly folded, each chain folds into a number of distinct globular domains joined by more linear polypeptide sequences; the immunoglobulin light chain folds into a variable (V L ) and a constant (C L ) domain, while the heavy chain folds into a variable (V H ) and three constant (C H , C H2 , C H3 ) domains.
  • the constant regions show less sequence diversity and are responsible for binding a number of natural proteins to elicit important biochemical events.
  • the Fc fragment binds to endogenous Fc receptors on the surface of lymphocytes.
  • the C H2 and C H3 domains of the first portion may be of any isotype, including one selected from the group consisting of IgA, IgD, IgE, and IgG.
  • the C H2 and C H3 domains may also be from any suitable source.
  • the C H2 and C H3 domains may originate from a human, mouse and other rodents like rats and degu, rabbit, monkey, or other mammalian source.
  • the C H2 and C H3 domains may be of the IgG isotype; in another example, the C H2 and C H3 domains are from human.
  • the C H2 and C H3 domains of the first portion may be of an isotype or comprise a sequence selected from the group consisting of:
  • the first portion may further comprise a sequence corresponding to the hinge region at the N-terminus of the C H2 domain.
  • the first portion may further comprise a sequence selected from the group consisting of:
  • EPKSCDKTHTCPPCP (SEQ ID NO: 5) for human IgG1; ERKCCVECPPCP (SEQ ID NO: 6) for human IgG2; ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPK SCDTPPPCPRCP (SEQ ID NO: 7) for human IgG3; ESKYGPPCPSCP (SEQ ID NO: 8) for human IgG4;
  • the first portion of the polypeptide construct of the present invention consists of naturally fused Fc and hinge regions for the various IgG isoforms and in embodiments is selected from the group consisting of SEQ ID NO:1-4 for the Fc region and SEQ ID NO:5-8 for the hinge region.
  • the first portion of the polypeptide construct of the present invention is selected from a group of sequences displaying variation in the N-terminal sequence as exemplified by SEQ ID NO:9-34. These differ in the number of cysteine residues retained from the hinge region as a means to modulating the degree of Fc-region dimerization and hence impacting on both efficacy and manufacturability.
  • the polypeptide construct comprises a variation in the constant domain, wherein at least one cysteine residue involved in cross-linking is deleted or substituted. Suitable substitutions include serine or alanine, and preferably by serine.
  • a substantially identical sequence may comprise one or more conservative amino acid mutations that still provide for proper folding upon secretion into the culturing medium. It is known in the art that one or more conservative amino acid mutations to a reference sequence may yield a mutant peptide with no substantial change in physiological, chemical, physico-chemical or functional properties compared to the reference sequence; in such a case, the reference and mutant sequences would be considered “substantially identical” polypeptides.
  • a conservative amino acid substitution is defined herein as the substitution of an amino acid residue for another amino acid residue with similar chemical properties (e.g. size, charge, or polarity). These conservative amino acid mutations may be made to the framework regions while maintaining the overall structure of the constant domains; thus the function of the Fc is maintained.
  • a conservative mutation may be an amino acid substitution.
  • Such a conservative amino acid substitution may substitute a basic, neutral, hydrophobic, or acidic amino acid for another of the same group.
  • basic amino acid it is meant hydrophilic amino acids having a side chain pK value of greater than 7, which are typically positively charged at physiological pH.
  • Basic amino acids include histidine (His or H), arginine (Arg or R), and lysine (Lys or K).
  • neutral amino acid also “polar amino acid”
  • hydrophilic amino acids having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
  • Polar amino acids include serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), and glutamine (Gln or Q).
  • hydrophobic amino acid (also “non-polar amino acid”) is meant to include amino acids exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of (Eisenberg et al, 1984). Hydrophobic amino acids include proline (Pro or P), isoleucine (Ile or I), phenylalanine (Phe or F), valine (Val or V), leucine (Leu or L), tryptophan (Trp or W), methionine (Met or M), alanine (Ala or A), and glycine (Gly or G). “Acidic amino acid” refers to hydrophilic amino acids having a side chain pK value of less than 7, which are typically negatively charged at physiological pH. Acidic amino acids include glutamate (Glu or E), and aspartate (Asp or D).
  • a conservative mutation in the C H2 and/or C H3 domain may be a substitution that enhances a property selected from the group consisting of the stability, half-life, or Fc properties of C H2 and/or C H3 domains or alter glycosylation of the C H2 and/or C H3 domain.
  • the mutation may be an alteration at position 228 (EU numbering, 241 according to Kabat) where the serine is substituted by a proline (S228P), which stabilizes the disulfide linkage within the Fc dimer.
  • Another alteration is the mutation at position 409 (EU numbering, 440 according to Kabat) where an arginine is substituted to a lysine for further stabilization of the Fc homodimer at the C H3 -domain level (Yang & Ambrogelly, 2014).
  • Yet another alteration within the C H2 and/or C H3 domain may be a substitution of Asn297 (EU numbering, 314 according to Kabat) by glycine or alanine to alter glycosylation of the constant domain.
  • the C H2 and/or C H3 domain may be altered by substitution of one or more threonine (T252L, T253S, and/or T256F; see [U.S. 62/777,375]) to increase half-life.
  • Particularly useful are those alterations that enhance Fc properties while remaining silent with respect to conformation, e.g., retaining Fc receptor binding.
  • the conservative mutations in the C H2 and/or C H3 domain may be a substitution that is naturally-occurring. Such mutations may occur in nature as minor sequence differences between species or race.
  • Sequence identity is used to evaluate the similarity of two sequences; it is determined by calculating the percent of residues that are the same when the two sequences are aligned for maximum correspondence between residue positions. Any known method may be used to calculate sequence identity; for example, computer software is available to calculate sequence identity. Without wishing to be limiting, sequence identity can be calculated by software such as NCBI BLAST2 service maintained by the Swiss Institute of Bioinformatics (and as found at ca.expasy.org/tools/blast/), or any other appropriate software that is known in the art.
  • the substantially identical sequences of the present invention may be at least 90% identical; in another example, the substantially identical sequences may have an identity selected from the group consisting of at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical, or any percentage there between, at the amino acid level to sequences described herein. Importantly, the substantially identical sequences retain the activity, specificity, and functionality of the reference sequence. In a non-limiting embodiment, the difference in sequence identity may be due to conservative amino acid mutation(s).
  • the first portion of the polypeptide construct of the present invention may comprise a Fc comprising a sequence selected from the group consisting of a sequence at least 95%, 98% or 99% identical to that of the Fc described herein.
  • the first portion of a construct will include at least an antibody region that preferably provides for cross-linking of the polypeptide constructs, thereby to provide a dimeric protein.
  • This first portion comprises at least the minimal CH2 and/or CH3 domain.
  • That portion can be altered (i) by substituting or deleting cysteine residues from the hinge regions (SEQ ID NO:5-8) involved in crosslinking between the antibody heavy chains or between the heavy and light chains in order to potentially improve preparation homogeneity and efficacy, and/or (ii) by deleting or suitably replacing (e.g., by mutation to alanine) the terminal lysine residue 447 (EU numbering, 478 according to Kabat) of an IgG heavy chain in order to improve chemical stability of C-terminal fusions to enzymatic proteolysis (e.g., by several serine proteases and typically by trypsin).
  • cysteine residues from the hinge regions (SEQ ID NO:5-8) involved in crosslinking between the antibody heavy chains or between the heavy and light chains in order to potentially improve preparation homogeneity and efficacy
  • deleting or suitably replacing e.g., by mutation to alanine
  • the terminal lysine residue 447 EU numbering, 478 according to Kabat
  • the first portion can also be extended to become a full Fc region, by including the CH1 domain. As a full Fc, this portion will provide normal Fc effector functions that include involvement in immune cell recruitment, ADCC, CDC and other antibody functions. Moreover, and in embodiments of the present invention, the first portion can include a complete antibody or any equivalent thereof.
  • the second portion is not an antibody that binds to an immune checkpoint protein such as PD-L1 (programmed death ligand 1) and is not an antibody that binds to an immunomodulating agent that counteracts immune tolerance of cancer cells, the nature and identity of which is as described in [U.S. Pat. No. 8,815,247], and is not an antibody that binds one of EGFR1, her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, and CTLA-4.
  • an immune checkpoint protein such as PD-L1 (programmed death ligand 1)
  • an immunomodulating agent that counteracts immune tolerance of cancer cells
  • the second portion of the polypeptide construct of the present invention comprises at least one and preferably two TGF- ⁇ superfamily receptor ectodomain/s (T ⁇ SR-ED); for example, the second portion may comprise one or two T ⁇ SR-ED.
  • T ⁇ SR-ED TGF- ⁇ superfamily receptor ectodomain/s
  • the ectodomain of the Transforming Growth Factor-I3 superfamily receptor (T ⁇ SR) is the N-terminal extracellular, ligand-binding portion of the receptor.
  • the T ⁇ SR ectodomain may bind a molecule selected from the group consisting of TGF- ⁇ , bone morphogenetic protein (BMP) including BMP2, BMP3, BMP4, BMPS, BMP, BMP6, BMP7, BMP8, BMP9, BMP10, BMP11, BMP12, BMP13, BMP14, an BMP15, activin including activins ⁇ A, ⁇ B and ⁇ C, growth differentiation factor (GDF-1) including GDF-3, GDF- ⁇ , GDF-9, and GDF-15, nodal, inhibin- ⁇ , anti-Mullerian hormone, Lefty-1, Lefty-2, arteman, persephin, neurturin, myostatin, or other known TGF- ⁇ superfamily ligands.
  • BMP bone morphogenetic protein
  • the T ⁇ R ectodomain may be selected from the group consisting of the human TGF- ⁇ receptor type II ectodomain (TI ⁇ R-II-ED), the human TGF- ⁇ receptor type IIb (TI ⁇ R-IIb) ectodomain, the human activin receptor type IIa (ActR-IIa) ectodomain, the human activin receptor type IIb (ActR-IIb) ectodomain, or the BMP type Ia (BMPR-Ia) ectodomain.
  • TI ⁇ R-II-ED human TGF- ⁇ receptor type II ectodomain
  • TI ⁇ R-IIb human TGF- ⁇ receptor type IIb
  • ActR-IIa human activin receptor type IIa
  • ActR-IIb human activin receptor type IIb
  • BMPR-Ia BMP type Ia
  • the ectodomain binds TGF- ⁇ 1 and/or TGF- ⁇ 3.
  • the ectodomain itself is a human TGF- ⁇ receptor type II ectodomain including particularly the TGF- ⁇ receptor type IIa (T ⁇ RIIa).
  • T ⁇ SR-ED is the TGF- ⁇ receptor type II ectodomain (T ⁇ RII-ED; SEQ ID NO:35).
  • the T ⁇ SR ectodomain-based portion may further comprise natural linkers.
  • natural linkers Appropriate, naturally-derived linkers that can be used to fuse two ectodomains head-to-tail are known to those of skill in the art; for example, and without wishing to be limiting, suitable natural linkers are described in [WO2008/113185].
  • the natural linker if present, may be selected from the group consisting of
  • the second portion of the polypeptide construct of the present invention may comprise the sequence selected from the group consisting of:
  • the TGF- ⁇ receptor ectodomain is the bone morphogenetic protein receptor la (BMPRIa; SEQ ID NO:69).
  • the natural linker if present, may be selected from the group consisting of
  • the second portion of the polypeptide construct of the present invention may comprise the sequence selected from the group consisting of:
  • the T6SR ectodomain is the activin receptor IIa (ActRIIA; SEQ ID NO:75).
  • the natural linker if present, may be selected from the group consisting of
  • second portion of the polypeptide construct of the present invention comprises the sequence selected from the group consisting of:
  • the TGF- ⁇ receptor ectodomain is the activin receptor IIb (ActRIIb; SEQ ID NO:81).
  • the natural linker if present, may be selected from the group consisting of
  • second portion of the polypeptide construct of the present invention comprises the sequence selected from the group consisting of:
  • the present constructs have an ectodomain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto.
  • the second portion comprises the entire extracellular portion of a T ⁇ SR-ED consisting of a sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:73, SEQ ID NO:79, SEQ ID NO:85, and a sequence substantially identical thereto.
  • the at least two ectodomain portion can have the same or different ectodomains, all belonging to the superfamily.
  • the ectodomains bind the same target.
  • the ectodomains originate from the same receptor species.
  • the ectodomains are identical and thus are homomeric.
  • the ectodomains are different and thus are heteromeric.
  • the ectodomain can be for instance a T ⁇ RII-ED that is type a, and another ectodomain can be a T ⁇ RII-ED that is type b.
  • a third ectodomain could be the same as either one of these, or different still.
  • the ectodomains may be all the same (homomers) or all different (heteromers), or any combination of superfamily ectodomains.
  • the second portion of the polypeptide construct of the present invention comprises a repeat of a given T ⁇ SR-ED selected from the group consisting of SEQ ID NO:46, 47, 48, 74, 80, 86, and a sequence substantially identical thereto.
  • the second portion of the polypeptide construct of the present invention comprises heteromeric repeats of two distinct T ⁇ SR-EDs genetically fused and selected from the group consisting of SEQ ID NO:61, 62, 63, 88, and a sequence substantially identical thereto.
  • the second portion of the polypeptide construct of the present invention comprises homo-multimeric and hetero-multimeric repeats of one or more T ⁇ SR-EDs selected for instance from the group consisting of SEQ ID NO:49, 50, 51, 64, 65, 66, 67, 68, and a sequence substantially identical thereto.
  • the first and second portions of the polypeptide construct of the present invention are linked.
  • linked it is meant that the two portions are covalently bonded.
  • the chemical bond may be achieved by chemical reaction, or may be the product of recombinant expression of the two portions in a single polypeptide chain.
  • the C-terminus of the first portion is linked directly to the N-terminus of the second portion, that is, no additional “linker” amino acids are present between the two portions.
  • polypeptide fusions of the present invention can be produced by direct linkage without use of any additional amino-acid sequence except those present in the Fc portion and in the receptor ectodomain portion.
  • glycine or glycine-serine linkers such as GGGGS, or [G 4 S] n
  • linkers such as GGGGS, or [G 4 S] n
  • Entropic factors are also a potential liability for glycine and glycine-serine linkers, which are highly flexible and may become partially restricted upon target binding, hence causing a loss of entropy unfavourable to binding affinity. Therefore, only the flexible, intrinsically disordered N-terminal regions of the T ⁇ SR receptor ectodomains were employed as natural linkers in embodiments of the present invention. However, the particular amino acid compositions and lengths of these intrinsically disordered linkers (e.g., SEQ ID NO:36, 37, 70, 76, 82) precluded accurate prediction of whether the resulting direct-fusion constructs will have the required geometry and favourable molecular interactions for correct binding to their intended dimeric ligands.
  • SEQ ID NO:36 amino acid compositions and lengths of these intrinsically disordered linkers
  • the first and second portions of the polypeptide construct are, in embodiments, connected by natural intrinsically disordered polypeptide linkers selected from the group consisting of SEQ ID NO:36, 37, 38, 53, 70, 76, 82, and a sequence substantially identical thereto.
  • T ⁇ SR-ED structured regions when multiple T ⁇ SR-ED structured regions are present, these can be fused directly or they can be connected by natural intrinsically disordered polypeptide linkers between the ectodomains, such as SEQ ID NO:40, 41, 42, 55, 58, 59, 60, 72, 78, 84, 87, and a sequence substantially identical thereto.
  • Non-limiting examples of full-length polypeptide constructs of the present invention that comprise the two aforementioned portions are selected from the group consisting of SEQ ID NO: 91-120, and a sequence substantially identical thereto.
  • the N-terminus of the second portion is linked to the C-terminus of the first portion (see for example FIGS. 2A , C, D, E, F, and G).
  • polypeptide constructs of the present invention display significantly greater potency of TGF- ⁇ neutralization compared to that of the TGF- ⁇ superfamily receptor ectodomain alone; for example, the polypeptide construct may be between at least 50-fold and 1 ⁇ 10 6 -fold more potent.
  • the polypeptide constructs of the present invention may have a TGF- ⁇ neutralization potency selected from the group consisting of at least 50-, 75-, 100-, 150-, 200-300-, 400-, 500-, 600, 1000-1500-, 2000-, 3000-, 4000-, 5000-, 6000-, 7000-, 8000-, 9000, 10000-, 20000-, 30000-, 40000-, 50000-, 60000-, 70000-, 80000-, 90000-, 100000-, 150000-, 200000-, 250000-, 300000-, 350000-, 400000-, 450000-, 500000-, 550000-600000-, 650000-, 700000-, 750000-, 800000-, 850000-, 900000-, 950000, or 1000000-fold, more potent than the T ⁇ SR-ED alone, or any amount there between.
  • the potency of the construct is at least 100-fold greater than the receptor ectodomain alone.
  • the polypeptide constructs of the present invention include a T ⁇ SR-ED that binds TGF- ⁇
  • the polypeptide construct may neutralize, to varying extents, all three isotypes of TGF- ⁇ (that is, TGF- ⁇ 1, TGF- ⁇ 2, and TGF- ⁇ )
  • polypeptide constructs of the present invention have, as assessed in cell-based assays, TGF- ⁇ neutralizing potencies that are significantly higher (100-fold or more) than those of bivalent comparator polypeptides, i.e. non-Fc-fused T22d35 and T2m-Fc.
  • those that contain two or more copies of the T ⁇ RII ectodomain fused to the C-terminus of the Fc constant region have potencies that are higher than those constructs that contain only one copy, as assessed in cell based assays.
  • the first portion within the construct is “headless”, i.e.
  • cysteine optimized “headless” constructs exhibit higher anti-tumor immuno-modulatory potencies than constructs in which the first portion is a full-sized antibody.
  • the polypeptide construct of the present invention is expressed as a single polypeptide chain. Once expressed, the polypeptide construct of the present invention forms a dimer wherein the C H2 and C H3 domains of the respective polypeptide constructs interact to form a properly assembled Fc region such as occurs when the expressed products are secreted into the culturing medium.
  • dimerized polypeptide constructs of the present invention are shown in FIGS. 2A and C-G.
  • homodimers may be formed by identical polypeptide constructs.
  • heterodimers may be formed by two different polypeptide constructs; thus, a heterodimer may be formed by two Fc region polypeptide constructs that have been engineered to induce heterodimerization and inhibit homodimerization.
  • the first portion of the polypeptide construct described above may further comprise, at its N-terminus, any suitable antigen-binding antibody fragment known in the art.
  • the first portion of the polypeptide construct may comprise C H2 and C H3 domains and one selected from the group consisting of a single-chain Fv (scFv; a molecule consisting of V L and V H connected with a peptide linker) and a single-domain antibody (sdAb, a fragment composed of a single V L or a single V H ; see for example FIG. 1C ).
  • the antigen-binding fragment may be formed by combining the polypeptide construct with a second polypeptide chain.
  • the first portion of the polypeptide construct may comprise C H2 and C H3 domains along with a C H1 and V H domains, which when combined with a second polypeptide comprising C L and V L form a full-size antibody (i.e., Fc and Fab; see for example FIG. 1D ).
  • the first portion of the polypeptide may comprise C H2 and C H3 domains along with V H , which when combined with a second polypeptide comprising a V L forms an Fc fused to a Fv.
  • the combination of constant domains and antigen-binding fragment may be naturally-occurring, or may be obtained by manipulation of a naturally-occurring antibody or by using recombinant methods.
  • the polypeptide constructs such as those just described may require a sequence selected from the group consisting of linker sequences, disulfide bonds, hinge region sequences, and other type of covalent bond to link them to the C H2 and C H3 domains; those of skill in the art will be familiar with various suitable approaches.
  • the polypeptide construct comprises an antibody Fc fragment linked at the C-terminus of each heavy chain to at least one TGF- ⁇ superfamily receptor ectodomain (T ⁇ SR-ED), as described above and as illustrated in FIG. 2 (A,D,E).
  • T ⁇ SR-ED TGF- ⁇ superfamily receptor ectodomain
  • the construct may further comprise an antigen-binding fragment at the N-terminus of the Fc; the antigen-binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb, also as described above.
  • the TGF- ⁇ receptor ectodomain does not interfere in the native function or specificity of the antigen-binding fragment.
  • the antigen-binding antibody fragment described above, when present, may be directed to any suitable antigen.
  • the antigen-binding antibody or fragment does not bind to an antigen that is PD-L1, EGFR1, her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • the present constructs can further comprise antibody or antibody fragments that target any antigen of interest. They can also comprise the antigen itself, or any other moiety of interest that is genetically encoded. Particular embodiments herein include the EGFR antibody cetuximab and its active fragments, Avastin, Herceptin, Synagis, FC5, or a poly-aspartate bone-localization motif, such a D10, or sequence substantially identical or equivalent thereto.
  • the present constructs can comprise a binding protein e.g., antibody and binding fragments thereof, that inhibits a checkpoint protein which may be CTLA-4, PD1, PDL1, PDL2, PDL3, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, CD28, CD86, or one of the B-7 family ligands or a combination thereof.
  • a checkpoint protein which may be CTLA-4, PD1, PDL1, PDL2, PDL3, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, CD28, CD86, or one of the B-7 family ligands or a combination thereof.
  • Illustrative immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-OX40, PD-LI monoclonal Antibody (Anti-B7-HI; MED14736), MK-3475 (PD-1 blocker), Nivolumab (anti-PDI antibody), CT-011 (anti-PDI antibody), BY55 monoclonal antibody, AMP224 (anti-PDLI antibody), BMS-936559 (anti-PDLI antibody), MPLDL3280A (anti-PDLI antibody), MSB0010718C (anti-PDLI antibody) and Yervoy/ipilimumab (anti-CTLA-4 checkpoint inhibitor).
  • CTLA-4 blocking antibody CTLA-4 blocking antibody
  • Anti-B7-HI PD-LI monoclonal Antibody
  • MK-3475 PD-1 blocker
  • Nivolumab anti-PDI antibody
  • CT-011 anti-PDI antibody
  • BY55 monoclonal antibody AMP224 (anti-PDLI antibody)
  • antibodies provided by the present constructs can include rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-6
  • Still other antibodies that can be included in the present constructs are rituximab, zanolimumab, hA20, AME-133, HumaLYM, trastuzumab, pertuzumab, IMC-3G3, ch806, KSB-102, MR1-1, SC100, SC101, SC103, alemtuzumab, muromonab-CD3, OKT4A, ibritumomab, gemtuzumab, alefacept, abciximab, basiliximab, palivizumab, motavizumab, infliximab, adalimumab, CDP-571, etanercept, ABX-CBL, ABX-IL8, ABX-MA1 pemtumomab, Therex, AS1405, natalizumab, HuBC-1, natalizumab, IDEC-131, VLA-1; CAT-152; J695, CAT
  • the constant domain/first portion of the constructs can comprise a polypeptide having medicinal properties, such as agents that stimulate the immune system, in particular in relation to the ability of the immune system to attack tumor cells.
  • polypeptides can include cytokines (such as interleukin-2) or growth factors that stimulate immune cells directly or indirectly (i.e. act by providing gas to the immune system), as well as ectodomains or other binding agents that neutralize ligands which inhibit immune cells, either directly or indirectly (i.e. act by releasing a brake on the immune system).
  • the constant domain/first portion of the constructs can comprise a polypeptide that does not have active medicinal properties per se, but rather provides a localization signal.
  • This localization motif will serve to focus the intrinsic TGF- ⁇ neutralization activity of the second portion of the construct to a particular region of the body.
  • the first portion comprised a long poly-aspartate bone-localization motif, preferably D10 or an equivalent bone-localization moiety, which acts to enhance localisation of the construct to bone.
  • Embodiments exemplifying polypeptide constructs of the present invention that include antigen-binding fragments at the N-terminus of the Fc region (first portion) are selected from the group consisting of SEQ ID NO: 121-131, and a sequence substantially identical thereto.
  • polypeptide constructs of the present invention that include other targeting agents, e.g., a poly-aspartate bone-localization motif, at the N-terminus of the Fc region (first portion), are exemplified by SEQ ID NO: 136-150.
  • the polypeptide construct of the present invention may also comprise additional sequences to aid in expression, detection or purification of a recombinant antibody or fragment thereof. Any such sequences or tags known to those of skill in the art may be used.
  • the antibody or fragment thereof may comprise a targeting or signal sequence (for example, but not limited to ompA), a detection/purification tag (for example, but not limited to c-Myc, His s , His 6 , or His 8 G), or a combination thereof.
  • the signal peptide may be MVLQTQVFISLLLWISGAYG (SEQ ID NO:89) or MDVVTWRILFLVAAATGTHA (SEQ ID NO:90).
  • the additional sequence may be a biotin recognition site such as that described in [WO/1995/04069] or in [WO/2004/076670].
  • linker sequences may be used in conjunction with the additional sequences or tags, or may serve as a detection/purification tag.
  • the present invention also encompasses nucleic acid sequences encoding the molecules as described herein. Given the degeneracy of the genetic code, a number of nucleotide sequences would have the effect of encoding the desired polypeptide, as would be readily understood by a skilled artisan.
  • the nucleic acid sequence may be codon-optimized for expression in various micro-organisms.
  • the present invention also encompasses vectors comprising the nucleic acids as just described, wherein the vectors typically comprise a promoter and signal sequence that are operably linked to the construct-encoding polynucleotide for driving expression thereof in the selected cellular production host.
  • the vectors can be the same or different provided both result in secretion of the dimeric polypeptide construct.
  • the invention encompasses cells, also referred to herein as transgenic cellular host, comprising the nucleic acid and/or vector as described, encoding a first polypeptide construct.
  • the host cells may comprise a second nucleic acid and/or vector encoding a second polypeptide construct different from the first polypeptide construct.
  • the co-expression of the first and second polypeptide constructs may lead to the formation of heterodimers.
  • the present invention also encompasses a composition comprising one or more than one polypeptide construct as described herein.
  • the composition may comprise a single polypeptide construct as described above, or may be a mixture of polypeptide constructs.
  • the composition may also comprise one or more than one polypeptide construct of the present invention linked to one or more than one cargo molecule.
  • the composition may comprise one or more than one polypeptide construct of the present invention linked to a cytotoxic drug in order to generate an antibody-drug conjugate (ADC) in accordance with the present invention.
  • ADC antibody-drug conjugate
  • the composition may also comprise a pharmaceutically acceptable diluent, excipient, or carrier.
  • the diluent, excipient, or carrier may be any suitable diluent, excipient, or carrier known in the art, and must be compatible with other ingredients in the composition, with the method of delivery of the composition, and is not deleterious to the recipient of the composition.
  • the composition may be in any suitable form; for example, the composition may be provided in suspension form, powder form (for example, but limited to lyophilised or encapsulated), capsule or tablet form.
  • the carrier when the composition is provided in suspension form, may comprise water, saline, a suitable buffer, or additives to improve solubility and/or stability; reconstitution to produce the suspension is effected in a buffer at a suitable pH to ensure the viability of the antibody or fragment thereof.
  • Dry powders may also include additives to improve stability and/or carriers to increase bulk/volume; for example, and without wishing to be limiting, the dry powder composition may comprise sucrose or trehalose.
  • the composition may be so formulated as to deliver the antibody or fragment thereof to the gastrointestinal tract of the subject.
  • the composition may comprise encapsulation, time-release, or other suitable technologies for delivery of the antibody or fragment thereof. It would be within the competency of a person of skill in the art to prepare suitable compositions comprising the present compounds.
  • the constructs of the present invention may be used to treat diseases or disorders associated with over-expression or over-activation of ligands of the TGF- ⁇ superfamily.
  • the disease or disorder can be selected from, but not limited to, cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.
  • TGF- ⁇ is a key factor inhibiting the antitumor response elicited by immunotherapies, such as immune checkpoint inhibitors (ICI's) (Hahn & Akporiaye, 2006).
  • ICI's immune checkpoint inhibitors
  • therapeutic response to ICI antibodies results primarily from the re-activation of tumor-localized T-cells.
  • Resistance to ICI antibodies is attributed to the presence of immunosuppressive mechanisms that result in a dearth of T-cells in the tumor microenvironment.
  • ICI antibodies need to be combined with agents that can activate T-cells and induce their recruitment into the tumor, i.e.
  • Fibrotic diseases include those that affect any organ of the body, including, but not limited to kidney, lung, liver, heart, skin and eye. These diseases include, but are not limited to, chronic obstructive pulmonary disease (COPD), glomerulonephritis, liver fibrosis, post-infarction cardiac fibrosis, restenosis, systemic sclerosis, ocular surgery-induced fibrosis, and scarring.
  • COPD chronic obstructive pulmonary disease
  • glomerulonephritis glomerulonephritis
  • liver fibrosis glomerulonephritis
  • post-infarction cardiac fibrosis post-infarction cardiac fibrosis
  • restenosis systemic sclerosis
  • systemic sclerosis ocular surgery-induced fibrosis
  • scarring scarring
  • MFS Marfan syndrome
  • Osteogenesis imperfecta (01).
  • fusion molecules comprising full-size antibody (FSA), V H H-IgG Fc, D10-Fc or “headless” Fc C-terminally-fused to the T22d35 or T2m ectodomains were constructed (Table 1). All constructs comprising a heavy chain included the signal sequence MDVVTWRILFLVAAATGTHA (SEQ ID NO:89) at the N-terminus, while constructs comprising a light chain included the signal sequence MVLQTQVFISLLLWISGAYG (SEQ ID NO:90) at the N-terminus.
  • the DNA coding for constructs were prepared synthetically (Biobasic Inc. or Genescript USA Inc.).
  • Cet-T2m and Cet-T22d35 constructs were produced by transient co-transfection of Chinese Hamster Ovary (CHO) cells with the heavy chain (HC)-T2m or (HC)-T22d35 construct combined with the Cetuximab light chain (LC) construct which then assembled as the Cetuximab-T22d35 (Cet-T22d35) or Cetuximab-T2m (Cet-T2m) fusion molecules.
  • CHO Chinese Hamster Ovary
  • HC heavy chain
  • LC Cetuximab light chain
  • FIG. 3E to 3H show the results from the analysis of the hIgG1Fc ⁇ K(C)-T2m construct (an example of Type C construct from FIG. 2 ).
  • FIG. 3E shows the (ProtA)-affinity column elution profile. Fraction 12-15 were pooled, subjected to a UPLC-SEC evaluation ( FIG. 3F ), further SEC purified to remove aggregates and re-evaluated by UPLC-SEC ( FIG. 3G ). This confirmed the high degree of purity of the hIgG1Fc ⁇ K(C)-T2m construct and the absence of aggregates.
  • SDS-PAGE FIG. 3H
  • under non-reducing (NR) and reducing (R) conditions shows bands of expected molecular weights, demonstrating the expected assembly of hIgG1Fc ⁇ K(C)-T2m as a disulphide linked dimer.
  • FIGS. 3I and 3J compare the level of aggregation of two “headless” Fc-T2m constructs (examples of Type C in FIG. 2 ).
  • the Fc-T2m construct is an IgG2-based construct without engineering of the hinge region, thus it contains four cysteine residues, whereas the hIgG2Fc ⁇ K(CC)-T2m has been engineered by N-terminal truncation of the hinge region to have only two cysteines in the hinge region. It can be seen that the Fc-T2m construct contains a high level of aggregates after Protein A purification, with a doublet peak remaining even after further SEC purification.
  • FIGS. 3K and 3L compare the level of aggregation of two “headless” Fc-T22d35 constructs (examples of Type A in FIG. 2 ).
  • the Fc-T22d35 construct is without engineering of the hinge-region cysteine residues whereas the hIgG1Fc ⁇ K(C)-T22d35 construct has been engineered by N-terminal truncation of the hinge to have only one cysteine in the hinge region. It can be seen that, similarly to Fc-T2m, the Fc-T22d35 construct contains a high level of aggregates after Protein A purification, with a doublet peak remaining as detected by UPLC-SEC even after further SEC purification.
  • TGF- ⁇ neutralization potencies of purified Fc-ectodomain fusion constructs were determined and compared to those of non-Fc-fused T22d35. It should be noted that non-Fc-fused T2m does not neutralize any of TGF- ⁇ 1, - ⁇ 2, or - ⁇ 3 (De Crescenzo et al, 2001).
  • TGF- ⁇ neutralization potencies for TGF- ⁇ 1, - ⁇ 2 and - ⁇ 3 were determined for purified fusion constructs using two cell-based signaling assays: 1) the Mv1Lu cell luciferase reporter assay with Mv1Lu cells having a PAI-1-luciferase reporter (as described in (Zwaagstra et al, 2012)) and an A549 cell/IL-11 release assay adapted to the MSD (Meso Scale Discovery) platform.
  • Mv1Lu cell luciferase reporter assay Briefly, cells were seeded onto 96-well plates (20,000 cells/well) and then treated with T2m, T22d35, or a fusion construct+25 pM TGF- ⁇ at 37° C. for 16 h in DMEM, 1% FBS, 0.1% BSA. Cells were then lysed and luciferase activity was measured (Promega Corp.) using a Synergy 2 plate reader (BioTek Instruments Inc.).
  • A549 cell IL-11 release assay Human A549 lung cancer cells (ATCC-CCL-185, Cedarlane Burlington ON) were seeded in 96-well plates (5 ⁇ 103 cells/well). The following day 10 pM TGF- ⁇ in complete media in the absence or presence of a serial dilution of fusion protein was incubated for 30 min at RT prior to adding to the cells.
  • IL-11 readouts were expressed as percent IL-11 release compared to control cells treated with TGF- ⁇ alone.
  • FIG. 4A shows representative TGF- ⁇ 1 (top panel), TGF- ⁇ 3 (middle panel) and TGF- ⁇ 2 (bottom panel) neutralization curves for Cet-T2m, Cet-T22d35 and T22d35 while Table 2 summarizes TGF- ⁇ 1, - ⁇ 2 and - ⁇ 3 neutralization IC 50 values.
  • TGF- ⁇ 1 and TGF- ⁇ 3 neutralization curves for the Cetuximab fusion constructs indicated extremely high potencies that lie in the picomolar range (determining a single IC 50 value in these experiments is difficult due to the biphasic nature of the curves).
  • the observed TGF- ⁇ 1 IC 50 value for Cet-T22d35 was in the picomolar range.
  • the TGF- ⁇ 1 IC 50 for non-Fc-fused T22d35 was approximately 1 nM.
  • TGF- ⁇ 1 IC50 value for Cet-T2m was also subpicomolar (but less potent than Cet-T22d35), whereas unfused T2m is not able to detectably neutralize TGF- ⁇ 1, even at concentrations above 500 nM (De Crescenzo et al, 2001).
  • T22d35 or T2m to the C-terminus of an IgG2-Fc region alone, i.e. an antibody with no Fab region present (Fc-T22d35 and Fc-T2m) [Type A and C constructs in FIG. 2 ] resulted in fusion proteins with similarly high neutralization potencies.
  • Fc-T22d35 and Fc-T2m an antibody with no Fab region present
  • fusing T2m to the N-terminus of an IgG2-Fc (T2m-Fc) generates a fusion protein that does not neutralize TGF- ⁇ 1 and - ⁇ 3 in the picomolar range, but rather in the range of 1 nanomolar (0.3 to 15 nM in Table 2) and lacks any activity towards TGF- ⁇ 2.
  • TGF- ⁇ neutralization IC 50 of fusion constructs T2m does not neutralize any of TGF- ⁇ 1, - ⁇ 2, or - ⁇ 3 (De Crescenzo et al, 2001). It should also be noted that the IC 50 values in the table below are estimates due to the biphasic nature of the curves.
  • a second cell-based assay an A549 cell IL-11 release assay.
  • This IL-11 release assay acts as a model of TGF- ⁇ -mediated biological responses that contribute to both tumor metastasis and fibrosis.
  • the neutralization potencies of T22d35, Fc-T2m, Fc-T22d35, Cet-T22d35, Her-T22d35, Ava-T22d35, Syn-T22d35 and FC5-Fc-T22d35 were compared.
  • the IC 50 value for Fc-T2m was 0.05 nM. This indicates that constructs with two ectodomains in the C-terminal portion may be more potent than a construct with one ectodomain in the C-terminal portion (as was observed in the Mv1 Lu assay, FIG. 4A ), however, it should be noted that Fc-T2m does not have an optimized N-terminus.
  • FIG. 4C An additional set of experiments in which the A549 cell IL-11 release assay was used to compare TGF- ⁇ neutralization potencies is shown in FIG. 4C .
  • the potencies of several “headless”-T2m constructs were assessed along with that of non-Fc-fused T22d35.
  • the potency of T22d35 was determined to be ⁇ 0.5 nM, consistent with the data shown in FIG. 4B .
  • FIG. 4C shows that all of the “headless”-T2m constructs exhibited high potencies with IC 50 s in the range of 5 pM (3 to 17 pM).
  • Binding to TGF- ⁇ Binding of T22d35, Cet-T22d35, and Cet-T2m to TGF- ⁇ 2 was measured using a competitive SPR binding experiment. In this assay, the molecule of interest was first allowed to bind to a fixed amount of TGF- ⁇ in solution. A 2-fold dilution series was prepared in PBS-0.05% Tween, starting with 1000 nM T22d35 trap or 20 nM Cet-T22d35 or Cet-T2m. Each diluted sample was pre-incubated with 1 nM TGF- ⁇ 2 for 30 min at room temperature to allow binding.
  • TGF- ⁇ 2 binding EC 50 values were determined by plotting the percent free TGF- ⁇ versus the protein concentration of the molecule of interest. Binding curves and EC 50 values are shown in FIG. 4D and Table 3.
  • EC 50 of Cetuximab-trap binding to TGF- ⁇ in solution is the Effective Concentration at which 50% of TGF- ⁇ is bound and is given in nM.
  • Example 1 The ability of an antibody alone or in a fusion construct of Example 1 to bind to its intended target antigen was evaluated using surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • Cetuximab to maintain its therapeutic function (i.e. inhibition of EGF-induced EGFR phosphorylation and signaling) when fused to either T2m or T22d35 (Example 1) was evaluated.
  • A549 cells were seeded in 24-well plates (100,000 cells/well) and either mock treated ( ⁇ ) or pre-treated with Cetuximab, Cet-T2m, or Cet-T22d35 (all at 10, 1 or 0.1 nM) or T22d35 (10 nM) at 37° C. for 3 h, then treated with 50 ng/mL EGF at 37° C. for 10 min.
  • Inhibition of EGFR signaling Inhibition of autocrine EGFR signaling results in varying degrees of cytotoxicity in EGFR-expressing cells treated with Cetuximab. Cytotoxicity of Cet-T22d35 was compared to Cetuximab and T22d35 in human breast cancer cells (MDA-MB-468) and immortalized keratinocyte cells (HaCaT). These cells exhibited significant Cetuximab cytotoxicity, due to their intrinsic dependence on the EGF signaling pathway for basal growth. The cells were seeded onto 96-well plates (MDA-MB-468, 2300 cells/well; HaCaT, 1500 cells/well) and then treated with different doses of inhibitor at 37° C. for 5 days.
  • MDA-MB-468 2300 cells/well
  • HaCaT 1500 cells/well
  • FC5 V H H to maintain its function (i.e. transmigrate the blood-brain barrier) when fused with the T2m or T22d35 moieties (see description in Example 2 and activities in Table 2) was evaluated.
  • Sv-ARBEC SV40-immortalized Adult Rat Brain Endothelial Cells
  • BBB blood-brain barrier
  • Sv-ARBEC cells 80,000 cells/membrane
  • the bottom chamber of the insert assembly contained 2 ml of growth medium supplemented with the immortalized neonatal rat astrocytes-conditioned medium in a 1:1 (v/v) ratio.
  • Quantified values can be directly plotted or the P app (apparent permeability coefficient) values can be determined using the following formula
  • FIG. 6 shows the results of the experiment.
  • the P app value of FC5-Fc-T22d35 was similar to the control FC5-Fc, indicating it was transported efficiently and that the fused T22d35 did not interfere with transport.
  • the P app value for FC5-Fc-T2m was approximately 50% less, compared to FC5-Fc-T22d35 and FC5-Fc, indicating somewhat reduced permeability. Nevertheless, the level of transport of FC5-Fc-T2m was about 4-fold greater than the negative controls (T2m, T22d35, and antibody A20.1).
  • EMT epithelial to mesenchymal transition
  • A549 cells were seeded in 24-well plates (8000 cells/well) and then treated with EGF (50 ng/mL)+TGF- ⁇ 1 (50 pM) at 37° C. for 3 days in the presence of Cet-T22d35, Cetuximab, or T22d35 (0, 0.05, 0.5, 5, 50, or 500 nM).
  • EGF 50 ng/mL
  • TGF- ⁇ 1 50 pM
  • Whole cell lysates were prepared and resolved by SDS-PAGE.
  • the proteins were transferred to nitrocellulose and then probed with an E-cadherin antibody (BD Transduction laboratories Biosciences) ( FIG. 7B ).
  • the E-Cadherin positive bands in the Western blot were quantified by densitometer detection and ImageJ analysis ( FIG. 7C ).
  • EGF+TGF- ⁇ treatment resulted in an EMT, as indicated by the disappearance of E-cadherin (compare non-treated and EGF+TGF- ⁇ lanes in the absence of inhibitors).
  • Cet-T22d35 blocked the EMT (E-cadherin disappearance) in a dose-dependent manner whereas 500 nM Cetuximab or T22d35 treatments only modestly blocked the EMT (E-cadherin levels ⁇ 20-25% of the non-treated control level).
  • Cet-T22d35, Cetuximab and T22d35 were further examined by flow cytometry using A549 cells treated with Cet-T22d35 or Cetuximab, (all at 50, 5, 0.5 nM) or the Cetuximab+T22d35 combination (50 nM+100 nM, 5 nM+10 nM, or 0.5 nM+1 nM, respectively) and evaluating the EMT associated changes in E-cadherin and N-cadherin cell surface expression levels ( FIG. 7D ).
  • PK studies were carried out in normal, healthy mice to determine whether fusion of T22d35 to an antibody increased its half-life in vivo, and whether removal of a lysine at the fusion site within constructs reduced the amount of cleavage occurring in vivo.
  • Results from Cet-T22d35 (construct Type D in FIG. 2 —containing a lysine at the fusion site): A single bolus of Cet-T22d35 protein (10 mgs/Kg) formulated in DPBS was intravenously injected (IV) into the tail vein of normal Balb/c mice and serum samples were collected from the submandibular vein at selected time points (0.5, 1, 2, 4, 8, 14, 24, 48, 96 h). Blood samples were centrifuged at 2000 g at 4° C. for 10 min and the serum supernatant was removed and stored frozen at ⁇ 80° C., prior to analyses. The samples were thawed at 4° C.
  • the isotope-labeled peptides were 13C/15N—(H2N-LPYHDFILEDAASPK-OH; SEQ ID NO:134) and 13C/15N—(H2N-ALPAPIEK-OH; SEQ ID NO:135) for T22d35 and Cetuximab, respectively (NewEngland Peptide). Trifluoroacetic acid was then added (0.5% final), followed by incubation at 37° C. for 30 min. The samples were centrifuged at 13000 rpm for 20 min and the supernatant was used analyzed via MRM-ILIS using an Agilent 1260 HPLC system coupled with Agilent QQQ6410B at 55° C. The PK profiles seen in FIG.
  • a FSA-T2m construct (Cet-T2m—Type F in FIG. 2 ) and three headless constructs, all with engineered N-termini, (hIgG1Fc ⁇ K(CC)-T2m, hIgG1Fc ⁇ K(C)-T2m, and hIgG2Fc ⁇ K(CC)-T2m—Type C in FIG. 2 ) were evaluated for their ability to inhibit tumor growth and to affect T-cell function in a syngeneic tumor model derived from 4T1 triple negative breast cancer cells.
  • the results presented in FIG. 9 show the effect on tumor growth (A) and T-cell function (B, C).
  • the effects of these Fc-fused ectodomain constructs were compared to those of a pan-specific neutralizing anti-TGF- ⁇ antibody, 1D11 and a non-Fc-fused ectodomain construct, T22d35.
  • mice Female BALB/c (H-2Kd) mice 6 weeks of age were purchased from The Jackson Laboratories and kept in filter-top cages.
  • the 4T1 breast cancer cells and B16F10 cells were purchased from American type culture collection and cultured in RPMI-1640 supplemented with 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 microgm/L streptomycin, 50 micromol/L 2-mercaptoethanol, and 10% fetal calf serum.
  • Mice were inoculated subcutaneously in the left flank with 100 uL sterile saline containing 5 ⁇ 10 4 4T1 cells.
  • T cells from mice treated with or without test agents to lyse target 4T1 tumor cells was measured using a CytoTox 96 nonradioactive cytotoxicity assay kit (Promega) according to the manufacturer's instructions. Briefly, na ⁇ ve target 4T1 cells or melanoma cell line B16F10 cells are plated and incubated for 4 hr with CD8+ effector T cells isolated from 4T1 tumor-bearing mice using CD8 magnetic MicroBeads (BD Bioscience). The isolated CD8+ cells are confirmed, by flow cytometry, to be over 85% CD8+. A range of ratios of effectors to target cells is tested (100:1, 50:1, 25:1).
  • Lactate dehydrogenase (LDH) release in response to effector T cells is measured in the buffer bathing target cells.
  • Target cells incubated in the absence of effector cells are used as a comparator to control for spontaneous LDH release.
  • Released LDH in culture supernatants is detected after a 30-min incubation using a coupled enzymatic assay. The intensity of the color formed is proportional to the number of lysed cells. Cytotoxic activity of CTL is calculated using the following formula:
  • Cytotoxic activity % [(absorbance) ⁇ (spontaneous effector cell LDH release) ⁇ (spontaneous target cell LDH release)]/[(maximal LDH release)—(spontaneous target cell LDH release)] ⁇ 100
  • FIG. 9A show the effect of the Fc-fused ectodomain constructs listed above on 4T1 tumor growth (the pan-specific neutralizing anti-TGF- ⁇ antibody, 1 D11, and a non-Fc-fused ectodomain construct, T22d35, being tested as comparators).
  • the pan-specific neutralizing anti-TGF- ⁇ antibody, 1 D11 and a non-Fc-fused ectodomain construct, T22d35, being tested as comparators.
  • all of the Fc-fused ectodomain constructs reduced tumor growth relative to the saline treatment when tested for significance by t-test.
  • the 1 D11 and T22d35 comparator treatments were observed to be less effective relative to the Fc-fused ectodomain treatments, and not significantly different from the saline control.
  • lymph nodes were removed from mice treated with or without test agents; T-cells were then isolated and tested for their capacity to lyse target 4T1 tumor cells (and B16F10 cells as a test of tumor specificity) using the methods described above.
  • CTLs cytotoxic T lymphocyte cells
  • the most potent constructs were the hIgG1Fc ⁇ K(CC)-T2m and hIgG2Fc ⁇ K(CC)-T2m constructs; both of these constructs containing two cysteines in the engineered hinge region. These constructs were more potent than the construct with one cysteine in the engineered hinge region, hIgG1Fc ⁇ K(C)-T2m, as well as being more potent than the full-size antibody-T2m construct, Cet-T2m.
  • the difference in potency between constructs with one versus two hinge region cysteines may result from the construct with one cysteine having a lower relative stability.
  • the lower potency of the full size antibody construct relative to the headless constructs with two hinge region cysteines may result from a difference in molecular weight, with the smaller constructs being able to penetrate the tumor microenvironment more effectively.
  • D10-hIgG1Fc-T2m fusions Upon arrival, male Balb/c mice were housed 3 mice/cage. On the day of the experiment, animals were shaved dorsal and ventral and treated with the hair removal cream, NAIR®.
  • mice were injected with a single intravenous bolus of 10 mg/kg of two CF770 labeled constructs with a deca-aspartate motif for bone targeting (D10) at their N-termini (D10-hIgG1Fc ⁇ K(CC)-T2m, D10-GSL-hIgG1Fc ⁇ K(CC)-T2m) or with a control construct without the D10 motif (hIgG1Fc ⁇ K(CC)-T2m) and whole body bio-distribution followed using both in vivo and ex-vivo near infrared imaging.
  • D10-hIgG1Fc ⁇ K(CC)-T2m D10-GSL-hIgG1Fc ⁇ K(CC)-T2m
  • hIgG1Fc ⁇ K(CC)-T2m whole body bio-distribution followed using both in vivo and ex-vivo near infrared imaging.
  • Imaging was conducted with a small-animal time-domain eXplore Optix pre-clinical imager MX3 (Advanced Research Technologies, ART) at various time points (prescan, 5 mins, 3 hr, 6 hr, 24 h, 48 h, 72 h, 96 h and 120 h).
  • the small animal time-domain eXplore Optix preclinical imagers consists of a 785-nm pulsed laser diode with a repetition frequency of 80 MHz and a time resolution of 12.5 ps light pulse was used for excitation.
  • the fluorescence emission beyond 813 nm was collected by a highly sensitive time-correlated single photon counting system and detected through a fast photomultiplier tube.
  • the data were recorded as temporal point-spread functions (TPSF) and the images were presented as fluorescence intensity maps using ART Optix Optiview analysis software 3.02.
  • mice were first anesthetized using isofluorane (1.5-2%), positioned on the animal stage within a chamber which allows for gaseous anesthesia and maintenance of animal temperature at 36° C.
  • the scanning of the mouse at each time point lasted up to 20 mins using a 2.5 mm step size and the mouse is placed back in its home cage between imaging time points.
  • mice were sacrificed by intracardiac perfusion using heparnized saline with deep anesthesia.
  • the organs (brain, heart, lungs, liver, kidney, spleen and right and left leg bones) were imaged ex-vivo using a 1.0 mm step size using the eXplore Optix pre-clinical imager MX3.
  • FIGS. 10A and B demonstrate that the fusion of the deca-aspartate D10 motif on the N-termini of the fusion constructs had no impact on their ability to neutralize TGF- ⁇ , i.e. the IC 50 of the construct lacking the D10 motif (hIgG1Fc ⁇ K(CC)-T2m) was 3 nM, which is the same as the value determined in FIG. 4C , while the IC 50 s of the D10 containing constructs, D10-hIgG1Fc ⁇ K(CC)-T2m and D10-GSL-hIgG1Fc ⁇ K(CC)-T2m, were very similar at 4-5 nM.
  • 10A and B also indicate that labeling with the CF770 dye reduced the ability of the constructs to neutralize TGF- ⁇ by approximately 4-fold. Since dye conjugation occurs at lysine residues, and since it is know that lysines are at the binding interface between the Type II ectodomain and TGF- ⁇ , it is not entirely surprising that labeling reduced neutralization potency. In any case, since this is a comparative study of differences in in vivo localization promoted by the D10 peptide, it was felt that partially active constructs would be informative.
  • FIGS. 10C and D demonstrate that the addition of the D10 peptide to the N-termini of the constructs greatly enhanced bone localization.
  • Images taken 120 h post-injection of the CF770 labeled fusions show a clear accumulation of the D10-fusions in the vertebrae.
  • Further ex vivo imaging of the brain, heart, lungs, liver, kidneys, spleen, and the left and right legs 120 h post-injection confirmed the specific accumulation of the D10-fusions in the bones.
  • the fluorescent signals observed in the kidneys and liver were similar for all fusions indicating that accumulation in these organs was not affected by the presence of the D10 sequence.
  • TGF- ⁇ neutralization activity of constructs may be increased within bone through the addition of the D10 peptide. This could result in more favourable dosing levels and schedules for the treatment of bone-related diseases, such as osteogenesis imperfecta, relative to that required for a similar construct without the D10 motif.
  • TGF-beta transforming growth factor-beta

Abstract

The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.

Description

    FIELD OF THE INVENTION
  • The present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and their use in TGF-β superfamily ligand neutralization.
    • BACKGROUND OF THE INVENTION
  • TGF-β is part of a superfamily of over 30 ligands that regulate several physiological processes, including cell proliferation, migration and differentiation. Perturbation of their levels and/or signaling gives rise to significant pathological effects. For instance, TGF-β and activin ligands play critical pathogenic roles in many diseases including cancer (Hawinkels & Ten Dijke, 2011; Massague et al, 2000; Rodgarkia-Dara et al, 2006). TGF-β, in particular, is considered as a critical regulator of tumor progression and is overexpressed by most tumor types. It favors tumorigenesis in part by inducing an epithelial-mesenchymal transition (EMT) in the epithelial tumor cells, leading to aggressive metastasis (Thiery et al, 2009). TGF-β also promotes tumorigenesis by acting as a powerful suppressor of the immune response in the tumor microenvironment (Li et al, 2006). In fact, TGF-β is recognized as one of the most potent immunosuppressive factors present in the tumor microenvironment. TGF-β interferes with the differentiation, proliferation and survival of many immune cell types, including dendritic cells, macrophages, NK cells, neutrophils, B-cells and T-cells; thus, it modulates both innate and adaptive immunity (Santarpia et al, 2015; Yang et al, 2010). The importance of TGF-beta in the tumor microenvironment is highlighted by evidence showing that, in several tumor types (including melanoma, lung, pancreatic, colorectal, hepatic and breast), elevated levels of TGF-β ligand are correlated with disease progression and recurrence, metastasis, and mortality. Hence, significant effort has been invested in devising anti-tumor therapeutic approaches that involve TGF-β inhibition (Arteaga, 2006; Mourskaia et al, 2007; Wojtowicz-Praga, 2003).
  • One approach to developing therapeutic agents that inhibit TGF-β function has been to use antibodies or soluble decoy receptors (also termed receptor ectodomain (ED)-based ligand traps) to bind and sequester ligand, thereby blocking access of ligand to its normal cell surface receptors (Zwaagstra et al, 2012). In general, receptor ED-based traps are a class of therapeutic agents that are able to sequester a wide range of ligands and that can be optimized using protein engineering approaches (Economides et al, 2003; Holash et al, 2002; Jin et al, 2009).
  • Previously, a novel protein engineering design strategy was used to generate single-chain, bivalent traps that are able to potently neutralize members of the TGF-β superfamily of ligands due to avidity effects (Zwaagstra et al, 2012) [WO 2008/113185; WO 2010/031168]. In this case, bivalency was achieved via covalent linkage of two TβRII ectodomains using portions of the intrinsically disordered regions (IDR) that flank the structured, ligand-binding domain of TβRII-ED. One example of these single-chain bivalent traps, T22d35, exhibited TGF-β neutralization potencies ˜100-fold higher than the monovalent non-engineered TβRII ectodomain, though it did not neutralize the TGF-β2 isoform and had a relatively short circulating half-life.
  • While research to date indicates that single-chain TGF-β traps have promising therapeutic potential, their circulating half-lives and manufacturability present challenges to the commercial application.
    • SUMMARY OF THE INVENTION
  • The present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and their use in TGF-β superfamily ligand neutralization.
  • In some aspects, the invention relates to TGF-β superfamily receptor ectodomain-based polypeptides that are similar to typical Fc fusions in design, in that the ectodomain is fused to a dimeric antibody constant domain. In particular, with respect to the present polypeptides, the Fc portion occupies the N-terminal position. Fc fusions in the prior art typically provide the Fc portion at the C-terminal end of the fusion. As will be evident from the results presented herein, this difference in orientation provides a number of significant advantages.
  • In other aspects, the present polypeptides incorporate at least two TGF-β superfamily receptor ectodomains that are linked in tandem to the C-terminus of an antibody constant domain.
  • Thus, there is provided a polypeptide construct comprising: a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a second portion comprising at least two TGF-β superfamily receptor ectodomains (TβSR-ED) linked in tandem; wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • There is also provided a polypeptide construct comprising: a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a second portion comprising at least one TGF-β superfamily receptor ectodomains (TβSR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and further wherein the first portion does not further comprise an antibody that binds to an antigen that is PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • There is provided a polypeptide construct comprising: a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED), wherein the N-terminus of the second portion is directly fused to the C-terminus of the first portion.
  • In an embodiment, there is provided a polypeptide construct comprising a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and wherein the polypeptide construct neutralizes TGF-β with at least 100-fold more potency than the TβSR-ED alone.
  • In a preferred embodiment, the second portion comprises one, two, or multiple TGF-β superfamily receptor ectodomain (TβSR-ED). In a preferred embodiment, the TβSR-ED is a TGF-β receptor type II ectodomain (TIβR-II-ED). In a preferred embodiment, the TβSR-ED comprises a sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto.
  • The second portion may comprise a sequence selected from the group consisting of SEQ ID NO:43-SEQ ID NO:51, SEQ ID NO:61-SEQ ID NO:68, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:88, and a sequence substantially identical thereto.
  • In a preferred embodiment, the first portion of a polypeptide construct of the present invention further comprises a CH1, a CH1 and VH, or CH1 and scFv.
  • There is provided a polypeptide construct of the present invention wherein the antibody heavy chain is of human origin. In a preferred embodiment, the antibody heavy chain is selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain. More preferably, the antibody heavy chain is a human IgG1.
  • In accordance with the present invention, the polypeptide construct shows longer in vivo half-life compared to the half-life of the second portion alone.
  • There is provided a polypeptide construct of the present invention, wherein the polypeptide construct is a single chain polypeptide.
  • In an embodiment, the polypeptide construct forms a dimeric polypeptide. In another embodiment, the polypeptide construct is heterodimeric.
  • There is provided a polypeptide construct selected from the group consisting of any one of SEQ ID NO:91 to SEQ ID NO:120, and a sequence substantially identical thereto.
  • There is provided a polypeptide construct according to the present invention, wherein the construct comprises an antibody, antigen binding fragment thereof, or a targeting moiety. In a preferred embodiment, the antibody, the antigen binding fragment, or the targeting moiety is at the N-terminus of the first portion.
  • In a preferred embodiment, the antigen binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb. In a preferred embodiment, the antigen binding fragment binds to any antigen, provided that it is not PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • In a preferred embodiment, a polypeptide construct of the present invention comprises an antibody selected from the group consisting of Cetuximab, Avastin, Herceptin, Synagis, and FC5. In a preferred embodiment, the antibody is Cetuximab.
  • In a preferred embodiment, a polypeptide construct of the present invention comprises a targeting moiety, wherein the targeting moiety comprises a poly-aspartate sequence motif for bone targeting. In a preferred embodiment, the targeting moiety comprises D10.
  • There is provided a polypeptide construct according to the present invention wherein the construct is a dimeric polypeptide; wherein the dimeric polypeptide comprises: a first single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and third constant domain (CH3) of an antibody heavy chain, and a heavy chain variable region of a given antibody; a second portion comprising one or more TGF-β superfamily receptor ectodomains (TβSR-ED), wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and a second single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and third constant domain (CH3) of an antibody heavy chain, and a light chain variable region of said given antibody; a second portion comprising one or more TGF-β superfamily receptor ectodomain (TβSR-ED) which is the same or different from the ectodomain(s) in the first polypeptide, wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • There is also provided a nucleic acid molecule encoding the polypeptide construct of the present invention. There is also provided a vector comprising the nucleic acid molecule of claim the present invention.
  • There is also provided a composition comprising one or more than one independently selected polypeptide construct of the present invention and a pharmaceutically-acceptable carrier, diluent, or excipient.
  • There is also provided a transgenic cellular host comprising the nucleic acid molecule or a vector of the present invention. The transgenic cellular host further comprising a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct.
  • There is also provided the use of a polypeptide construct according to the present invention for treatment of a medical condition, disease or disorder; wherein the medi medical condition, disease or disorder comprises, but is not limited to, cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.
  • In a preferred embodiment, there therefore provided a polypeptide construct comprising:
      • a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
      • a second portion comprising at least two TGF-β superfamily receptor ectodomains (TβSR-ED),
      • wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • The antibody constant domain can further comprise, either linked thereto or formed integrally therewith, a binding agent such as a full size antibody, a ligand or any other protein of interest. In the alternative, the antibody constant domain comprises only the CH2 and/or CH3 regions, and not a full size antibody. In these and other types of constructs, the CH2 and/or CH3 region can be altered by deleting or substituting amino acids including one or more of the cysteines that provide cross-linking when the present constructs are provided as dimeric constructs.
  • In other aspects of the present invention, there is provided a polypeptide construct that incorporates one or more such ectodomains. When the constructs comprise only one ectodomain linked to the antibody constant domain, then the construct is further characterized by at least one of the following: (1) when the constant domain further comprises a full sized antibody, that antibody does not bind effectively to PD-L1 or to an immunoregulatory antigen selected, (2) the constant domain comprises only the CH2 and/or CH3 regions, (3) the constant domain comprises an amino acid alteration relative to a wild type counterpart, such as a cysteine residue alteration; and (4) the first portion is linked to the second portion directly and without intervening amino acids.
  • In another of its aspects, the present invention provides a polypeptide construct comprising
      • a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
      • a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED), wherein
  • the N-terminus of the second portion is linked to the C-terminus of the first portion. These polypeptide constructs can neutralize TGF-β, and with at least 100-fold more potency than the TβSR-ED alone.
  • The second portion of the polypeptide construct of the present invention may comprise one or two or more TβSR-ED. In a preferred embodiment the construct comprises two or more independently selected ectodomains linked in tandem and to the C-terminus of the constant domain. The TβSR-ED may be selected from the group consisting of a TGF-β receptor type II ectodomain (TβRII-ED), a bone morphogenetic protein receptor type la ectodomain (BMPR-ED), an activin receptor type IIa ectodomain (ActRIIA-ED), and an activin receptor type IIb ectodomain (ActRIIb-ED). In another preferred embodiment, the ectodomain is a TIβR-II ectodomain.
  • In the polypeptide construct described herein, the first portion further may comprise a CH1, a CH1 and VH, or a CH1 and scFv. It may constitute an Fc region, an antibody, or any ligand binding agent or moiety.
  • The polypeptide construct of the present invention may comprise a CH2 and CH3 from an antibody heavy chain that is of human or mouse origin. For example, and without wishing to be limiting, the antibody heavy chain may be selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain. In embodiments, the constant domain in the constructs is CH2 per se, or CH3 per se or CH2-CH3.
  • The polypeptide construct described herein may show longer in vivo half-life compared to the half-life of TβSR-ED alone.
  • In one example, the polypeptide construct of the present invention may be a single chain polypeptide. The polypeptide construct as described herein may also form a dimeric polypeptide. This dimeric polypeptide may be heterodimeric.
  • The present invention further provides a polypeptide construct comprising
      • a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
      • a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
  • wherein the N-terminus of the second portion is linked to the C-terminus of the first portion; additionally, in the construct as just described, the first portion is not derived from certain antibodies discussed infra.
  • The present invention also provides a polypeptide construct, comprising:
      • a first single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a heavy chain variable region of a given antibody; and a second portion comprising one or more TGF-β superfamily receptor ectodomains (TβSR-ED),
  • wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and
      • a second single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and a light chain variable region of said given antibody; and a second portion comprising one or more TGF-β superfamily receptor ectodomain (TβSR-ED) which is the same or different from the ectodomain(s) in the first polypeptide, wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
  • In alternative constructs of the present invention, the polypeptide construct comprises an antibody Fc fragment linked at the C-terminus of each heavy chain to at least one TGF-β superfamily receptor ectodomain (TβSR-ED), as described above. In embodiments the receptor ectodomain portion comprises two independently selected ectodomains that are linked in tandem, i.e., in a linear manner. In some embodiments, the ectodomains are the same in sequence, or least the same with respect to their target ligand. The construct may further comprise a binding fragment or moiety at the N-terminus of the Fc; the binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb, or any other binding moiety such as a motif for bone targeting, also as described above. In the polypeptide constructs as described above, the TGF-β receptor ectodomain does not interfere in the native function or specificity of the binding fragment.
  • The present invention also provides a nucleic acid molecule encoding the polypeptide constructs as described herein. A vector comprising the nucleic acid molecule just described is also encompassed by the invention. The invention also includes a transgenic cellular host comprising the nucleic acid molecule or a vector as described herein; the cellular host may further include a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct. Systems used to produce the present polypeptides can be secretion systems, particularly in the case where dimerization through disulfide bridges is required, and the expression polynucleotides thus encode secretion signals that are cleaved by the host upon secretion into the culturing medium.
  • Compositions comprising one or more than one independently selected polypeptide construct described herein and a pharmaceutically-acceptable carrier, diluent, or excipient are also encompassed by the present invention.
  • Additional aspects and advantages of the present invention will be apparent in view of the following description. The detailed descriptions and examples, while indicating preferred embodiments of the invention, are given by way of illustration only, as various changes and modifications within the scope of the invention will become apparent to those skilled in the art in light of the teachings of this invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and other features of the invention will now be described by way of example, with reference to the appended drawings, wherein:
  • FIG. 1A is a schematic diagram showing TGF-β Type II receptor ectodomain (TβRII-ED)-based molecules T2m and T22d35 along with their sequences (SEQ ID NO:43 and 46, respectively). Natural linker sequences (SEQ ID NO:36, 39 and 40) are underlined and depicted as dark grey lines; the sequence of the TIβR-II-ED structured domain (SEQ ID NO:35) is shown in bold, and the domain labeled and depicted in dark grey; the site of the fusion of natural linkers is depicted by a slash. FIGS. 1B-D are schematic diagrams of IgG Fc-based scaffolds: an IgG Fc region (FIG. 1B), a VHH-IgG Fc (comprising a VHH single domain antibody fused to the N-terminus of an Fc region; FIG. 1C), and a full-size antibody (FIG. 1D).
  • FIG. 2 is a schematic representation of TGF-β superfamily receptor-ectodomain-based fusion constructs of the present invention. (A) represents constructs in which T22d35 (dark grey) is fused to the C-terminus of IgG Fc regions ( IgG isoforms 1, 2, 3 or 4) with no Fab or other functional binding moiety at the N-terminus (Fc-T22d35, A), (D) represents constructs in which T22d35 (dark grey) is fused to the C-terminus of the IgG Fc region of full-size antibodies with heavy and light chain Fabs (FSA-T22d35, D), (E) represents constructs in which T22d35 (dark grey) is fused to the C-terminus of IgG Fc regions that have a non-Fab binding/localization moiety at the N-terminus, such as the variable region of a camelid VHH antibody (VHH-Fc-T22d35) or a deca-aspartate motif for bone targeting (D10-Fc-T22d35). Similarly, (B), (C) and (F) and (G) represent constructs in which T2m (the TGF-β Type II receptor ectodomain, TβRII-ED—dark grey) is fused at the N-terminus of an IgG Fc (T2m-Fc, B) or the C-terminus of IgG Fc regions with no Fab or other functional binding moiety at the N-terminus (Fc-T2m, C), or the C-terminus of full-size antibodies with heavy and light chain Fabs (FSA-T2m, F), or the C-terminus of IgG Fc regions that have a non-Fab binding/localization moiety at the N-terminus, such as the variable region of a camelid VHH antibody (VHH-Fc-T2m, G) or a deca-aspartate motif for bone targeting (D10-Fc-T2m).
  • FIG. 3 presents (ProtA)-affinity column elution profiles, size exclusion (SEC) purification profiles, SDS-PAGE gels, and UPLC-SEC profiles of representatives of constructs type C and D in FIG. 2. FIG. 3A is a (ProtA)-affinity column elution profile for T22d35 fused to the Cetuximab FSA (Cet-T22d35—a representative of construct D in FIG. 2). FIG. 3B is the size exclusion (SEC) purification profile of the Cet-T22d35. FIG. 3C show 4-15% SDS-PAGE gels of ProtA-purified Cet-T22d35 under reducing (left panel) and non-reducing (right panel) conditions (CetHC-T22d35, Cetuximab heavy chain fused to T22d35; CetLC, Cetuximab light chain). Lanes 1 are the pooled Prot-A eluted fractions, while lanes 2 are the pooled SEC fractions. FIG. 3D shows the UPLC-SEC profile of ProtA-purified Cet-T22d35. FIG. 3E shows the (ProtA)-affinity column elution profile for hIgG1FcΔK(C)-T2m (a construct with T2m fused to an Fc region with no functional binding moiety at the N-terminus; a representative of construct D in FIG. 2). FIG. 3F, G, H show the UPLC-SEC profile before SEC (F), the UPLC-SEC profile after SEC (G) and the SDS-PAGE (NR & R) (H) of hIgG1FcΔK(C)-T2m.
  • FIG. 4A shows graphs depicting the efficient inhibition of TGF-β1 (top panel), TGF-β3 (middle panel) and TGF-β2 (bottom panel) signaling in Mv1 Lu luciferase reporter cells by Cet-T2m (a representative of construct F in FIG. 2) and Cet-T22d35 (a representative of construct D in FIG. 2), compared to the significantly lower inhibition potency of non-Fc-fused T22d35.
  • FIG. 4B shows graphs and a summary table depicting the efficient inhibition of TGF-β1 signaling in an A549/IL-11 cell-based assay by several representatives of FSA-T22d35 constructs (Type D construct from FIG. 2), compared to the lower inhibition potency of Fc-T2m (Type C construct) and non-Fc-fused T22d35.
  • FIG. 4C shows graphs and a summary table depicting the efficient inhibition of TGF-β1 signaling in an A549/IL-11 release cell-based assay by several representatives of “headless”-T2m constructs (Type C construct from FIG. 2), compared to the lower inhibition potency of non-Fc-fused T22d35.
  • FIG. 4D is a graph showing competitive SPR analysis of binding of Cetuximab-fusion constructs to TGF-β isoforms in solution, compared to T22d35.
  • FIG. 5A is a SDS-PAGE gel showing the inhibition of EGFR phosphorylation in A549 cells by Cetuximab-fusion constructs. FIG. 5B is a graph showing Cet-T22d35 (triangles) cytotoxicity in MDA-MB-468 and HaCat cells compared to Cetuximab (circles) and T22d35 (squares).
  • FIG. 6 is a bar graph showing the apparent permeability coefficient (Papp) values, as a measure of transport of FC5-Fc, FC5-Fc-fusion constructs, T22d35, and T2m across a human brain endothelial cell barrier in vitro, relative to a non-transporting VHH control (A20.1).
  • FIG. 7 demonstrates the Cet-T22d35 inhibition of EGF+TGF-β1 induced EMT in A549 cells. FIG. 7A shows pictures of cultured A549 cells showing their morphologies before treatment (left panel A) and after treatment with EGF+TGF-β1 (right panel B). FIG. 7B shows a western blot of whole cell lysates of A549 cells treated with EGF+TGF-β1 in the presence or absence of various concentrations of Cetuximab (Cetux), Cet-T22d35 or T22d35, probed for the epithelial marker E-Cadherin, while FIG. 7C is the densitometer quantification of the E-cadherin bands in the Western blot. Results show that Cet-T22d35 is much more potent than T22d35 alone or Cetuximab alone in upregulating E-cadherin, i.e. blocking EMT. FIG. 7D shows the inhibition of EGF+TGF-β-induced EMT by Cetuximab (Cetux), Cet-T22d35, T22d35 or Cet-T22d35 plus T22d35 as measured by flow cytometry detection of the epithelial E-Cadherin (top panel) and mesenchymal N-Cadherin (bottom panel) markers.
  • FIG. 8A represents the pharmacokinetic (PK) profile of Cet-T22d35 in the serum collected from BALB/C mice that were injected with a single dose of Cet-T22d35. The fusion construct appears to be cleaved in vivo; the terminal half-life of the T22d35 potion of the construct was determined to be 45.8 hours, while the terminal half-life of the Cetuximab portion of the construct was determined to be 262.5 hours. FIG. 8B represents the PK profiles and data table (serum half-lives in bold) for constructs in which the lysine at the C-terminus of the Fc region was removed, i.e. is not present at the fusion joint between the Fc region and T2m (CetΔK-T2m, hIgG1FcΔK(SS)-T2m, hIgG1FcΔK(ΔC)-T2m, and hIg2GFcΔK(SS)-T2m). The data demonstrate that the removal of the lysine prevents cleavage of the constructs in vivo.
  • FIGS. 9A, 9B and 9C present graphs showing the effect of “headless” Fc-T2m constructs (representatives of construct C in FIG. 2) and a FSA-T2m construct (a representative of construct F in FIG. 2) on tumor growth and T-cell function in an immune-competent syngeneic triple negative breast cancer (4T1) model (for comparison, the effects of the 1D11 antibody and non-Fc-fused T22d35 are also shown). The results demonstrate the improved efficacy on T-cell function of two headless-T2m constructs relative to the FSA-T2m construct, and relative to 1D11 and non-Fc-fused T22d35.
  • FIG. 10 shows data illustrating enhanced bone localization of two constructs containing a deca-aspartate motif for bone targeting at the N-terminus of the Fc region (D10-hIgG1FcΔK(CC)-T2m (SEQ ID NO:136) and D10-GSL-hIgG1FcΔK(CC)-T2m (SEQ ID NO:137)—representatives of construct G in FIG. 2). FIGS. 10A and B show results from an A549/IL-11 release cell-based assay demonstrating that the addition of D10 at the N-terminus did not affect TGF-β neutralization potency. FIGS. 10C and D show images demonstrating significant enhancement of the accumulation of the D10-containing constructs in bones relative to a construct without D10.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and uses thereof. More specifically, the present invention relates to TGF-β superfamily receptor ectodomain fusion molecules and their use in TGF-β superfamily ligand neutralization.
  • The present invention provides polypeptide constructs, comprising
      • a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
      • a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
        wherein the N-terminus of the second portion (ectodomain) is linked to the C-terminus of the first portion (Fc region), and wherein the polypeptide construct neutralizes TGF-β with at least 100-fold more potency than the TβSR-ED alone. The polypeptide construct referred to herein is a synthetic polypeptide produced via protein engineering. It comprises two protein “portions” (or “parts”) that are linked to form the chimeric polypeptide construct. When the polypeptide construct is expressed, two polypeptide chains dimerize, such that the CH2 and CH3 domains form an antibody Fc region.
  • In specific embodiments of the present invention, descriptions of which are elaborated further herein, there are provided polypeptide constructs in which TGF-β superfamily receptor-ectodomains were fused to IgG Fc regions. Specifically, the T2m (single ectodomain) or T22d35 (double ectodomain) moieties were linked (fused) to the C-terminal end of the Fc region. It was observed that fusion constructs of this type have advantages relative to several other versions of receptor-ectodomain based molecules, including non-Fc fused monovalent or multivalent TGF-β receptor ectodomain constructs (such as T2m and T22d35) and constructs in which a receptor ectodomain is fused to the N-terminus of an Fc region. In particular, the constructs have improved manufacturability due to the presence of the Fc region (for example, purification can be accomplished using protein A chromatography). The Fc region also allows for improved circulating half-lives. Importantly, the present constructs have substantially higher TGF-β neutralization potencies compared to T2m and T22d35 alone or to constructs where a receptor ectodomain is fused to the N-terminus of an Fc region. Thus, an advantage of the present invention is unexpected high potency TGF-β superfamily ligand neutralization, including some degree of neutralization of TGF-β2, which was not observed for the non-Fc fused constructs T2m and T22d35. Finally, constructs in accordance with embodiments of the present invention, that is where the ectodomain(s) is/are fused to the C-terminus of an Fc region of an antibody, allows for preservation of the structure and function of the natural N-terminal regions/domains of an antibody; as such, antigen binding to the antibody CDR regions is not perturbed. This leads to the generation of a bifunctional construct able to interact with the target of the antibody while interacting with, and neutralizing, members of the TGF-β superfamily of ligands.
  • The invention relates not only to bifunctional constructs, but also to constructs that are monofunctional, and comprise an Fc region that consists only of the CH2 and/or CH3 regions of an antibody constant region. Preferably, the G1, G2 or G4 subclasses are used, and particularly G1 as well as G2. These constructs are monofunctional in the sense that the constant region itself has no particular activity, other than to act as a structure through which dimers of the polypeptide constructs can form. These minimal constant regions can also be altered to provide some benefit, by incorporating the corresponding hinge regions (SEQ ID NO:5-8) and optionally changing the cysteine residue composition. Thus, some or all of the cysteine residues involved in bridging the two Fc fragments or naturally used to bridge between the heavy and light chains of a full-length antibody can be replaced or deleted. These cysteine residues are seen in hinge sequences listed in SEQ ID NO:5-8. First, not all of the naturally-occurring inter-hinge disulfide bonds need to be formed for the Fc homodimerization to occur, while noting that the stability of the Fc homodimer may depend on the number of intermolecular disulphide bridges. Secondly and perhaps more importantly, the presence of hinge-region cysteine residues may become problematic when the Fc region lacks its N-terminal Fab fragment (i.e., is a headless Fc) as in the case of some polypeptide constructs of the present invention. This leads to untethering and exposure of these hinge-region cysteines, and in turn that may result in complex mixtures of high-order polymeric chains, which creates manufacturability issues in addition to potentially diminishing the intended biological activity and efficacy. Because it is practically impossible to predict the outcome of varying the number of inter-hinge disulphide bridges for the “headless” polypeptide constructs of the present invention, we generated a systematic array of N-terminal Fc variants for all four human IgG isotypes either by a deletion approach (in which hinge-region cysteine residues are progressively eliminated by N-terminal truncations) or by a mutagenesis approach (in which hinge-region cysteine residues are progressively mutated to serine from the N-terminus of the hinge region). Non-limiting examples of such N-terminal variants of headless Fc regions are listed in SEQ ID NO:9-34.
  • In the present disclosure, an “antibody”, also referred to in the art as “immunoglobulin” (Ig), refers to a protein constructed from paired heavy and light polypeptide chains; various Ig isotypes exist, including IgA, IgD, IgE, IgG, and IgM. The structure of an antibody and of each of the domains is well-established and familiar to those of skill in the art, though is summarized herein. When an antibody is correctly folded, each chain folds into a number of distinct globular domains joined by more linear polypeptide sequences; the immunoglobulin light chain folds into a variable (VL) and a constant (CL) domain, while the heavy chain folds into a variable (VH) and three constant (CH, CH2, CH3) domains. Once paired, interaction of the heavy and light chain variable domains (VH and VL) and first constant domain (CL and CH,) results in the formation of a Fab (Fragment, antigen-binding) containing the binding region (Fv); interaction of two heavy chains results in pairing of CH2 and CH3 domains, leading to the formation of a Fc (Fragment, crystallisable). Characteristics described herein for the CH2 and CH3 domains also apply to the Fc.
  • While the light and heavy chain variable regions show significant sequence diversity between antibodies, the constant regions show less sequence diversity and are responsible for binding a number of natural proteins to elicit important biochemical events. Specifically, and without wishing to be limiting, the Fc fragment binds to endogenous Fc receptors on the surface of lymphocytes.
  • The CH2 and CH3 domains of the first portion may be of any isotype, including one selected from the group consisting of IgA, IgD, IgE, and IgG. The CH2 and CH3 domains may also be from any suitable source. For example and without wishing to be limiting, the CH2 and CH3 domains may originate from a human, mouse and other rodents like rats and degu, rabbit, monkey, or other mammalian source. In one example, the CH2 and CH3 domains may be of the IgG isotype; in another example, the CH2 and CH3 domains are from human.
  • In a specific, non-limiting example, the CH2 and CH3 domains of the first portion may be of an isotype or comprise a sequence selected from the group consisting of:
      • a human IgG1, for example but not limited to SEQ ID NO:1 (APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK) as comprised in P01857 of the UniProtKB/Swiss-Prot database;
      • a human IgG2, for example but not limited to SEQ ID NO:2 (APPVAGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVQFNWYVDGVEVHNAK TKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK), as comprised in P01859 of the UniProtKB/Swiss-Prot database;
      • a human IgG3, for example but not limited to SEQ ID NO:3 (APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNA KTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDG SFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK), as comprised in P01860 of the UniProtKB/Swiss-Prot database;
      • a human IgG4, for example but not limited to SEQ ID NO:4 (APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK), as comprised in P01861 of the UniProtKB/Swiss-Prot database; and
      • a sequence substantially identical to any of the sequences listed above.
  • In the protein constructs of the present invention, the first portion may further comprise a sequence corresponding to the hinge region at the N-terminus of the CH2 domain. For example, the first portion may further comprise a sequence selected from the group consisting of:
  • EPKSCDKTHTCPPCP (SEQ ID NO: 5) for human IgG1;
    ERKCCVECPPCP (SEQ ID NO: 6) for human IgG2;
    ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPK
    SCDTPPPCPRCP (SEQ ID NO: 7) for human IgG3;
    ESKYGPPCPSCP (SEQ ID NO: 8) for human IgG4;
      • and a sequence substantially identical to any of the sequences listed above.
  • Thus, the first portion of the polypeptide construct of the present invention consists of naturally fused Fc and hinge regions for the various IgG isoforms and in embodiments is selected from the group consisting of SEQ ID NO:1-4 for the Fc region and SEQ ID NO:5-8 for the hinge region.
  • In specific embodiments, the first portion of the polypeptide construct of the present invention is selected from a group of sequences displaying variation in the N-terminal sequence as exemplified by SEQ ID NO:9-34. These differ in the number of cysteine residues retained from the hinge region as a means to modulating the degree of Fc-region dimerization and hence impacting on both efficacy and manufacturability. Thus, in embodiments, the polypeptide construct comprises a variation in the constant domain, wherein at least one cysteine residue involved in cross-linking is deleted or substituted. Suitable substitutions include serine or alanine, and preferably by serine. A substantially identical sequence may comprise one or more conservative amino acid mutations that still provide for proper folding upon secretion into the culturing medium. It is known in the art that one or more conservative amino acid mutations to a reference sequence may yield a mutant peptide with no substantial change in physiological, chemical, physico-chemical or functional properties compared to the reference sequence; in such a case, the reference and mutant sequences would be considered “substantially identical” polypeptides. A conservative amino acid substitution is defined herein as the substitution of an amino acid residue for another amino acid residue with similar chemical properties (e.g. size, charge, or polarity). These conservative amino acid mutations may be made to the framework regions while maintaining the overall structure of the constant domains; thus the function of the Fc is maintained.
  • In a non-limiting example, a conservative mutation may be an amino acid substitution. Such a conservative amino acid substitution may substitute a basic, neutral, hydrophobic, or acidic amino acid for another of the same group. By the term “basic amino acid” it is meant hydrophilic amino acids having a side chain pK value of greater than 7, which are typically positively charged at physiological pH. Basic amino acids include histidine (His or H), arginine (Arg or R), and lysine (Lys or K). By the term “neutral amino acid” (also “polar amino acid”), it is meant hydrophilic amino acids having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Polar amino acids include serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N), and glutamine (Gln or Q). The term “hydrophobic amino acid” (also “non-polar amino acid”) is meant to include amino acids exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of (Eisenberg et al, 1984). Hydrophobic amino acids include proline (Pro or P), isoleucine (Ile or I), phenylalanine (Phe or F), valine (Val or V), leucine (Leu or L), tryptophan (Trp or W), methionine (Met or M), alanine (Ala or A), and glycine (Gly or G). “Acidic amino acid” refers to hydrophilic amino acids having a side chain pK value of less than 7, which are typically negatively charged at physiological pH. Acidic amino acids include glutamate (Glu or E), and aspartate (Asp or D).
  • In another non-limiting example, a conservative mutation in the CH2 and/or CH3 domain may be a substitution that enhances a property selected from the group consisting of the stability, half-life, or Fc properties of CH2 and/or CH3 domains or alter glycosylation of the CH2 and/or CH3 domain. For example, and without wishing to be limiting in any manner, the mutation may be an alteration at position 228 (EU numbering, 241 according to Kabat) where the serine is substituted by a proline (S228P), which stabilizes the disulfide linkage within the Fc dimer. Another alteration is the mutation at position 409 (EU numbering, 440 according to Kabat) where an arginine is substituted to a lysine for further stabilization of the Fc homodimer at the CH3-domain level (Yang & Ambrogelly, 2014). Yet another alteration within the CH2 and/or CH3 domain may be a substitution of Asn297 (EU numbering, 314 according to Kabat) by glycine or alanine to alter glycosylation of the constant domain. In yet another example, the CH2 and/or CH3 domain may be altered by substitution of one or more threonine (T252L, T253S, and/or T256F; see [U.S. 62/777,375]) to increase half-life. Particularly useful are those alterations that enhance Fc properties while remaining silent with respect to conformation, e.g., retaining Fc receptor binding.
  • In yet another non-limiting example, the conservative mutations in the CH2 and/or CH3 domain may be a substitution that is naturally-occurring. Such mutations may occur in nature as minor sequence differences between species or race.
  • Sequence identity is used to evaluate the similarity of two sequences; it is determined by calculating the percent of residues that are the same when the two sequences are aligned for maximum correspondence between residue positions. Any known method may be used to calculate sequence identity; for example, computer software is available to calculate sequence identity. Without wishing to be limiting, sequence identity can be calculated by software such as NCBI BLAST2 service maintained by the Swiss Institute of Bioinformatics (and as found at ca.expasy.org/tools/blast/), or any other appropriate software that is known in the art.
  • The substantially identical sequences of the present invention may be at least 90% identical; in another example, the substantially identical sequences may have an identity selected from the group consisting of at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical, or any percentage there between, at the amino acid level to sequences described herein. Importantly, the substantially identical sequences retain the activity, specificity, and functionality of the reference sequence. In a non-limiting embodiment, the difference in sequence identity may be due to conservative amino acid mutation(s). In a non-limiting example, the first portion of the polypeptide construct of the present invention may comprise a Fc comprising a sequence selected from the group consisting of a sequence at least 95%, 98% or 99% identical to that of the Fc described herein.
  • Accordingly, it will be appreciated that the first portion of a construct will include at least an antibody region that preferably provides for cross-linking of the polypeptide constructs, thereby to provide a dimeric protein. This first portion comprises at least the minimal CH2 and/or CH3 domain. That portion can be altered (i) by substituting or deleting cysteine residues from the hinge regions (SEQ ID NO:5-8) involved in crosslinking between the antibody heavy chains or between the heavy and light chains in order to potentially improve preparation homogeneity and efficacy, and/or (ii) by deleting or suitably replacing (e.g., by mutation to alanine) the terminal lysine residue 447 (EU numbering, 478 according to Kabat) of an IgG heavy chain in order to improve chemical stability of C-terminal fusions to enzymatic proteolysis (e.g., by several serine proteases and typically by trypsin). These changes have a positive impact on potency and/or manufacturability, as revealed herein. The first portion can also be extended to become a full Fc region, by including the CH1 domain. As a full Fc, this portion will provide normal Fc effector functions that include involvement in immune cell recruitment, ADCC, CDC and other antibody functions. Moreover, and in embodiments of the present invention, the first portion can include a complete antibody or any equivalent thereof. In certain embodiments, such as when a construct comprises just one ectodomain that is a TGF-β receptor II ectodomain, there is the proviso that the second portion is not an antibody that binds to an immune checkpoint protein such as PD-L1 (programmed death ligand 1) and is not an antibody that binds to an immunomodulating agent that counteracts immune tolerance of cancer cells, the nature and identity of which is as described in [U.S. Pat. No. 8,815,247], and is not an antibody that binds one of EGFR1, her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, and CTLA-4.
  • The second portion of the polypeptide construct of the present invention comprises at least one and preferably two TGF-β superfamily receptor ectodomain/s (TβSR-ED); for example, the second portion may comprise one or two TβSR-ED. The ectodomain of the Transforming Growth Factor-I3 superfamily receptor (TβSR) is the N-terminal extracellular, ligand-binding portion of the receptor. Without wishing to be limiting in any manner, the TβSR ectodomain may bind a molecule selected from the group consisting of TGF-β, bone morphogenetic protein (BMP) including BMP2, BMP3, BMP4, BMPS, BMP, BMP6, BMP7, BMP8, BMP9, BMP10, BMP11, BMP12, BMP13, BMP14, an BMP15, activin including activins βA, βB and βC, growth differentiation factor (GDF-1) including GDF-3, GDF-β, GDF-9, and GDF-15, nodal, inhibin-α, anti-Mullerian hormone, Lefty-1, Lefty-2, arteman, persephin, neurturin, myostatin, or other known TGF-β superfamily ligands. For example, the TβR ectodomain may be selected from the group consisting of the human TGF-β receptor type II ectodomain (TIβR-II-ED), the human TGF-β receptor type IIb (TIβR-IIb) ectodomain, the human activin receptor type IIa (ActR-IIa) ectodomain, the human activin receptor type IIb (ActR-IIb) ectodomain, or the BMP type Ia (BMPR-Ia) ectodomain.
  • In a preferred embodiment the ectodomain binds TGF-β1 and/or TGF-β3. In another preferred embodiment, the ectodomain itself is a human TGF-β receptor type II ectodomain including particularly the TGF-β receptor type IIa (TβRIIa). In one specific, non-limiting example, the TβSR-ED is the TGF-β receptor type II ectodomain (TβRII-ED; SEQ ID NO:35).
  • In the second portion as described above, the TβSR ectodomain-based portion may further comprise natural linkers. Appropriate, naturally-derived linkers that can be used to fuse two ectodomains head-to-tail are known to those of skill in the art; for example, and without wishing to be limiting, suitable natural linkers are described in [WO2008/113185].
  • In this embodiment, the natural linker, if present, may be selected from the group consisting of
  • (SEQ ID NO: 36)
    IPPHVQKSVNNDMIVTDNNGAVKFP;
    (SEQ ID NO: 37)
    IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFP;
    (SEQ ID NO: 39)
    SEEYNTSNPD;
    (SEQ ID NO: 40)
    SEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFP;
    (SEQ ID NO: 41)
    SEEYNTSNPDIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVT
    DNNGAVKFP;
    and
    a combination thereof.
  • In a specific, non-limiting example, the second portion of the polypeptide construct of the present invention may comprise the sequence selected from the group consisting of:
      • A single TGF-β Type II receptor ectodomain, such as:
  • (SEQ ID NO: 43, also referred to herein as T2m)
    IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD;
    (SEQ ID NO: 44)
    IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQ
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE
    EYNTSNPD;
      • A TGF-β Type II receptor ectodomain “doublet”, in which a TGF-β Type II receptor ectodomain is linked with another TGF-β Type II receptor ectodomain, which ectodomains can be the same or different TGF-β superfamily receptor ectodomains, such as:
  • (SEQ ID NO: 46, also referred to herein as T22d35)
    IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD;
    (SEQ ID NO: 47)
    IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQ
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE
    EYNTSNPDIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDN
    NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND
    ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
    NDNIIFSEEYNTSNPD;

    and
      • a sequence substantially identical thereto. “Substantially identical” is as defined above.
  • In another specific, non-limiting example, the TGF-β receptor ectodomain is the bone morphogenetic protein receptor la (BMPRIa; SEQ ID NO:69). In this embodiment, the natural linker, if present, may be selected from the group consisting of
  • (SEQ ID NO: 70)
    QNLDSMLHGTGMKSDSDQKKSENGVTLAPED;
    (SEQ ID NO: 71)
    PVVIGPFFDGSIR;
    (SEQ ID NO: 72)
    PVVIGPFFDGSIRQNLDSMLHGTGMKSDSDQKKSENGVTLAPED;

    and
      • a combination thereof.
  • Thus, in a specific, non-limiting example, the second portion of the polypeptide construct of the present invention may comprise the sequence selected from the group consisting of:
  • (SEQ ID NO: 74)
    QNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTLPFLKCYCSGHCPDDAINN
    TCITNGHCFAIIEEDDQGETTLASGCMKYEGSDFQCKDSPKAQLRRTIECC
    RTNLCNQYLQPTLPPVVIGPFFDGSIRQNLDSMLHGTGMKSDSDQKKSENG
    VTLAPEDTLPFLKCYCSGHCPDDAINNTCITNGHCFAIIEEDDQGETTLAS
    GCMKYEGSDFQCKDSPKAQLRRTIECCRTNLCNQYLQPTLPPVVIGPFFDG
    SIR;

    and
      • a sequence substantially identical thereto. “Substantially identical” is as defined above.
  • In another specific, non-limiting example, the T6SR ectodomain is the activin receptor IIa (ActRIIA; SEQ ID NO:75). In this embodiment, the natural linker, if present, may be selected from the group consisting of
  • (SEQ ID NO: 76)
    AILGRSE;
    (SEQ ID NO: 77)
    EMEVTQPTSNPVTPKPPYYNI;
    (SEQ ID NO: 78)
    EMEVTQPTSNPVTPKPPYYNIAILGRSE;

    and
      • a combination thereof.
  • Thus, another specific non-limiting example of the second portion of the polypeptide construct of the present invention comprises the sequence selected from the group consisting of:
  • (SEQ ID NO: 80)
    AILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGS
    IEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEME
    VTQPTSNPVTPKPPYYNIAILGRSETQECLFFNANWEKDRTNQTGVEPCYG
    DKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFC
    CCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNI;

    and
      • a sequence substantially identical thereto. “Substantially identical” is as defined above.
  • In another specific, non-limiting example, the TGF-β receptor ectodomain is the activin receptor IIb (ActRIIb; SEQ ID NO:81). In this embodiment, the natural linker, if present, may be selected from the group consisting of
  • (SEQ ID NO: 82)
    SGRGEAET;
    (SEQ ID NO: 83)
    EAGGPEVTYEPPPTAPT;
    (SEQ ID NO: 84)
    EAGGPEVTYEPPPTAPTSGRGEAET;

    and
      • a combination thereof.
  • Thus, another specific non-limiting example of the second portion of the polypeptide construct of the present invention comprises the sequence selected from the group consisting of:
  • (SEQ ID NO: 86)
    SGRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGT
    IELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAG
    GPEVTYEPPPTAPTSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDK
    RLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEG
    NFCNERFTHLPEAGGPEVTYEPPPTAPT;

    and
      • a sequence substantially identical thereto. “Substantially identical” is as defined above.
  • Thus, in various embodiments of the present invention, the present constructs have an ectodomain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto. In other embodiments, the second portion comprises the entire extracellular portion of a TβSR-ED consisting of a sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:73, SEQ ID NO:79, SEQ ID NO:85, and a sequence substantially identical thereto.
  • The at least two ectodomain portion can have the same or different ectodomains, all belonging to the superfamily. In embodiments, the ectodomains bind the same target. In other embodiments, the ectodomains originate from the same receptor species. In other embodiments, the ectodomains are identical and thus are homomeric. In other embodiments the ectodomains are different and thus are heteromeric. In these embodiments, the ectodomain can be for instance a TβRII-ED that is type a, and another ectodomain can be a TβRII-ED that is type b. A third ectodomain could be the same as either one of these, or different still. For example, when there is more than one ectodomain in the second portion of the polypeptide construct of the present invention, the ectodomains may be all the same (homomers) or all different (heteromers), or any combination of superfamily ectodomains.
  • Thus, in embodiments, the second portion of the polypeptide construct of the present invention comprises a repeat of a given TβSR-ED selected from the group consisting of SEQ ID NO:46, 47, 48, 74, 80, 86, and a sequence substantially identical thereto.
  • In specific embodiments, the second portion of the polypeptide construct of the present invention comprises heteromeric repeats of two distinct TβSR-EDs genetically fused and selected from the group consisting of SEQ ID NO:61, 62, 63, 88, and a sequence substantially identical thereto.
  • In yet other embodiments, the second portion of the polypeptide construct of the present invention comprises homo-multimeric and hetero-multimeric repeats of one or more TβSR-EDs selected for instance from the group consisting of SEQ ID NO:49, 50, 51, 64, 65, 66, 67, 68, and a sequence substantially identical thereto.
  • In the protein construct of the present invention, the first and second portions of the polypeptide construct of the present invention are linked. By the term “linked”, it is meant that the two portions are covalently bonded. The chemical bond may be achieved by chemical reaction, or may be the product of recombinant expression of the two portions in a single polypeptide chain. In one specific, non-limiting example, the C-terminus of the first portion is linked directly to the N-terminus of the second portion, that is, no additional “linker” amino acids are present between the two portions. In the case where no linker is present, that is to say direct fusion of the two portions, there will be a direct link between the N-terminus of the full ectodomain and the C-terminus of the antibody constant regions CH2-CH3. For example, in fusing the Fc variant SEQ ID NO:9 to the SEQ ID NO:43 via the intrinsically disordered linker with SEQ ID NO:36, which is part of the TβRII-ED (i.e., no additional “linker” amino acids added), one connects the glycine at the last position of SEQ ID NO:9 to the isoleucine at the first position of SEQ ID NO:43.
  • A common practice when producing fusion constructs is to introduce glycine or glycine-serine linkers (such as GGGGS, or [G4S]n) between the fused components. As taught in the above paragraph, the polypeptide fusions of the present invention can be produced by direct linkage without use of any additional amino-acid sequence except those present in the Fc portion and in the receptor ectodomain portion. One thus can refrain from utilizing foreign sequences as linkers, providing an advantage due to their potential for undesired immunogenicity and their added molecular weight. Entropic factors are also a potential liability for glycine and glycine-serine linkers, which are highly flexible and may become partially restricted upon target binding, hence causing a loss of entropy unfavourable to binding affinity. Therefore, only the flexible, intrinsically disordered N-terminal regions of the TβSR receptor ectodomains were employed as natural linkers in embodiments of the present invention. However, the particular amino acid compositions and lengths of these intrinsically disordered linkers (e.g., SEQ ID NO:36, 37, 70, 76, 82) precluded accurate prediction of whether the resulting direct-fusion constructs will have the required geometry and favourable molecular interactions for correct binding to their intended dimeric ligands.
  • The first and second portions of the polypeptide construct are, in embodiments, connected by natural intrinsically disordered polypeptide linkers selected from the group consisting of SEQ ID NO:36, 37, 38, 53, 70, 76, 82, and a sequence substantially identical thereto.
  • In embodiments, when multiple TβSR-ED structured regions are present, these can be fused directly or they can be connected by natural intrinsically disordered polypeptide linkers between the ectodomains, such as SEQ ID NO:40, 41, 42, 55, 58, 59, 60, 72, 78, 84, 87, and a sequence substantially identical thereto.
  • Non-limiting examples of full-length polypeptide constructs of the present invention that comprise the two aforementioned portions are selected from the group consisting of SEQ ID NO: 91-120, and a sequence substantially identical thereto.
  • It is particularly important to note that, in the polypeptide constructs of the present invention, the N-terminus of the second portion is linked to the C-terminus of the first portion (see for example FIGS. 2A, C, D, E, F, and G).
  • Some of the polypeptide constructs of the present invention display significantly greater potency of TGF-β neutralization compared to that of the TGF-β superfamily receptor ectodomain alone; for example, the polypeptide construct may be between at least 50-fold and 1×106-fold more potent. For example, the polypeptide constructs of the present invention may have a TGF-β neutralization potency selected from the group consisting of at least 50-, 75-, 100-, 150-, 200-300-, 400-, 500-, 600, 1000-1500-, 2000-, 3000-, 4000-, 5000-, 6000-, 7000-, 8000-, 9000, 10000-, 20000-, 30000-, 40000-, 50000-, 60000-, 70000-, 80000-, 90000-, 100000-, 150000-, 200000-, 250000-, 300000-, 350000-, 400000-, 450000-, 500000-, 550000-600000-, 650000-, 700000-, 750000-, 800000-, 850000-, 900000-, 950000, or 1000000-fold, more potent than the TβSR-ED alone, or any amount there between. In one example, the potency of the construct is at least 100-fold greater than the receptor ectodomain alone.
  • Additionally, when the polypeptide constructs of the present invention include a TβSR-ED that binds TGF-β, the polypeptide construct may neutralize, to varying extents, all three isotypes of TGF-β (that is, TGF-β1, TGF-β2, and TGF-β)
  • The polypeptide constructs of the present invention have, as assessed in cell-based assays, TGF-β neutralizing potencies that are significantly higher (100-fold or more) than those of bivalent comparator polypeptides, i.e. non-Fc-fused T22d35 and T2m-Fc. Within the series of polypeptide constructs of the present invention, those that contain two or more copies of the TβRII ectodomain fused to the C-terminus of the Fc constant region have potencies that are higher than those constructs that contain only one copy, as assessed in cell based assays. Additionally, within the series of polypeptide constructs of the present invention, if the first portion within the construct is “headless”, i.e. does not contain a Fab region, the potencies of the constructs are increased by engineering (optimizing) the number of cysteines in the hinge region at the “revealed” N-terminus. Engineering of the cysteine residues at the N-termini of “headless” constructs also markedly reduces the aggregation propensity of the constructs. Lastly, within the series of polypeptide constructs of the present invention, in vivo in tumor models, cysteine optimized “headless” constructs exhibit higher anti-tumor immuno-modulatory potencies than constructs in which the first portion is a full-sized antibody.
  • The polypeptide construct of the present invention is expressed as a single polypeptide chain. Once expressed, the polypeptide construct of the present invention forms a dimer wherein the CH2 and CH3 domains of the respective polypeptide constructs interact to form a properly assembled Fc region such as occurs when the expressed products are secreted into the culturing medium. For example, and without wishing to be limiting, examples of dimerized polypeptide constructs of the present invention are shown in FIGS. 2A and C-G. In one example, homodimers may be formed by identical polypeptide constructs. Alternatively, heterodimers may be formed by two different polypeptide constructs; thus, a heterodimer may be formed by two Fc region polypeptide constructs that have been engineered to induce heterodimerization and inhibit homodimerization.
  • The first portion of the polypeptide construct described above may further comprise, at its N-terminus, any suitable antigen-binding antibody fragment known in the art. For example, and without wishing to be limiting in any manner, the first portion of the polypeptide construct may comprise CH2 and CH3 domains and one selected from the group consisting of a single-chain Fv (scFv; a molecule consisting of VL and VH connected with a peptide linker) and a single-domain antibody (sdAb, a fragment composed of a single VL or a single VH; see for example FIG. 1C). In other instances, the antigen-binding fragment may be formed by combining the polypeptide construct with a second polypeptide chain. For example, the first portion of the polypeptide construct may comprise CH2 and CH3 domains along with a CH1 and VH domains, which when combined with a second polypeptide comprising CL and VL form a full-size antibody (i.e., Fc and Fab; see for example FIG. 1D). In another example, the first portion of the polypeptide may comprise CH2 and CH3 domains along with VH, which when combined with a second polypeptide comprising a VL forms an Fc fused to a Fv.
  • The combination of constant domains and antigen-binding fragment may be naturally-occurring, or may be obtained by manipulation of a naturally-occurring antibody or by using recombinant methods. The polypeptide constructs such as those just described may require a sequence selected from the group consisting of linker sequences, disulfide bonds, hinge region sequences, and other type of covalent bond to link them to the CH2 and CH3 domains; those of skill in the art will be familiar with various suitable approaches.
  • In alternative constructs of the present invention, the polypeptide construct comprises an antibody Fc fragment linked at the C-terminus of each heavy chain to at least one TGF-β superfamily receptor ectodomain (TβSR-ED), as described above and as illustrated in FIG. 2(A,D,E). The construct may further comprise an antigen-binding fragment at the N-terminus of the Fc; the antigen-binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb, also as described above. In the polypeptide constructs as described above, the TGF-β receptor ectodomain does not interfere in the native function or specificity of the antigen-binding fragment.
  • The antigen-binding antibody fragment described above, when present, may be directed to any suitable antigen. In certain limited embodiments, the antigen-binding antibody or fragment does not bind to an antigen that is PD-L1, EGFR1, her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
  • The present constructs can further comprise antibody or antibody fragments that target any antigen of interest. They can also comprise the antigen itself, or any other moiety of interest that is genetically encoded. Particular embodiments herein include the EGFR antibody cetuximab and its active fragments, Avastin, Herceptin, Synagis, FC5, or a poly-aspartate bone-localization motif, such a D10, or sequence substantially identical or equivalent thereto.
  • The present constructs can comprise a binding protein e.g., antibody and binding fragments thereof, that inhibits a checkpoint protein which may be CTLA-4, PD1, PDL1, PDL2, PDL3, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, CD28, CD86, or one of the B-7 family ligands or a combination thereof.
  • Illustrative immune checkpoint inhibitors include Tremelimumab (CTLA-4 blocking antibody), anti-OX40, PD-LI monoclonal Antibody (Anti-B7-HI; MED14736), MK-3475 (PD-1 blocker), Nivolumab (anti-PDI antibody), CT-011 (anti-PDI antibody), BY55 monoclonal antibody, AMP224 (anti-PDLI antibody), BMS-936559 (anti-PDLI antibody), MPLDL3280A (anti-PDLI antibody), MSB0010718C (anti-PDLI antibody) and Yervoy/ipilimumab (anti-CTLA-4 checkpoint inhibitor).
  • Other antibodies provided by the present constructs can include rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, EGFR-binding antibodies cetuximab, nimotuzumab, necitumumab, panitumumab, matuzumab, and zalutumumab, as well as ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab, eculizumab, pexelizumab, abciximab, ranibizimumab, mepolizumab, TNX-355, or MYO-029.
  • Still other antibodies that can be included in the present constructs are rituximab, zanolimumab, hA20, AME-133, HumaLYM, trastuzumab, pertuzumab, IMC-3G3, ch806, KSB-102, MR1-1, SC100, SC101, SC103, alemtuzumab, muromonab-CD3, OKT4A, ibritumomab, gemtuzumab, alefacept, abciximab, basiliximab, palivizumab, motavizumab, infliximab, adalimumab, CDP-571, etanercept, ABX-CBL, ABX-IL8, ABX-MA1 pemtumomab, Therex, AS1405, natalizumab, HuBC-1, natalizumab, IDEC-131, VLA-1; CAT-152; J695, CAT-192, CAT-213, BR3-Fc, LymphoStat-B, TRAIL-R1mAb, bevacizumab, ranibizumab, omalizumab, efalizumab, MLN-02, zanolimumab, HuMax-IL 15, HuMax-Inflam, HuMax-Cancer, HuMax-Lymphoma, HuMax-TAC, clenoliximab, lumiliximab, BEC2, IMC-1C11, DC101, labetuzumab, arcitumomab, epratuzumab, tacatuzumab, MyelomaCide, LkoCide, ProstaCide, ipilimumab, MDX-060, MDX-070, MDX-018, MDX-1106, MDX-1103, MDX-1333, MDX-214, MDX-1100, MDX-CD4, MDX-1388, MDX-066, MDX-1307, HGS-TR2J, FG-3019, BMS-66513, SGN-30, SGN-40, tocilizumab, CS-1008, IDM-1, golimumab, CNTO 1275, CNTO 95, CNTO 328, mepolizumab, MOR101, MOR102, MOR201, visilizumab, HuZAF, volocixmab, ING-1, MLN2201, daclizumab, HCD122, CDP860, PRO542, C14, oregovomab, edrecolomab, etaracizumab, siplizumab, lintuzumab, Hu1D10, Lym-1, efalizumab, ICM3, galiximab, eculizumab, pexelizumab, LDP-01, huA33, WX-G250, sibrotuzumab, Chimeric KW-2871, hu3S193, huLK26; bivatuzumab, ch14.18, 3F8, BC8, huHMFG1, MORAb-003, MORAb-004, MORAb-009, denosumab, PRO-140, 1D09C3, huMikbeta-1, NI-0401, NI-501, cantuzumab, HuN901, 8H9, chTNT-1/B, bavituximab, huJ591, HeFi-1, Pentacea, abagovomab, tositumomab, 105AD7, GMA161 and GMA321.
  • In other embodiments, the constant domain/first portion of the constructs can comprise a polypeptide having medicinal properties, such as agents that stimulate the immune system, in particular in relation to the ability of the immune system to attack tumor cells. These polypeptides can include cytokines (such as interleukin-2) or growth factors that stimulate immune cells directly or indirectly (i.e. act by providing gas to the immune system), as well as ectodomains or other binding agents that neutralize ligands which inhibit immune cells, either directly or indirectly (i.e. act by releasing a brake on the immune system).
  • In other embodiments, the constant domain/first portion of the constructs can comprise a polypeptide that does not have active medicinal properties per se, but rather provides a localization signal. This localization motif will serve to focus the intrinsic TGF-β neutralization activity of the second portion of the construct to a particular region of the body. In one example, the first portion comprised a long poly-aspartate bone-localization motif, preferably D10 or an equivalent bone-localization moiety, which acts to enhance localisation of the construct to bone. By increasing the TGF-β neutralization activity of the construct within bone, more favourable dosing levels and schedules may be required for the treatment of bone-related diseases, such as osteogenesis imperfecta, relative to that required for a similar construct without the D10 motif.
  • Embodiments exemplifying polypeptide constructs of the present invention that include antigen-binding fragments at the N-terminus of the Fc region (first portion) are selected from the group consisting of SEQ ID NO: 121-131, and a sequence substantially identical thereto.
  • In other embodiments, polypeptide constructs of the present invention that include other targeting agents, e.g., a poly-aspartate bone-localization motif, at the N-terminus of the Fc region (first portion), are exemplified by SEQ ID NO: 136-150.
  • The polypeptide construct of the present invention may also comprise additional sequences to aid in expression, detection or purification of a recombinant antibody or fragment thereof. Any such sequences or tags known to those of skill in the art may be used. For example, and without wishing to be limiting, the antibody or fragment thereof may comprise a targeting or signal sequence (for example, but not limited to ompA), a detection/purification tag (for example, but not limited to c-Myc, Hiss, His6, or His8G), or a combination thereof. In another example, the signal peptide may be MVLQTQVFISLLLWISGAYG (SEQ ID NO:89) or MDVVTWRILFLVAAATGTHA (SEQ ID NO:90). In a further example, the additional sequence may be a biotin recognition site such as that described in [WO/1995/04069] or in [WO/2004/076670]. As is also known to those of skill in the art, linker sequences may be used in conjunction with the additional sequences or tags, or may serve as a detection/purification tag.
  • The present invention also encompasses nucleic acid sequences encoding the molecules as described herein. Given the degeneracy of the genetic code, a number of nucleotide sequences would have the effect of encoding the desired polypeptide, as would be readily understood by a skilled artisan. The nucleic acid sequence may be codon-optimized for expression in various micro-organisms. The present invention also encompasses vectors comprising the nucleic acids as just described, wherein the vectors typically comprise a promoter and signal sequence that are operably linked to the construct-encoding polynucleotide for driving expression thereof in the selected cellular production host. The vectors can be the same or different provided both result in secretion of the dimeric polypeptide construct.
  • Furthermore, the invention encompasses cells, also referred to herein as transgenic cellular host, comprising the nucleic acid and/or vector as described, encoding a first polypeptide construct. The host cells may comprise a second nucleic acid and/or vector encoding a second polypeptide construct different from the first polypeptide construct. The co-expression of the first and second polypeptide constructs may lead to the formation of heterodimers.
  • The present invention also encompasses a composition comprising one or more than one polypeptide construct as described herein. The composition may comprise a single polypeptide construct as described above, or may be a mixture of polypeptide constructs. The composition may also comprise one or more than one polypeptide construct of the present invention linked to one or more than one cargo molecule. For example, and without wishing to be limiting in any manner, the composition may comprise one or more than one polypeptide construct of the present invention linked to a cytotoxic drug in order to generate an antibody-drug conjugate (ADC) in accordance with the present invention.
  • The composition may also comprise a pharmaceutically acceptable diluent, excipient, or carrier. The diluent, excipient, or carrier may be any suitable diluent, excipient, or carrier known in the art, and must be compatible with other ingredients in the composition, with the method of delivery of the composition, and is not deleterious to the recipient of the composition. The composition may be in any suitable form; for example, the composition may be provided in suspension form, powder form (for example, but limited to lyophilised or encapsulated), capsule or tablet form. For example, and without wishing to be limiting, when the composition is provided in suspension form, the carrier may comprise water, saline, a suitable buffer, or additives to improve solubility and/or stability; reconstitution to produce the suspension is effected in a buffer at a suitable pH to ensure the viability of the antibody or fragment thereof. Dry powders may also include additives to improve stability and/or carriers to increase bulk/volume; for example, and without wishing to be limiting, the dry powder composition may comprise sucrose or trehalose. In a specific, non-limiting example, the composition may be so formulated as to deliver the antibody or fragment thereof to the gastrointestinal tract of the subject. Thus, the composition may comprise encapsulation, time-release, or other suitable technologies for delivery of the antibody or fragment thereof. It would be within the competency of a person of skill in the art to prepare suitable compositions comprising the present compounds.
  • The constructs of the present invention may be used to treat diseases or disorders associated with over-expression or over-activation of ligands of the TGF-β superfamily. The disease or disorder can be selected from, but not limited to, cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.
  • In the field of cancer therapy, it has recently been demonstrated that TGF-β is a key factor inhibiting the antitumor response elicited by immunotherapies, such as immune checkpoint inhibitors (ICI's) (Hahn & Akporiaye, 2006). Specifically, therapeutic response to ICI antibodies results primarily from the re-activation of tumor-localized T-cells. Resistance to ICI antibodies is attributed to the presence of immunosuppressive mechanisms that result in a dearth of T-cells in the tumor microenvironment. Thus, it is now recognized that in order to elicit responses in resistant patients, ICI antibodies need to be combined with agents that can activate T-cells and induce their recruitment into the tumor, i.e. reversing of the “non-T-cell-inflamed” tumor phenotype. One publication noted that overcoming the non-T-cell-inflamed tumor microenvironment is the most significant next hurdle in immuno-oncology (Gajewski, 2015).
  • We have shown using a proof-of-principle TGF-β trap, T22d35, that blocking of TGF-β effectively reverses the “non-T cell inflamed” tumor phenotype (Zwaagstra et al, 2012). This positions anti-TGF-β molecules as potential synergistic combinations with ICI's and other immunotherapeutics. In support of this, a 2014 study (Holtzhausen et al., ASCO poster presentation) examined effects of a TGF-β blocker when combined an anti-CTLA-4 antibody in a physiologically-relevant transgenic melanoma model. The study demonstrated that while anti-CTLA-4 antibody monotherapy failed to suppress melanoma progression, the combination of the TGF-β antagonist and anti-CTLA-4 antibody significantly and synergistically suppressed both primary melanoma tumor growth as well as melanoma metastasis. These observations correlated with significant increases in effector T-cells in melanoma tissues.
  • Fibrotic diseases include those that affect any organ of the body, including, but not limited to kidney, lung, liver, heart, skin and eye. These diseases include, but are not limited to, chronic obstructive pulmonary disease (COPD), glomerulonephritis, liver fibrosis, post-infarction cardiac fibrosis, restenosis, systemic sclerosis, ocular surgery-induced fibrosis, and scarring.
  • Genetic disorders of connective tissue include, but are not limited to, Marfan syndrome (MFS) and Osteogenesis imperfecta (01).
  • The present invention will be further illustrated in the following examples. However, it is to be understood that these examples are for illustrative purposes only and should not be used to limit the scope of the present invention in any manner.
    • EXAMPLE 1 Production and Purification of Fusion Molecules
  • Several fusion molecules comprising full-size antibody (FSA), VHH-IgG Fc, D10-Fc or “headless” Fc C-terminally-fused to the T22d35 or T2m ectodomains were constructed (Table 1). All constructs comprising a heavy chain included the signal sequence MDVVTWRILFLVAAATGTHA (SEQ ID NO:89) at the N-terminus, while constructs comprising a light chain included the signal sequence MVLQTQVFISLLLWISGAYG (SEQ ID NO:90) at the N-terminus. The DNA coding for constructs were prepared synthetically (Biobasic Inc. or Genescript USA Inc.). Constructs comprising FSA, D10-Fc and “headless” Fc were cloned into the EcoR1 (5′ end) and BamH1 (3′ end) sites and those comprising VHH-IgG Fc were cloned into the HindIII (5′ end) and BamH1 (3′ end) sites of the pTT5 mammalian expression plasmid vector (Durocher et al, 2002).
  • TABLE 1
    FSA-, VHH-IgG Fc-, D10-Fc- and Fc-fusion constructs produced.
    The letter in brackets in the construct column refers
    to the type of construct as illustrated in FIG. 2.
    Fusion Antibody Construct
    Construct ED Scaffold source SEQ ID NO:
    Cet-T2m (F) T2m FSA (hIgG1) Cetuximab 121, 123
    Cet-T22d35 (D) T22d35 FSA (hIgG1) Cetuximab 121, 122
    Her-T22d35 (D) T22d35 FSA (hIgG1) Herceptin 124, 125
    Ava-T22d35 (D) T22d35 FSA (hIgG1) Avastin 126, 127
    Syn-T22d35 (D) T22d35 FSA (hIgG1) Synagis 128, 129
    FC5-Fc-T22d35 (E) T22d35 VHH-Fc FC5-Fc 130
    (mIgG2)
    FC5-Fc-T2m (G) T2m VHH-Fc FC5-Fc 131
    (mIgG2)
    D10-Fc-T2m (G) T2m Fc huIgG 136-139
    (several variants with
    differing D10 linkage
    and IgG isotype)
    Fc-T22d35 (A) T22d35 Fc huIgG 100, 105
    (several variants with
    differing N-termini
    and IgG isotype)
    Fc-T2m (C) T2m Fc huIgG 91-97
    (several variants with
    differing N-termini
    and IgG isotype)
    T2m-Fc (R&D) (B) T2m Fc huIgG1 132
    T2m-Fc (B) T2m Fc huIgG2 133
  • The Cet-T2m and Cet-T22d35 constructs were produced by transient co-transfection of Chinese Hamster Ovary (CHO) cells with the heavy chain (HC)-T2m or (HC)-T22d35 construct combined with the Cetuximab light chain (LC) construct which then assembled as the Cetuximab-T22d35 (Cet-T22d35) or Cetuximab-T2m (Cet-T2m) fusion molecules. Briefly, CetHC-T22d35 (SEQ ID NO:122) and CetLC (SEQ ID NO:121) plasmid DNAs (ratio=3:2) were co-transfected into a 10 L Wavebag culture of CHO-3E7 cells in FreeStyle F17 medium (Invitrogen) containing 4 mM glutamine and 0.1% Kolliphor p-188 (Sigma) in a Wavebag maintained at 37° C. Transfection conditions were: DNA (50% HC+LC plasmids, 30% ssDNA, 15% AKT plasmid, 5% GFP plasmid): PEI(polyethylenimine)pro (Polyplus) (ratio=1:2.5). At 24 hours post-transfection, 10% Tryptone N1feed (TekniScience Inc.) and 0.5 mM Vaporic acid (VPA, Sigma) were added and the temperature was shifted to 32° C. to promote the production and secretion of the fusion proteins and maintained for 15 days post transfection after which the cells were harvested. At final harvest the cell viability was 89.6%. The harvest supernatant (10.8 L) was filtered (0.2 μm) and loaded onto a 55 mL Protein A MabSelect Sure 55 mL column (GE Healthcare). The column was washed with 2 column volumes of PBS and protein was eluted with 3 column volumes of 0.1 M sodium citrate pH 3.6. To maximize the yield, the flow through was reloaded onto the Protein A column and eluted as described above. Eluted fractions were neutralized with 1 M Tris, evaluated by SDS-PAGE and those containing Cet-T22d35 were pooled (FIG. 3A) and subsequently loaded onto a Hi-load Superdex S200 26/60 size exclusion chromatography (SEC) column (GE Healthcare) equilibrated in formulation buffer (DPBS without Ca2+, without Mg2+). Protein was eluted using 1 column volume formulation buffer, collected into successive fractions and detected by UV absorbance at 280 nM (FIG. 3B). The main peak SEC fractions containing Cet-T22d35 protein were then pooled and concentrated to a concentration of 7.8 mg/mL. The final yield was 533 mg.
  • Similar transfection, production and purification methods were performed for the other FSA-trap examples listed in Table 1. In the case of the VHH-Fc IgG-, D10 and “headless” Fc-fusion molecules the composition of the transfection mixture was modified as follows: DNA (80% plasmid construct, 15% AKT plasmid, 5% GFP plasmid): PElpro (ratio 1:2.5).
  • The integrity of the pooled Prot-A and SEC fractions of Cet-T22d35 protein was analyzed by SDS-PAGE (4-15% polyacrylamide) under reducing and non-reducing conditions (FIG. 3C) and by UPLC-SEC (FIG. 3D). For UPLC-SEC, 2-10 μg of protein in DPBS (Hyclone, minus Ca2+, minus Mg2+) was injected onto a Waters BEH200 SEC column (1.7 μm, 4.6×150 mm, SN:01773430816818) and resolved under a flow rate of 0.4 mL/min for 8.5 min at room temperature, using the Waters Acquity UPLC H-Class Bio-System. Protein peaks were detected at 280 nM (Acquity PDA detector). Coomassie brilliant blue (CBB) staining of the gels shows the CetHC-T22d35 (˜110 Kd) and CetLC bands (-30 Kd) under reducing conditions while under non-reducing conditions a 250 Kd band is detected which represents the fully assembled and highly pure Cet-T22d35 fusion protein. Additional UPLC-SEC analysis of the SEC purified, pooled ProtA sample confirmed the high degree of purity (99.42%) of the Cet-T22d35 protein and the absence of aggregates. Together, these results demonstrate the manufacturability of the Cet-T22d35 fusion protein.
  • Similar methods were used to analyse expression levels, purifiability, aggregation levels, and dimeric assembly of several other Fc-ectodomain constructs. The results from these studies are shown in FIG. 3E to L.
  • FIG. 3E to 3H show the results from the analysis of the hIgG1FcΔK(C)-T2m construct (an example of Type C construct from FIG. 2). FIG. 3E shows the (ProtA)-affinity column elution profile. Fraction 12-15 were pooled, subjected to a UPLC-SEC evaluation (FIG. 3F), further SEC purified to remove aggregates and re-evaluated by UPLC-SEC (FIG. 3G). This confirmed the high degree of purity of the hIgG1FcΔK(C)-T2m construct and the absence of aggregates. SDS-PAGE (FIG. 3H) under non-reducing (NR) and reducing (R) conditions shows bands of expected molecular weights, demonstrating the expected assembly of hIgG1FcΔK(C)-T2m as a disulphide linked dimer.
  • FIGS. 3I and 3J compare the level of aggregation of two “headless” Fc-T2m constructs (examples of Type C in FIG. 2). The Fc-T2m construct is an IgG2-based construct without engineering of the hinge region, thus it contains four cysteine residues, whereas the hIgG2FcΔK(CC)-T2m has been engineered by N-terminal truncation of the hinge region to have only two cysteines in the hinge region. It can be seen that the Fc-T2m construct contains a high level of aggregates after Protein A purification, with a doublet peak remaining even after further SEC purification. In contrast, hIgG2FcΔK(CC)-T2m, which has an engineered N-terminus, exhibited low levels of aggregates after only Protein A purification. These results demonstrate the advantage of carrying out N-terminal engineering of headless Fc-T2m constructs to reduce aggregation.
  • FIGS. 3K and 3L compare the level of aggregation of two “headless” Fc-T22d35 constructs (examples of Type A in FIG. 2). The Fc-T22d35 construct is without engineering of the hinge-region cysteine residues whereas the hIgG1FcΔK(C)-T22d35 construct has been engineered by N-terminal truncation of the hinge to have only one cysteine in the hinge region. It can be seen that, similarly to Fc-T2m, the Fc-T22d35 construct contains a high level of aggregates after Protein A purification, with a doublet peak remaining as detected by UPLC-SEC even after further SEC purification. In contrast, hIgG1FcΔK(C)-T22d35, which has an engineered N-terminus, exhibited lower levels of aggregates after Protein A purification. Further SEC purification yielded a singlet peak as detected by UPLC-SEC, confirming the absence of aggregates. These results demonstrate the advantage of carrying out N-terminal engineering of headless Fc-T22d35 constructs to reduce aggregation.
    • EXAMPLE 2 Neutralization and Binding of TGF43 by Fusion Constructs
  • The TGF-β neutralization potencies of purified Fc-ectodomain fusion constructs were determined and compared to those of non-Fc-fused T22d35. It should be noted that non-Fc-fused T2m does not neutralize any of TGF-β1, -β2, or -β3 (De Crescenzo et al, 2001).
  • TGF-β neutralization potencies for TGF-β1, -β2 and -β3 were determined for purified fusion constructs using two cell-based signaling assays: 1) the Mv1Lu cell luciferase reporter assay with Mv1Lu cells having a PAI-1-luciferase reporter (as described in (Zwaagstra et al, 2012)) and an A549 cell/IL-11 release assay adapted to the MSD (Meso Scale Discovery) platform.
  • Mv1Lu cell luciferase reporter assay: Briefly, cells were seeded onto 96-well plates (20,000 cells/well) and then treated with T2m, T22d35, or a fusion construct+25 pM TGF-β at 37° C. for 16 h in DMEM, 1% FBS, 0.1% BSA. Cells were then lysed and luciferase activity was measured (Promega Corp.) using a Synergy 2 plate reader (BioTek Instruments Inc.).
  • A549 cell IL-11 release assay: Human A549 lung cancer cells (ATCC-CCL-185, Cedarlane Burlington ON) were seeded in 96-well plates (5×103 cells/well). The following day 10 pM TGF-β in complete media in the absence or presence of a serial dilution of fusion protein was incubated for 30 min at RT prior to adding to the cells. After 21 h of incubation (37° C., 5% CO2, humidified atmosphere) conditioned medium was harvested and added to MSD Streptavidin Gold plates (Meso Scale Diagnostics, Gaithersburg, Md.) that were coated with 2 μg/mL biotinylated mouse anti-human IL-11 antibody (MAB618, R&D Systems, Minneapolis, Minn.). After 18 h (4° C.) plates were washed with PBS containing 0.02% Tween 20, a 2 μg/mL SULFO-tagged goat anti-human IL-11 antibody (AF-218-NA, R&D Systems Minneapolis, Minn.) was added and plates were incubated for 1 h at RT. After a final wash, plates were read in a MESO QuickPlex SQ120 machine (Meso Scale Diagnostics, Gaithersburg, Md.). IL-11 readouts were expressed as percent IL-11 release compared to control cells treated with TGF-β alone.
  • In one set of experiments, using the Mv1 Lu cell reporter assay, the neutralization potency of Cet-T2m (construct Type F in FIG. 2), Cet-T22d35 (construct Type D in FIG. 2) and T22d35 (non-Fc-fused) were compared. FIG. 4A shows representative TGF-β1 (top panel), TGF-β3 (middle panel) and TGF-β2 (bottom panel) neutralization curves for Cet-T2m, Cet-T22d35 and T22d35 while Table 2 summarizes TGF-β1, -β2 and -β3 neutralization IC50 values. Unexpectedly, the TGF-β1 and TGF-β3 neutralization curves for the Cetuximab fusion constructs indicated extremely high potencies that lie in the picomolar range (determining a single IC50 value in these experiments is difficult due to the biphasic nature of the curves). The observed TGF-β1 IC50 value for Cet-T22d35 was in the picomolar range. In contrast, the TGF-β1 IC50 for non-Fc-fused T22d35 was approximately 1 nM. This illustrates that there is a large increase in T22d35 potency upon fusion to the C-terminus of the Fc region of Cetuximab (due to the biphasic nature of the Cet-T22d35 curve, the fold difference is difficult to determine in these experiments). The TGF-β1 IC50 value for Cet-T2m was also subpicomolar (but less potent than Cet-T22d35), whereas unfused T2m is not able to detectably neutralize TGF-β1, even at concentrations above 500 nM (De Crescenzo et al, 2001). This demonstrates that, similar to T22d35, a very significant increase in T2m potency occurs upon fusion to the C-terminus of the Fc region of Cetuximab. Both Cet-T22d35 and Cet-T2m neutralized TGF-β2 (IC50 nM range), whereas T22d35 and T2m (De Crescenzo et al, 2001) alone did not, even at a concentration of 800 nM, again showing the remarkable increase in neutralization potency that occurs upon fusion of T22d35 or T2m to the C-terminus of an Fc region.
  • In another set of experiments using the Mv1Lu cell reporter assay, similar extremely high potencies of TGF-β neutralization were observed for other C-terminus Fc fusion constructs (Table 2), e.g. for constructs in which T22d35 or T2m were fused with FSAs such as Herceptin (Her-T22d35), Avastin (Ava-T22d35) or Synagis (Syn-T22d35) [Type F and D constructs in FIG. 2], or with the blood-brain barrier crossing Fc-fused FC5 VHH antibody (FC5-Fc-T22d35 and FC5-Fc-T2m) [Type E and G constructs in FIG. 2]. In addition, fusion of T22d35 or T2m to the C-terminus of an IgG2-Fc region alone, i.e. an antibody with no Fab region present (Fc-T22d35 and Fc-T2m) [Type A and C constructs in FIG. 2] resulted in fusion proteins with similarly high neutralization potencies. However, fusing T2m to the N-terminus of an IgG2-Fc (T2m-Fc) generates a fusion protein that does not neutralize TGF-β1 and -β3 in the picomolar range, but rather in the range of 1 nanomolar (0.3 to 15 nM in Table 2) and lacks any activity towards TGF-β2. These results are similar to those obtained with commercially available N-terminally IgG1 Fc-fused TGF-β Type II receptor ectodomain (T2m-Fc (R&D Systems)) (0.3 to 0.5 nM in Table 2). Together, these results thus demonstrate that fusion of TGF-β superfamily receptor ectodomains to the C-terminus of an Fc domain in the context of full-size antibodies, a VHH-Fc, or an Fc region alone, give rise to unexpectedly high TGF-β neutralization potencies.
  • TABLE 2
    TGF-β neutralization IC50 of fusion constructs. It should be noted
    that T2m does not neutralize any of TGF-β1, -β2, or -β3 (De Crescenzo
    et al, 2001). It should also be noted that the IC50 values in the table
    below are estimates due to the biphasic nature of the curves.
    TGF-β1 TGF-β3 TGF-β2
    Av IC50 (nM) Av IC50 (nM) Av IC50 (nM)
    Cet-T22d35 0.000,001 0.000,002 13.6
    Cet-T2m 0.000,1 0.000,0015 129.2
    T22d35 1.232 0.033 No neutralization
    Her-T22d35 0.000,13 0.000,05 7.89
    Ava-T22d35 0.000,000,72 0.000,00038 8.60
    Syn-T22d35 0.000,042 0.000,0001 35.2
    FC5-Fc-T22d35 0.000,001 0.000,001 96.2
    FC5-Fc-T2m 0.000,017 0.000,015 432.9
    Fc-T22d35 0.001,445 0.000,026 108.4
    T2m-Fc (R&D) 0.506 0.323 No neutralization
    T2m-Fc 14.523 0.276 No neutralization
    Fc-T2m 0.009,923 0.000,766 460.5
  • In order to confirm the relative potencies of Fc-ectodomain constructs, a second cell-based assay, an A549 cell IL-11 release assay, was used. This IL-11 release assay acts as a model of TGF-β-mediated biological responses that contribute to both tumor metastasis and fibrosis. In the set of experiments shown in FIG. 4B, the neutralization potencies of T22d35, Fc-T2m, Fc-T22d35, Cet-T22d35, Her-T22d35, Ava-T22d35, Syn-T22d35 and FC5-Fc-T22d35 were compared. It can be seen that the neutralization curves in this assay are not biphasic, making it less challenging than the Mv1Lu assay to determine and compare IC50 values. All of the constructs in which T22d35 was fused to the C-terminus of an Fc region exhibited IC50 values in the range of 5 pM, corroborating the extremely high potency observed for these constructs in the Mv1Lu assay. It can also be seen in FIG. 4B that the IC50 value for non-Fc-fused T22d35 was ˜0.5 nM. This indicates that a ˜100-fold increase in potency occurs upon fusion of T22d35 to the C-terminus of an Fc region. The IC50 value for Fc-T2m was 0.05 nM. This indicates that constructs with two ectodomains in the C-terminal portion may be more potent than a construct with one ectodomain in the C-terminal portion (as was observed in the Mv1 Lu assay, FIG. 4A), however, it should be noted that Fc-T2m does not have an optimized N-terminus.
  • An additional set of experiments in which the A549 cell IL-11 release assay was used to compare TGF-β neutralization potencies is shown in FIG. 4C. Here, the potencies of several “headless”-T2m constructs were assessed along with that of non-Fc-fused T22d35. The potency of T22d35 was determined to be ˜0.5 nM, consistent with the data shown in FIG. 4B. This is illustrative of the robustness of the A549 cell IL-11 release assay. It can also be seen in FIG. 4C that all of the “headless”-T2m constructs exhibited high potencies with IC50s in the range of 5 pM (3 to 17 pM). These values are in the same range as those of the T22d35-containing constructs shown in FIG. 4B, and are 10-fold higher potency than that of the “headless”-T2m containing construct also shown in FIG. 4B (Fc-T2m). Since all of the T2m-containing constructs in FIG. 4C have engineered N-termini, whereas Fc-T2m does not, these results indicate that engineering of the cysteine residues of the hinge region of “headless” constructs is able to increase their potency by approximately 10-fold.
  • We have also compared the potencies of constructs that include three TβRII structured ectodomains with constructs carrying two ectodomains using the A549 cell IL-11 release assay. We observed that the triple-repeat based constructs (SEQ ID NO:111 and SEQ ID NO:116) are potent in neutralizing TGF-β1 in this assay, and typically have improved 1050 values relative to the corresponding double-repeat based constructs (SEQ ID NO:100 and SEQ ID NO:106, respectively). All constructs involved in this comparative study had the same engineered N-terminus of the Fc portion, hIgG1FcΔK(C).
  • Binding to TGF-β: Binding of T22d35, Cet-T22d35, and Cet-T2m to TGF-β2 was measured using a competitive SPR binding experiment. In this assay, the molecule of interest was first allowed to bind to a fixed amount of TGF-β in solution. A 2-fold dilution series was prepared in PBS-0.05% Tween, starting with 1000 nM T22d35 trap or 20 nM Cet-T22d35 or Cet-T2m. Each diluted sample was pre-incubated with 1 nM TGF-β2 for 30 min at room temperature to allow binding. The mixture was then flowed over immobilized, pan-specific anti-TGF-β antibody 1D11 (2000 RU 1D11) in order to quantify the amount of ligand left unbound (TβRII ectodomain and 1D11 bind to a similar epitope on TGF-β) using a Biacore T200 instrument. The TGF-β2 binding EC50 values were determined by plotting the percent free TGF-β versus the protein concentration of the molecule of interest. Binding curves and EC50 values are shown in FIG. 4D and Table 3. In the case of TGF-β2 binding, a 100-fold increase in binding was observed between Cet-T22d35 and unfused T22d35 (EC50˜1 nM versus>100 nM, respectively), indicating that C-terminal fusion of the T22d35 trap to antibody provides a gain in affinity for the TGF-β2 isoform. This correlates with the ability of Cet-T22d35 to neutralize TGF-β2 in the 10 nM range, and the inability of unfused T22d35 to neutralize TGF-β2, as observed in the Mv1Lu-Luc cell reporter assay.
  • TABLE 3
    EC50 of Cetuximab-trap binding to TGF-β in solution.
    EC50 is the Effective Concentration at which 50% of TGF-β
    is bound and is given in nM.
    Trap variant EC50 for TGF-β2
    T22d35 >100
    Cetuximab-T2m 1.17
    Cetuximab-T22d35 0.50
    Note:
    T2m alone shows an IC50 of greater than 1000 nM (Zwaagstra et al, 2012), and thus is not considered neutralizing.
    • EXAMPLE 3A Validation of Antibody Binding
  • The ability of an antibody alone or in a fusion construct of Example 1 to bind to its intended target antigen was evaluated using surface plasmon resonance (SPR).
  • Direct binding of Cet-T22d35 or Cetuximab to the EGF receptor extracellular domain (EGFR-ED) was quantified by SPR using a BIAcore T200 instrument, performed in the standard manner. Briefly, Cet-T22d35 or Cetuximab alone were captured on the SPR CM5 chip using immobilized anti-human IgG Fc-specific antibody (2000 RU). Variable concentrations of EGFR-ED in PBS-0.05% Tween were then flowed over the capture surface at 100 μl/min and 25° C. The resulting sensorgrams (data not shown) were analyzed using the Biacore T200 evaluation software. The KD values of Cet-T22d35 and Cetuximab were very similar (847 and 708 pM, respectively), indicating that fusion of T22d35 to the Fc portion of Cetuximab does not appreciably alter binding to EGFR-ED, compared to the non-fused FSA. Similar SPR methods and analyses were performed for other antibody-trap fusion examples, compared with their corresponding target antigens (see Table 4).
  • From Table 4 it is evident for each exemplified construct that fusion of a TGF-β superfamily receptor ectodomain(s) to the C-terminus of the Fc region of an antibody did not significantly alter antigen-binding affinities and KD values of the antibody. This indicates that the ectodomain(s) can be readily fused to any antibody without compromising the ability the antibody to bind its target antigen.
  • TABLE 4
    SPR determination of antigen-binding affinity of
    T22d35 fusion constructs or antibodies alone.
    Antigen Ka (1/Ms) Kd (1/s) KD (M)
    Cetuximab- EGFR 1.22 × 106 8.65 × 10−4 7.08 × 10−10
    T22d35
    Cetuximab EGFR 1.03 × 106 8.45 × 10−4 8.47 × 10−10
    Her-T22d35 Her2 8.30 × 104 5.30 × 10−5 6.37 × 10−10
    Herceptin Her2 6.88 × 104 5.03 × 10−5 7.33 × 10−10
    Syn-T22d35 RSV-F 3.55 × 104 1.42 × 10−3 4.10 × 10−9 
    Synagis RSV-F 2.57 × 104 1.68 × 10−3 6.60 × 10−9 
    NOTE:
    FC-5-Fc, FC5-Fc-T2m, and FC-5-Fc-T22d35 binding affinity was assessed via the transwell functional assay (see Example 3C).
    • EXAMPLE 3B Validation of Cetuximab Function
  • The ability of Cetuximab to maintain its therapeutic function (i.e. inhibition of EGF-induced EGFR phosphorylation and signaling) when fused to either T2m or T22d35 (Example 1) was evaluated.
  • Phosphorylation of EGFR: The ability of Cetuximab-comprising constructs to inhibit EGF-induced phosphorylation of EGFR in human lung cancer A549 cells was evaluated. A549 cells were seeded in 24-well plates (100,000 cells/well) and either mock treated (−) or pre-treated with Cetuximab, Cet-T2m, or Cet-T22d35 (all at 10, 1 or 0.1 nM) or T22d35 (10 nM) at 37° C. for 3 h, then treated with 50 ng/mL EGF at 37° C. for 10 min. Whole cell lysates were prepared and resolved by SDS-PAGE, western blotted and probed with anti-phosphoTyrosine antibody (Clone 4G10, Millipore 05-321). As shown in FIG. 5A, Cetuximab and Cet-T2m and Cet-T22d35 inhibited EGFR phosphorylation to similar extents, whereas T22d35 had no effect, relative to the +EGF control. These results thus confirm that the TGF-β superfamily receptor ectodomain moieties in Cetuximab-T2m and Cetuximab-T22d35 fusion proteins do not interfere with the function of the Cetuximab antibody (i.e. inhibition of EGF induced EGFR signaling).
  • Inhibition of EGFR signaling: Inhibition of autocrine EGFR signaling results in varying degrees of cytotoxicity in EGFR-expressing cells treated with Cetuximab. Cytotoxicity of Cet-T22d35 was compared to Cetuximab and T22d35 in human breast cancer cells (MDA-MB-468) and immortalized keratinocyte cells (HaCaT). These cells exhibited significant Cetuximab cytotoxicity, due to their intrinsic dependence on the EGF signaling pathway for basal growth. The cells were seeded onto 96-well plates (MDA-MB-468, 2300 cells/well; HaCaT, 1500 cells/well) and then treated with different doses of inhibitor at 37° C. for 5 days. Cell viability was measured using sulforhodamine reagent to determine the percentage of viable cells relative to mock-treated controls. Results are shown in FIG. 5B and Table 5. The IC50 values for Cet-T22d35 and Cetuximab were similar in both cell lines (0.2-1.4 nM range), while T22d35 resulted in no cytotoxicity. These results further confirm that the TGF-β superfamily receptor ectodomain moiety in Cetuximab-T22d35 does not interfere with the function of the Cetuximab antibody.
  • TABLE 5
    Cetuximab-T22d35 cytotoxicity in MDA-MB-468 and HaCat cells.
    The cytotoxic potency IC50 values are given in nM.
    MDA-MB-468 IC50 HaCaT IC50
    Cetuximab 0.50 0.33
    Cetuximab-T22d35 1.42 0.22
    T22d35 0 0
    • EXAMPLE 3C Validation of FC5 Function
  • The ability of FC5 VHH to maintain its function (i.e. transmigrate the blood-brain barrier) when fused with the T2m or T22d35 moieties (see description in Example 2 and activities in Table 2) was evaluated.
  • Briefly, SV40-immortalized Adult Rat Brain Endothelial Cells (Sv-ARBEC) were used to generate an in vitro blood-brain barrier (BBB) model as described (Garberg et al, 2005; Haqqani et al, 2013). Sv-ARBEC cells (80,000 cells/membrane) were seeded on 0.1 mg/mL rat tail collagen type I-coated tissue culture inserts (pore size-1 μm; surface area 0.9 cm2, Falcon) in 1 ml of growth medium. The bottom chamber of the insert assembly contained 2 ml of growth medium supplemented with the immortalized neonatal rat astrocytes-conditioned medium in a 1:1 (v/v) ratio. Equimolar amounts (5.6 μM) of positive (FC5-Fc) control; negative controls (A20.1); and T22d35, T2m, FC5-Fc-T22d35 or FC5-Fc-T2m were tested for their ability to cross the Sv-ARBEC cell monolayer. Following exposure of equimolar amounts of the proteins to the luminal side of the BBB, samples were taken after 15, 30, and 60 min from the abluminal side. The protein content of each sample was then quantified by mass spectrometry (multiple reaction monitoring-isotype labeled internal standards; MRM-ILIS) as described by (Haqqani et al, 2013) (see method description below).
  • Quantified values can be directly plotted or the Papp (apparent permeability coefficient) values can be determined using the following formula
  • Papp = d Q r / d t A × C 0
  • The Papp value is commonly used to determine the specific permeability of a molecule, and is a measure of transport across the brain endothelial monolayer. [Qr/dt=cumulative amount in the receiver (bottom) compartment versus time; A=area of the cell monolayer; C0=initial concentration of the dosing solution (top chamber)].
  • FIG. 6 shows the results of the experiment. The Papp value of FC5-Fc-T22d35 was similar to the control FC5-Fc, indicating it was transported efficiently and that the fused T22d35 did not interfere with transport. The Papp value for FC5-Fc-T2m was approximately 50% less, compared to FC5-Fc-T22d35 and FC5-Fc, indicating somewhat reduced permeability. Nevertheless, the level of transport of FC5-Fc-T2m was about 4-fold greater than the negative controls (T2m, T22d35, and antibody A20.1).
    • EXAMPLE 4 Inhibition of Epithelial to Mesenchymal Transition
  • Treatment of A549 cells with EGF plus TGF-β results in a strong epithelial to mesenchymal transition (EMT). The EMT is phenotypically characterized by changes in cell morphology (tight cellular junctions with “cobble-stone” appearance converts to elongated cells, see FIG. 7A) and changes in the adherin junction proteins E-cadherin and N-cadherin. The ability of the fusion constructs to block EMT was assessed in A549 cells by western blotting (E-cadherin) and flow cytometry (E-cadherin and N-cadherin).
  • Briefly, for the western blot analysis, A549 cells were seeded in 24-well plates (8000 cells/well) and then treated with EGF (50 ng/mL)+TGF-β1 (50 pM) at 37° C. for 3 days in the presence of Cet-T22d35, Cetuximab, or T22d35 (0, 0.05, 0.5, 5, 50, or 500 nM). Whole cell lysates were prepared and resolved by SDS-PAGE. The proteins were transferred to nitrocellulose and then probed with an E-cadherin antibody (BD Transduction laboratories Biosciences) (FIG. 7B). The E-Cadherin positive bands in the Western blot were quantified by densitometer detection and ImageJ analysis (FIG. 7C). EGF+TGF-β treatment resulted in an EMT, as indicated by the disappearance of E-cadherin (compare non-treated and EGF+TGF-β lanes in the absence of inhibitors). Cet-T22d35 blocked the EMT (E-cadherin disappearance) in a dose-dependent manner whereas 500 nM Cetuximab or T22d35 treatments only modestly blocked the EMT (E-cadherin levels ˜20-25% of the non-treated control level).
  • The ability of Cet-T22d35, Cetuximab and T22d35 to block the EGF+TGF-β EMT response was further examined by flow cytometry using A549 cells treated with Cet-T22d35 or Cetuximab, (all at 50, 5, 0.5 nM) or the Cetuximab+T22d35 combination (50 nM+100 nM, 5 nM+10 nM, or 0.5 nM+1 nM, respectively) and evaluating the EMT associated changes in E-cadherin and N-cadherin cell surface expression levels (FIG. 7D). In this experiment the molar amounts of the molecules of interest used in ‘T22d35 alone’ and ‘Cetuximab+T22d35’ groups were two-fold higher than for Cet-T22d35 in order to correspond with a 2:1 trap/antibody ratio in the Cet-T22d35 fusion molecule. A549 cells were seeded in 6-well plates (30,000 cells/well) and pre-treated with the inhibitors at 37° C. for 1 h, followed by added treatment with EGF (10 ng/mL)+TGF-β1 (10 pM) and incubation at 37° C. for 3 days. Cells were then dissociated from the plate using 1 mL Dissociation Buffer (Sigma)/well, centrifuged at 2000 rpm for 2 min and re-suspended in 100 μl RPMI-5 media at 4° C. AlexaFluor488-E-cadherin (Santa Cruz, SC21791) and AlexaFluor647-N-cadherin (BD Biosciences, 563434) antibodies (1/25 v/v dilutions) were added and samples were incubated at 4° C. for 1 h. Cells were then centrifuged, washed once in RPMI-5, and re-suspended in 400 μl RPMI-5 containing 15 μg/mL propidium iodide (Life Technologies) at 4° C. Mean fluorescent intensities (MFI) were measured by flow cytometry (BD LS RII flow cytometer, BD Biosciences) to quantify E-cadherin and N-cadherin levels. The results show that Cet-T22d35 was more effective in preventing down-regulation of E-cadherin (FIG. 7D, top panel) and up-regulation of N-cadherin (FIG. 7D, bottom panel), as a measure of blocking EMT, compared to Cetuximab, T22d34 or the Cetuximab+T22d35 combination at each respective dose, and is most notable at the lowest dose used (0.5 nM).
    • EXAMPLE 5 Pharmacokinetic (PK) Studies on Constructs with and Without a Lysine Residue at the Fusion Site Between the C-Terminus of the Fc Region and the N-Terminus of the Ectodomain
  • PK studies were carried out in normal, healthy mice to determine whether fusion of T22d35 to an antibody increased its half-life in vivo, and whether removal of a lysine at the fusion site within constructs reduced the amount of cleavage occurring in vivo.
  • Results from Cet-T22d35 (construct Type D in FIG. 2—containing a lysine at the fusion site): A single bolus of Cet-T22d35 protein (10 mgs/Kg) formulated in DPBS was intravenously injected (IV) into the tail vein of normal Balb/c mice and serum samples were collected from the submandibular vein at selected time points (0.5, 1, 2, 4, 8, 14, 24, 48, 96 h). Blood samples were centrifuged at 2000 g at 4° C. for 10 min and the serum supernatant was removed and stored frozen at −80° C., prior to analyses. The samples were thawed at 4° C. and analyzed via mass spectrometry (multiple reaction monitoring-isotype labeled internal standards; MRM-LIS) in order to measure the levels of both the Cetuximab and T22d35 trap moieties. Briefly, 20 μl of sample was thawed and treated with mild detergents (0.1% RapiGest SF, Waters; 5.5 mM TCEP) at 95° C. for 10 min. The sample was cooled to room temperature and Iodoacetamide (IAA) in 50 mM Ammonium Bicarbonate was added to a final concentration of 10 mM IAA, followed by incubation for 40 min in the dark. DTT (10 mM final) was then added and the sample was incubated at room temperature for 15 min, followed by trypsin digestion (Sigma, 0.8 mg/mL final) at 37° C. for 18 h. A mixture of 5 μM each of isotope-labeled trap and cetuximab peptides (formulated in 30% acetonitrile, 0.1% formic acid) were added to final concentrations of 1 μM, as internal standards for quantification. The isotope-labeled peptides were 13C/15N—(H2N-LPYHDFILEDAASPK-OH; SEQ ID NO:134) and 13C/15N—(H2N-ALPAPIEK-OH; SEQ ID NO:135) for T22d35 and Cetuximab, respectively (NewEngland Peptide). Trifluoroacetic acid was then added (0.5% final), followed by incubation at 37° C. for 30 min. The samples were centrifuged at 13000 rpm for 20 min and the supernatant was used analyzed via MRM-ILIS using an Agilent 1260 HPLC system coupled with Agilent QQQ6410B at 55° C. The PK profiles seen in FIG. 8A show that the levels of the Cetuximab and T22d35 moieties diverge at early time points (<10 h) after injection, indicating different kinetics and suggesting possible cleavage of T22d35 from the Cet-T22d35 protein in vivo. Nevertheless, analysis of these curves using a two compartmental model (Phoenix WinNonlin SoftwareVersion 6.3) indicated that the average terminal half-life (T1/2 β) of the T22d35 component was 45.8 h. This represents a 7.6-fold increase compared to the previously determined half-life for unfused T22d35 (T1/2 β˜6 h). As well, the PK profile shows that the Cetuximab moiety was maintained in the blood, with a T1/2 β=262.5 h, indicating that the Cetuximab moiety has a long circulating half-life.
  • Results from several constructs with lysine deleted at the fusion site:
  • The same methods that were used in the PK study of Cet-T22d35 (FIG. 8A) were applied to assess the PK of CetΔK-T2m (Type F in FIG. 2) as well as several “headless” T2m constructs (Type C in FIG. 2; hIgG1FcΔK(SS)-T2m, hIgG1FcΔK(ΔC)-T2m, and hIgG2FcΔK(SS)-T2m), all of which have the lysine deleted at the fusion site. The data shown in FIG. 8B indicate that no detectable cleavage of these constructs is occurring in vivo since the levels of the Fc moieties (closed symbols) and ectodomain moieties (open symbols) do not diverge over time. Additionally, all of the constructs exhibit similar long circulating half-lives with T1/2 βs of approximately 100 h. This represents an improvement to the half-life of the ectodomain moiety of the construct which has a lysine at the fusion site, presented in FIG. 8A (45.8 h).
    • EXAMPLE 6 Efficacy Studies Comparing the Effect of “Headless” Fc-T2m and FSA-T2M Constructs on Tumor Growth (A) and T-Cell Function (B and C) in an Immune-Competent Syngeneic Triple Negative Breast Cancer (4T1) Model
  • A FSA-T2m construct (Cet-T2m—Type F in FIG. 2) and three headless constructs, all with engineered N-termini, (hIgG1FcΔK(CC)-T2m, hIgG1FcΔK(C)-T2m, and hIgG2FcΔK(CC)-T2m—Type C in FIG. 2) were evaluated for their ability to inhibit tumor growth and to affect T-cell function in a syngeneic tumor model derived from 4T1 triple negative breast cancer cells. The results presented in FIG. 9 show the effect on tumor growth (A) and T-cell function (B, C). The effects of these Fc-fused ectodomain constructs were compared to those of a pan-specific neutralizing anti-TGF-β antibody, 1D11 and a non-Fc-fused ectodomain construct, T22d35.
  • The protocols used for these syngeneic mouse model studies are described in (Zheng et al, 2013). Briefly, female BALB/c (H-2Kd) mice 6 weeks of age were purchased from The Jackson Laboratories and kept in filter-top cages. The 4T1 breast cancer cells and B16F10 cells were purchased from American type culture collection and cultured in RPMI-1640 supplemented with 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 microgm/L streptomycin, 50 micromol/L 2-mercaptoethanol, and 10% fetal calf serum. Mice were inoculated subcutaneously in the left flank with 100 uL sterile saline containing 5×104 4T1 cells. Tumors were grown to ˜100 mm3, as measured by caliper, then mice were randomized and divided into the six treatment groups (8 animals/group) (Day 0). Treatments commenced on Day 1 and continued for 15 days with the animals being dosed at 5 mg/kg twice per week such that they received a total of 4 doses. Tumor growth was monitored by caliper measurements 3× per week. Animals were euthanized by exsanguination under anaesthesia on Day 15; T cells were isolated from draining lymph nodes and assessed for their capacity to kill mouse 4T1 and B16F10 tumour cells ex vivo. The capacity of T cells from mice treated with or without test agents to lyse target 4T1 tumor cells was measured using a CytoTox 96 nonradioactive cytotoxicity assay kit (Promega) according to the manufacturer's instructions. Briefly, naïve target 4T1 cells or melanoma cell line B16F10 cells are plated and incubated for 4 hr with CD8+ effector T cells isolated from 4T1 tumor-bearing mice using CD8 magnetic MicroBeads (BD Bioscience). The isolated CD8+ cells are confirmed, by flow cytometry, to be over 85% CD8+. A range of ratios of effectors to target cells is tested (100:1, 50:1, 25:1). Lactate dehydrogenase (LDH) release in response to effector T cells is measured in the buffer bathing target cells. Target cells incubated in the absence of effector cells are used as a comparator to control for spontaneous LDH release. Released LDH in culture supernatants is detected after a 30-min incubation using a coupled enzymatic assay. The intensity of the color formed is proportional to the number of lysed cells. Cytotoxic activity of CTL is calculated using the following formula:

  • Cytotoxic activity %=[(absorbance)−(spontaneous effector cell LDH release)−(spontaneous target cell LDH release)]/[(maximal LDH release)—(spontaneous target cell LDH release)]×100
  • The results presented in FIG. 9A show the effect of the Fc-fused ectodomain constructs listed above on 4T1 tumor growth (the pan-specific neutralizing anti-TGF-β antibody, 1 D11, and a non-Fc-fused ectodomain construct, T22d35, being tested as comparators). As can be seen in FIG. 9A, all of the Fc-fused ectodomain constructs reduced tumor growth relative to the saline treatment when tested for significance by t-test. The 1 D11 and T22d35 comparator treatments were observed to be less effective relative to the Fc-fused ectodomain treatments, and not significantly different from the saline control. These results demonstrate that constructs with an ectodomain fused to the C-terminus of an Fc region have significant anti-tumor potency, with the efficacy being higher than the 1 D11 and T22d35 comparators. There was no significant difference between the FSA-T2m construct (Cet-T2m) and the constructs that have no Fab, i.e. are “headless” (hIgG1FcΔK(CC)-T2m, hIgG1FcΔK(C)-T2m, and hIgG2FcΔK(CC)-T2m) with respect to their effect on tumor growth. The high anti-tumor potency of these Fc-ectodomain fusions relative to comparators likely results from high potency neutralization of TGF-β combined with a favourable circulating half-life.
  • To investigate whether these Fc-ectodomain fusions exhibit an immuno-modulatory effect in vivo on cytotoxic T lymphocyte cells (CTLs) present in tumor draining lymph nodes, lymph nodes were removed from mice treated with or without test agents; T-cells were then isolated and tested for their capacity to lyse target 4T1 tumor cells (and B16F10 cells as a test of tumor specificity) using the methods described above.
  • As shown in FIG. 9B, treatment of the animals with Fc-ectodomain fusions significantly increased the ability of draining lymph node T-cells to lyse target 4T1 tumor cells ex vivo. It can be seen that this immuno-stimulatory effect is specific to 4T1 cells since the T-cells were not able to effectively lyse B16F10 melanoma cells (FGURE 9C; maximal lysis of ˜15% for B16F10 cells and ˜80% for 4T1 cells). When administered at the same 5 mg/kg dose as the Fc-ectodomain fusions, the non-Fc-fused comparator molecule, T22d35, had no effect above saline. This is consistent with its lack of effect on tumor volume. Although the 1 D11 antibody had no statistically significant effect on tumor volume (FIG. 9A), it did increase the ability of lymph node T-cells to lyse 4T1 tumor cells.
  • Interestingly, with respect to the Fc-ectodomain fusions of this invention, the most potent constructs were the hIgG1FcΔK(CC)-T2m and hIgG2FcΔK(CC)-T2m constructs; both of these constructs containing two cysteines in the engineered hinge region. These constructs were more potent than the construct with one cysteine in the engineered hinge region, hIgG1FcΔ K(C)-T2m, as well as being more potent than the full-size antibody-T2m construct, Cet-T2m. The difference in potency between constructs with one versus two hinge region cysteines may result from the construct with one cysteine having a lower relative stability. The lower potency of the full size antibody construct relative to the headless constructs with two hinge region cysteines may result from a difference in molecular weight, with the smaller constructs being able to penetrate the tumor microenvironment more effectively.
    • EXAMPLE 7 In Vitro and In Vivo Studies Illustrating Enhanced Bone Localization of Constructs Containing a Deca-Aspartate Motif for Bone Targeting at the N-Terminus of the Fc Region
  • In vivo studies were carried out to investigate whether the addition of a 10 amino acid long poly-aspartate bone-localization motif (D10) to the N-terminus of the Fc region of constructs will promote their localization to bone. Optical imaging of D10-hIgG1Fc-T2m fusions: Upon arrival, male Balb/c mice were housed 3 mice/cage. On the day of the experiment, animals were shaved dorsal and ventral and treated with the hair removal cream, NAIR®. Mice were injected with a single intravenous bolus of 10 mg/kg of two CF770 labeled constructs with a deca-aspartate motif for bone targeting (D10) at their N-termini (D10-hIgG1FcΔK(CC)-T2m, D10-GSL-hIgG1FcΔK(CC)-T2m) or with a control construct without the D10 motif (hIgG1FcΔK(CC)-T2m) and whole body bio-distribution followed using both in vivo and ex-vivo near infrared imaging. Imaging was conducted with a small-animal time-domain eXplore Optix pre-clinical imager MX3 (Advanced Research Technologies, ART) at various time points (prescan, 5 mins, 3 hr, 6 hr, 24 h, 48 h, 72 h, 96 h and 120 h).
  • The small animal time-domain eXplore Optix preclinical imagers consists of a 785-nm pulsed laser diode with a repetition frequency of 80 MHz and a time resolution of 12.5 ps light pulse was used for excitation. The fluorescence emission beyond 813 nm was collected by a highly sensitive time-correlated single photon counting system and detected through a fast photomultiplier tube. The data were recorded as temporal point-spread functions (TPSF) and the images were presented as fluorescence intensity maps using ART Optix Optiview analysis software 3.02.
  • For in vivo optical imaging, mice were first anesthetized using isofluorane (1.5-2%), positioned on the animal stage within a chamber which allows for gaseous anesthesia and maintenance of animal temperature at 36° C. The scanning of the mouse at each time point lasted up to 20 mins using a 2.5 mm step size and the mouse is placed back in its home cage between imaging time points.
  • At the end of the imaging protocol (120 hrs) animals were sacrificed by intracardiac perfusion using heparnized saline with deep anesthesia. The organs (brain, heart, lungs, liver, kidney, spleen and right and left leg bones) were imaged ex-vivo using a 1.0 mm step size using the eXplore Optix pre-clinical imager MX3.
  • Data analysis was done using eXplore Optix Optiview analysis software 3.02 (Advanced Research Technologies, Montreal, QC) to estimate the fluorescence total and average fluorescence intensity in region of interest containing the ex-vivo organs.
  • The results shown in FIGS. 10A and B demonstrate that the fusion of the deca-aspartate D10 motif on the N-termini of the fusion constructs had no impact on their ability to neutralize TGF-β, i.e. the IC50 of the construct lacking the D10 motif (hIgG1FcΔK(CC)-T2m) was 3 nM, which is the same as the value determined in FIG. 4C, while the IC50s of the D10 containing constructs, D10-hIgG1FcΔK(CC)-T2m and D10-GSL-hIgG1FcΔK(CC)-T2m, were very similar at 4-5 nM. The results in FIGS. 10A and B also indicate that labeling with the CF770 dye reduced the ability of the constructs to neutralize TGF-β by approximately 4-fold. Since dye conjugation occurs at lysine residues, and since it is know that lysines are at the binding interface between the Type II ectodomain and TGF-β, it is not entirely surprising that labeling reduced neutralization potency. In any case, since this is a comparative study of differences in in vivo localization promoted by the D10 peptide, it was felt that partially active constructs would be informative.
  • The results shown in FIGS. 10C and D demonstrate that the addition of the D10 peptide to the N-termini of the constructs greatly enhanced bone localization. Images taken 120 h post-injection of the CF770 labeled fusions show a clear accumulation of the D10-fusions in the vertebrae. Further ex vivo imaging of the brain, heart, lungs, liver, kidneys, spleen, and the left and right legs 120 h post-injection confirmed the specific accumulation of the D10-fusions in the bones. The fluorescent signals observed in the kidneys and liver were similar for all fusions indicating that accumulation in these organs was not affected by the presence of the D10 sequence. These results indicate that the TGF-β neutralization activity of constructs may be increased within bone through the addition of the D10 peptide. This could result in more favourable dosing levels and schedules for the treatment of bone-related diseases, such as osteogenesis imperfecta, relative to that required for a similar construct without the D10 motif.
  • The embodiments and examples described herein are illustrative and are not meant to limit the scope of the invention as claimed. Variations of the foregoing embodiments, including alternatives, modifications and equivalents, are intended by the inventors to be encompassed by the claims. Furthermore, the discussed combination of features might not be necessary for the inventive solution.
  • LISTING OF SEQUENCES
    SEQ
    ID
    NO: Sequence Description
      1 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG Human IgG1 Fc
    VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI region
    EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
    NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
    HYTQKSLSLSPGK
      2 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGV Human IgG2 Fc
    EVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIE region
    KTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESN
    GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGK
      3 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDG Human IgG3 Fc
    VEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI region
    EKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
    SGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHN
    RFTQKSLSLSPGK
      4 APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG Human IgG4 Fc
    VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI region
    EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
    NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN
    HYTQKSLSLSLGK
      5 EPKSCDKTHTCPPCP Human IgG1
    hinge region
      6 ERKCCVECPPCP Human IgG2
    hinge region
      7 ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKS Human IgG3
    CDTPPPCPRCP hinge region
      8 ESKYGPPCPSCP Human IgG4
    hinge region
      9 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG hIgG1FcΔK-ΔC
    VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI Fc variant
    EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
    NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
    HYTQKSLSLSPG
     10 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C Fc
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL variant
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPG
     11 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK Fc variant
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPG
     12 EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG1FcΔK-S Fc
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK variant
    EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
    VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
    GNVFSCSVMHEALHNHYTQKSLSLSPG
     13 EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG1ΔK-SS Fc
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK variant
    EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
    VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
    GNVFSCSVMHEALHNHYTQKSLSLSPG
     14 EPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG1FcΔK-SSS
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK Fc variant
    EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
    VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
    GNVFSCSVMHEALHNHYTQKSLSLSPG
     15 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGV hIgG2FcΔK-ΔC
    EVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIE Fc variant
    KTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESN
    GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPG
     16 PPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWY hIgG2FcΔK-C Fc
    VDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLP variant
    APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVE
    WESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
    LHNHYTQKSLSLSPG
     17 VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF hIgG2FcΔK-CC
    NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNK Fc variant
    GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    SVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
    HEALHNHYTQKSLSLSPG
     18 ERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED hIgG2Fc-CCCC
    PEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC Fc variant
    KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
    YPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPGK
     19 ERKSSVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED hIgG2FcΔK-SS
    PEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC Fc variant
    KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
    YPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPG
     20 ERKSSVESPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED hIgG2FcΔK-SSS
    PEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC Fc variant
    KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
    YPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPG
     21 ERKSSVESPPSPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED hIgG2FcΔK-SSSS
    PEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKC Fc variant
    KVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
    YPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVF
    SCSVMHEALHNHYTQKSLSLSPG
     22 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDG hIgG3FcΔK-ΔC
    VEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI Fc variant
    EKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
    SGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHN
    RFTQKSLSLSPG
     23 PRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKW hIgG3FcΔK-C Fc
    YVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKAL variant
    PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV
    EWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHE
    ALHNRFTQKSLSLSPG
     24 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG3FcΔK-CC
    EVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCK Fc variant
    VSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
    PSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFS
    CSVMHEALHNRFTQKSLSLSPG
     25 EPKSSDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG3FcΔK-S Fc
    SHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGK variant
    EYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCL
    VKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQ
    GNIFSCSVMHEALHNRFTQKSLSLSPG
     26 EPKSSDTPPPSPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG3FcΔK-SS
    SHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGK Fc variant
    EYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCL
    VKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQ
    GNIFSCSVMHEALHNRFTQKSLSLSPG
     27 EPKSSDTPPPSPRSPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV hIgG3FcΔK-SSS
    SHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGK Fc variant
    EYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCL
    VKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQ
    GNIFSCSVMHEALHNRFTQKSLSLSPG
     28 APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG hIgG4FcΔK-AC
    VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI Fc variant
    EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
    NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHN
    HYTQKSLSLSLG
     29 PSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW hIgG4FcΔK-C Fc
    YVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL variant
    PSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE
    ALHNHYTQKSLSLSLG
     30 ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK Fc variant
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLG
     31 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P Fc variant
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLG
     32 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K Fc
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG variant
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLG
     33 ESKYGPPSPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-S Fc
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK variant
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLG
     34 ESKYGPPSPSSPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-SS
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK Fc variant
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLG
     35 QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET TβRII-ED
    VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIF structured domain
     36 IPPHVQKSVNNDMIVTDNNGAVKFP TβRII-ED N-term
    unstructured
    region and natural
    linker
     37 IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFP TβRIIb-ED N-term
    unstructured
    region and natural
    linker
     38 IPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFP TβRIIb-ED Cys-
    mutated N-term
    unstructured
    region and natural
    linker
     39 SEEYNTSNPD TβRII-ED C-term
    unstructured
    region and natural
    linker
     40 SEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFP TβRII-ED natural
    linker
     41 SEEYNTSNPDIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVT TβRIIb-ED natural
    DNNGAVKFP linker
     42 SEEYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVT TβRIIb-ED Cys-
    DNNGAVKFP mutated linker
     43 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRII-ED
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE monomer, also
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD termed T2 or T2m
     44 IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQ TβbRIIb-ED
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV monomer, also
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE termed T2b
    EYNTSNPD
     45 IPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQ TβRIIb-ED
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV monomer Cys-
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE mutated in the
    EYNTSNPD linker region, also
    termed T2bAA
     46 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRII-ED dimer,
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE also termed T2- 
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTD T2 or T22d35
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD
     47 IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQ TβRIIb-ED dimer,
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV also termed T2-
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE T2b
    EYNTSNPDIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDN
    NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND
    ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
    NDNIIFSEEYNTSNPD
     48 IPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQ TβRIIb-ED dimer
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV Cys-mutated in
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE the linker region,
    EYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDN also termed T2-
    NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND T2bAA
    ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
    NDNIIFSEEYNTSNPD
     49 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRII-ED trimer,
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE also termed T2-
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTD T2-T2
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
    FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPY
    HDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     50 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRIIb-ED trimer,
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE also termed T2-
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKD T2b-T2b
    EIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKS
    CMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAA
    SPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSD
    VEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     51 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRIIb-ED trimer
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE Cys-mutated in
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKD the linker regions,
    EIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKS also termed T2- 
    CMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAA T2bAA-T2bAA
    SPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSD
    VEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     52 ALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRP TβRI-ED
    FVCAPSSKTGSVTTTYCCNQDHCNKIEL structured domain
     53 AALLPGAT TβRI-ED N-term
    unstructured
    region and natural
    linker
     54 PTTVKSSPGLGPVE TβRI-ED C-term
    unstructured
    region and natural
    linker
     55 PTTVKSSPGLGPVEAALLPGAT TβRI-ED natural
    linker
     56 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE monomer, also
    termed T1 or T1m
     57 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-ED dimer,
    DLIPRDRPFVCAPSSKTGSVTITYCCNQDHCNKIELPTTVKSSPGLGPVEA also termed T1-
    ALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEID T1
    LIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE
     58 PTTVKSSPGLGPVEIPPHVQKSVNNDMIVTDNNGAVKFP TβRI-TβRII-ED
    natural linker
     59 PTTVKSSPGLGPVEIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINND TβRI-TβRIIb-ED
    MIVTDNNGAVKFP natural linker
     60 SEEYNTSNPDAALLPGAT TβRII-TβRI-ED
    natural linker
     61 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-TβRII-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEI dimer T1-T2
    PPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITS
    ICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK
    KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     62 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-TβRII-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEI dimer T1-T2b
    PPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
     63 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRI-TβRII-ED
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE dimer T2-T1
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDAALLPGATALQCFCHLC
    TKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKT
    GSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE
     64 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-TβRII-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEI trimer T1-T2-T2
    PPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITS
    ICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK
    KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDN
    NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND
    ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
    NDNIIFSEEYNTSNPD
     65 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-TβRII-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEI trimer T1-T2-T2b
    PPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITS
    ICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK
    KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKDE
    IICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC
    MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS
    PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     66 AALLPGATALQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEI TβRI-TβRII-ED
    DLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEI trimer T1-T2-
    PPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQL T2bAA
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPD
     67 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRI-TβRII-ED
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE trimer T2-T2-T1
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDAALLPGATALQCFCHLCTKDNFTCVTDGLCFVSV
    TETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKI
    ELPTTVKSSPGLGPVE
     68 IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT TβRI-TβRII-ED
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE timer T2-T2bAA-
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKD T1
    EIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKS
    CMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAA
    SPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDAALLPGATA
    LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPF
    VCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVE
     69 TLPFLKCYCSGHCPDDAINNTCITNGHCFAIIEEDDQGETTLASGCMKYEG BMPRIa-ED
    SDFQCKDSPKAQLRRTIECCRTNLCNQYLQPTLP structured domain
     70 QNLDSMLHGTGMKSDSDQKKSENGVTLAPED BMPRIa-ED N-
    term unstructured
    region and natural
    linker
     71 PVVIGPFFDGSIR BMPRIa-ED C-
    term unstructured
    region and natural
    linker
     72 PVVIGPFFDGSIRQNLDSMLHGTGMKSDSDQKKSENGVTLAPED BMPRIa-ED
    natural linker
     73 QNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTLPFLKCYCSGHCPDDAINN BMPRIa-ED
    TCITNGHCFAIIEEDDQGETTLASGCMKYEGSDFQCKDSPKAQLRRTIECC monomer
    RTNLCNQYLQPTLPPVVIGPFFDGSIR
     74 QNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTLPFLKCYCSGHCPDDAINN BMPRIa-ED
    TCITNGHCFAIIEEDDQGETTLASGCMKYEGSDFQCKDSPKAQLRRTIECC dimer
    RTNLCNQYLQPTLPPVVIGPFFDGSIRQNLDSMLHGTGMKSDSDQKKSENG
    VTLAPEDTLPFLKCYCSGHCPDDAINNTCITNGHCFAIIEEDDQGETTLAS
    GCMKYEGSDFQCKDSPKAQLRRTIECCRTNLCNQYLQPTLPPVVIGPFFDG
    SIR
     75 TQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQG ActRIIa-ED
    CWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFP structured domain
     76 AILGRSE ActRIIa-ED N-
    term unstructured
    region and natural
    linker
     77 EMEVTQPTSNPVTPKPPYYNI ActRIIa-ED C-
    term unstructured
    region and natural
    linker
     78 EMEVTQPTSNPVTPKPPYYNIAILGRSE ActRIIa-ED
    natural linker
     79 AILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGS ActRIIa-ED
    IEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEME monomer
    VTQPTSNPVTPKPPYYNI
     80 AILGRSETQECLFFNANwEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGS ActRIIa-ED dimer
    IEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEME
    VTQPTSNPVTPKPPYYNIAILGRSETQECLFFNANWEKDRTNQTGVEPCYG
    DKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFC
    CCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNI
     81 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGC ActRIIb-ED
    WLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLP structured domain
     82 SGRGEAET ActRIIb-ED N-
    term unstructured
    region and natural
    linker
     83 EAGGPEVTYEPPPTAPT ActRIIb-ED C-
    term unstructured
    region and natural
    linker
     84 EAGGPEVTYEPPPTAPTSGRGEAET ActRIIb-ED
    natural linker
     85 SGRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGT ActRIIb-ED
    IELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAG monomer
    GPEVTYEPPPTAPT
     86 SGRGEAETRECIYYNANWELERTNQSGLERCEGEQDRRLHCYASWRNSSGT ActRIIb-ED dimer
    IELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAG
    GPEVTYEPPPTAPTSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDK
    RLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEG
    NFCNERFTHLPEAGGPEVTYEPPPTAPT
     87 EMEVTQPTSNPVTPKPPYYNIQNLDSMLHGTGMKSDSDQKKSENGVTLAPE ActRIIa-BMPRIa-
    D ED natural linker
     88 AILGRSETQECLFFNANwEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGS ActRIla-BMPRIa-
    IEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEME ED dimer
    VTQPTSNPVTPKPPYYNIQNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTL
    PFLKCYCSGHCPDDAINNTCITNGHCFAIIEEDDQGETTLASGCMKYEGSD
    FQCKDSPKAQLRRTIECCRTNLCNQYLQPTLPPVVIGPFFDGSIR
     89 MDWTWRILFLVAAATGTHA Signal peptide
     90 MVLQTQVFISLLLWISGAYG Signal peptide
     91 APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG hIgG1FcΔK-ΔC-
    VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI T2m fusion
    EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
    NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
    HYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCD
    NQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFIL
    EDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     92 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C-
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL T2m fusion
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     93 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC-
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK T2m fusion
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCK
    FCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHD
    PKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYN
    TSNPD
     94 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGV hIgG2FcΔK-ΔC-
    EVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIE T2m fusion
    KTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESN
    GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDN
    QKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
    DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     95 PPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWY hIgG2FcΔK-C-
    VDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLP T2m fusion
    APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVE
    WESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
    LHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFS
    TCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
    FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     96 APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGV hIgG2FcΔK-CC-
    EVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIE T2m fusion
    KTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESN
    GQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDN
    QKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
    DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
     97 MDWTWRILFLVAAATGTHAERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL hIgG2Fc-CCCC-
    MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRV T2 fusion, also
    VSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPP termed Fc-T2m
    SREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSF
    FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQKS
    VNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE
    VCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETF
    FMCSCSSDECNDNIIFSEEYNTSNPD
     98 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-T2m fusion
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
     99 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K-T2m
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
    100 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C-
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL T22d35 fusion
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDI
    PPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITS
    ICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK
    KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    101 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC-
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK T22d35 fusion
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCK
    FCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHD
    PKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYN
    TSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS
    NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPK
    CIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    102 VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF hIgG2FcΔK-CC-
    NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNK T22d35 fusion
    GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    SVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
    HEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV
    RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLP
    YHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNP
    DIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSI
    TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMK
    EKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    103 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-T22d35
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC
    MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS
    PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    104 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K-
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG T22d35 fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC
    MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS
    PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    105 MDWTWRILFLVAAATGTHAERKCCVECPPCPAPPVAGPSVFLFPPKPKDTL hIgG2Fc-CCCC-
    MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRV T22d35 fusion,
    VSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPP also termed Fc-
    SREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSF T22d35
    FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQKS
    VNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQE
    VCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETF
    FMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFP
    QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET
    VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS
    EEYNTSNPD
    106 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C-T2-
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL T2bAA fusion
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDI
    PPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
    107 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC-
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK T2-T2bAA fusion
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCK
    FCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHD
    PKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYN
    TSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGA
    VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENI
    TLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDN
    IIFSEEYNTSNPD
    108 VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF hIgG2FcΔK-CC-
    NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNK T2-T2bAA fusion
    GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    SVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
    HEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV
    RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLP
    YHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNP
    DIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFP
    QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET
    VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS
    EEYNTSNPD
    109 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-T2-T2bAA
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPD
    110 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K-T2-
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG T2bAA fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPD
    111 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C-T2-
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL T2-T2 fusion
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDI
    PPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITS
    ICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK
    KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDN
    NGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKND
    ENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
    NDNIIFSEEYNTSNPD
    112 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC-
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK T2-T2-T2 fusion
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCK
    FCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHD
    PKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYN
    TSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMS
    NCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPK
    CIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNND
    MIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVA
    VWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCS
    CSSDECNDNIIFSEEYNTSNPD
    113 VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF hIgG2FcΔK-CC-
    NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNK T2-T2-T2 fusion
    GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    SVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
    HEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV
    RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLP
    YHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNP
    DIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSI
    TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMK
    EKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVT
    DNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRK
    NDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSD
    ECNDNIIFSEEYNTSNPD
    114 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-T2-T2-T2
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC
    MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS
    PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVN
    NDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC
    VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM
    CSCSSDECNDNIIFSEEYNTSNPD
    115 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K-T2-
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG T2-T2 fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSC
    MSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAAS
    PKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVN
    NDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC
    VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM
    CSCSSDECNDNIIFSEEYNTSNPD
    116 PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW hIgG1FcΔK-C-T2-
    YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL T2bAA-T2bAA
    PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV fusion
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRF
    STCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYH
    DFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDI
    PPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPD
    117 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP hIgG1FcΔK-CC-
    EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK T2-T2bAA-T2bAA
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY fusion
    PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCK
    FCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHD
    PKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYN
    TSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGA
    VKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENI
    TLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDN
    IIFSEEYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDM
    IVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAV
    WRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSC
    SSDECNDNIIFSEEYNTSNPD
    118 VECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF hIgG2FcΔK-CC-
    NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNK T2-T2bAA-T2bAA
    GLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDI fusion
    SVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
    HEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV
    RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLP
    YHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNP
    DIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNNGAVKFP
    QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET
    VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS
    EEYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD
    119 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-T2-T2bAA-
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG T2bAA fusion
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINN
    DMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCV
    AVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC
    SCSSDECNDNIIFSEEYNTSNPD
    120 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE hIgG4FcΔK-CC-
    DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK 228P-409K-T2-
    CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG T2bAA-T2bAA
    FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNV fusion
    FSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPDIPPHVQKSDVEMEAQKDEIIAPSANRTAHPLRHINN
    DMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCV
    AVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMC
    SCSSDECNDNIIFSEEYNTSNPD
    121 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYA Cetuximab LC
    SESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGT
    KLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC
    122 QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVI Cetuximab HC-
    WSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYY T22d35
    DYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
    EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
    SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
    VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
    DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
    YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQKSVN
    NDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC
    VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM
    CSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
    123 QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVI Cetuximab HC-
    WSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYY T2m
    DYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
    EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
    SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
    VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
    DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
    YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQKSVN
    NDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC
    VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM
    CSCSSDECNDNIIFSEEYNTSNPD
    124 DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSA Herceptin LC
    SFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGT
    KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC
    125 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARI Herceptin HC-
    YPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGD T22d35
    GFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
    PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
    VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
    ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
    SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
    RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQKSV
    NNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEV
    CVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFF
    MCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQ
    LCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV
    CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSE
    EYNTSNPD
    126 DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKCLIYFT Avastin LC
    SSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGT
    KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC
    127 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWI Avastin HC-
    NTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHY T22d35
    YGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
    ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD
    TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
    RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
    PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
    SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKIPPHVQ
    KSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKP
    QEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGE
    TFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVK
    FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITL
    ETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNII
    FSEEYNTSNPD
    128 DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTS Synagis LC
    KLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTK
    LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    129 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLA Synagis HC-
    DIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMI T22d35
    TNWYFDVWGAGTTVTVSSASTKGPSVFPLAPSSAAAAGGTAALGCLVKDYF
    PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
    VNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
    ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
    SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
    RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVN
    NDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC
    VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFM
    CSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQL
    CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
    HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEE
    YNTSNPD
    130 EVQLQASGGGLVQAGGSLRLSCAASGFKITHYTMGWFRQAPGKEREFVSRI FC5-Fc-T22d35
    TWGGDNTFYSNSVKGRFTISRDNAKNTVYLQMNSLKPEDTADYYCAAGSTS
    TATPLRVDYWGKGTQVTVSSASEPRGPTIKPCPPCKCPAPNLLGGPSVFIF
    PPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRE
    DYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRA
    PQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEP
    VLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGT
    GIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSI
    TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMK
    EKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVT
    DNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRK
    NDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSD
    ECNDNIIFSEEYNTSNPD
    131 EVQLQASGGGLVQAGGSLRLSCAASGFKITHYTMGWFRQAPGKEREFVSRI FC5-Fc-T2m
    TWGGDNTFYSNSVKGRFTISRDNAKNTVYLQMNSLKPEDTADYYCAAGSTS
    TATPLRVDYWGKGTQVTVSSASEPRGPTIKPCPPCKCPAPNLLGGPSVFIF
    PPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHRE
    DYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRA
    PQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEP
    VLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGT
    GIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSI
    TSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMK
    EKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    132 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLC T2-hIgG1Fc
    KFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCH fusion from R&D,
    DPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEY also termed T2m-
    NTSNPDMDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV Fc (R&D)
    TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
    QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    133 MDWTWRILFLVAAATGTHAIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCD T2-hIgG2Fc-
    VRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKL CCCC fusion,
    PYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSN also termed T2m-
    PDERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH Fc
    EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEY
    KCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK
    GFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
    VFSCSVMHEALHNHYTQKSLSLSPG
    134 LPYHDFILEDAASPK Isotope-labelled
    peptide for
    T22d35
    135 ALPAPIEK Isotope-labelled
    peptide for
    Cetuximab
    136 DDDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC D10-hIgG1FcΔK-
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD CC-T2m fusion
    WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
    SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
    SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPD
    137 DDDDDDDDDDGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP D10-G3S-
    EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV hIgG1FcΔK-CC-
    LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT T2m fusion
    KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
    TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIV
    TDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWR
    KNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSS
    DECNDNIIFSEEYNTSNPD
    138 DDDDDDDDDDPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS D10-hIgG1FcΔK-
    HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE C-T2m fusion
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
    KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
    NVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVKFP
    QLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET
    VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS
    EEYNTSNPD
    139 DDDDDDDDDDGGGSGGGSPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV D10-(G3S)2-
    TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH hIgG1FcΔK-C-
    QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN T2m fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD
    140 DDDDDDDDDDVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD D10-hIgG2FcΔK-
    VSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNG CC-T2m fusion
    KEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC
    LVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ
    QGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVK
    FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITL
    ETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNII
    FSEEYNTSNPD
    141 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH CC-228P-T2m
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD
    142 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH CC-228P-409K-
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN T2m fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPD
    143 DDDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC D10-hIgG1FcΔK-
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD CC-T22d35 fusion
    WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
    SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
    SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFS
    TCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
    FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    144 DDDDDDDDDDVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD D10-hIgG2FcΔK-
    VSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNG CC-T22d35 fusion
    KEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC
    LVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ
    QGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVK
    FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITL
    ETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNII
    FSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDN
    QKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
    DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    145 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH CC-228P-T22d35
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
    FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPY
    HDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    146 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKpREEQFNSTYRVVSVLTVLH CC-228P-409K-
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN T22d35 fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
    FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPY
    HDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    147 DDDDDDDDDDDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC D10-hIgG1FcΔK-
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD CC-T2-T2-T2
    WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV fusion
    SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
    SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNN
    GAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDE
    NITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECN
    DNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFS
    TCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
    FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIP
    PHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSI
    CEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKK
    KPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    148 DDDDDDDDDDVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD D10-hIgG2FcΔK-
    VSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNG CC-T2-T2-T2
    KEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC fusion
    LVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ
    QGNVFSCSVMHEALHNHYTQKSLSLSPGIPPHVQKSVNNDMIVTDNNGAVK
    FPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITL
    ETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNII
    FSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDN
    QKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
    DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDIPPHVQ
    KSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKP
    QEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGE
    TFFMCSCSSDECNDNIIFSEEYNTSNPD
    149 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH CC-228P-T2-T2-
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN T2 fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
    FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPY
    HDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    150 DDDDDDDDDDESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV D10-hIgG4FcΔK-
    TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH CC-228P-409K- 
    QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN T2-T2-T2 fusion
    QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGIPPHVQKSVNNDMIVTD
    NNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
    DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDE
    CNDNIIFSEEYNTSNPDIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
    FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPY
    HDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT
    SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKE
    KKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
    • REFERENCES
  • All patents, patent applications and publications referred to throughout the application are listed below.
  • Arteaga C L (2006) Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37
  • De Crescenzo G, Grothe S, Zwaagstra J, Tsang M, O'Connor-McCourt M D (2001) Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding. J Biol Chem 276: 29632-29643
  • Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30: E9
  • Economides A N, Carpenter L R, Rudge J S, Wong V, Koehler-Stec E M, Hartnett C, Pyles E A, Xu X, Daly T J, Young M R, Fandl J P, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang T T, Radziejewski C, Yancopoulos G D, Stahl N (2003) Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9: 47-52
  • Eisenberg D, Schwarz E, Komaromy M, Wall R (1984) Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol 179: 125-142
  • Gajewski T F (2015) The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol 42: 663-671
  • Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst R D, Lindmark T, Mabondzo A, Nilsson J E, Raub T J, Stanimirovic D, Terasaki T, Oberg J O, Osterberg T (2005) In vitro models for the blood-brain barrier. Toxicol In Vitro 19: 299-334
  • Hahn T, Akporiaye E T (2006) Targeting transforming growth factor beta to enhance cancer immunotherapy. Curr Oncol 13: 141-143
  • Haqqani A S, Caram-Salas N, Ding W, Brunette E, Delaney C E, Baumann E, Boileau E, Stanimirovic D (2013) Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. Mol Pharm 10: 1542-1556
  • Hawinkels L J, Ten Dijke P (2011) Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 29: 140-152
  • Holash J, Davis S, Papadopoulos N, Croll S D, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, loffe E, Huang T, Radziejewski C, Bailey K, Fandl J P, Daly T, Wiegand S J, Yancopoulos G D, Rudge J S (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
  • Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B, Shepard H M (2009) Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med 15: 11-20
  • Li M O, Wan Y Y, Sanjabi S, Robertson A K, Flavell R A (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146
  • Massague J, Blain S W, Lo R S (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309
  • Mourskaia A A, Northey J J, Siegel P M (2007) Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med Chem 7: 504-514
  • Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, Berger W, Schulte-Hermann R, Grusch M (2006) The activin axis in liver biology and disease. Mutat Res 613: 123-137
  • Santarpia M, Gonzalez-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R (2015) Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 4: 728-742
  • Thiery J P, Acloque H, Huang R Y, Nieto M A (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890
  • Wojtowicz-Praga S (2003) Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21: 21-32
  • Yang L, Pang Y, Moses H L (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31: 220-227
  • Yang X, Ambrogelly A (2014) Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies. Curr Opin Biotechnol 30: 225-229
  • Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim T E, Urquhart B, Min W (2013) Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer 132: 967-977
  • Zwaagstra J C, Sulea T, Baardsnes J, Lenferink A E, Collins C, Cantin C, Paul-Roc B, Grothe S, Hossain S, Richer L P, L'Abbe D, Tom R, Cass B, Durocher Y, O'Connor-McCourt M D (2012) Engineering and therapeutic application of single-chain bivalent TGF-beta family traps. Mol Cancer Ther 11: 1477-1487
  • WO/1995/04069
  • WO/2004/076670
  • WO 2008/113185
  • WO 2010/031168
  • U.S. Pat. No. 8,815,247
  • U.S. Pat. No. 6,277,7375
  • US2015/0225483

Claims (35)

1. A polypeptide construct comprising:
a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
a second portion comprising at least two TGF-β superfamily receptor ectodomains (TβSR-ED) linked in tandem,
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
2. A polypeptide construct comprising:
a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomains (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion,
and further wherein the first portion does not further comprise an antibody that binds to an antigen that is PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
3. A polypeptide construct comprising:
a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
wherein the N-terminus of the second portion is directly fused to the C-terminus of the first portion.
4. A polypeptide construct comprising
a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and wherein the polypeptide construct neutralizes TGF-β with at least 100-fold more potency than the TβSR-ED alone.
5. The polypeptide construct of claims 2-4, wherein the second portion comprises one TβSR-ED.
6. The polypeptide construct of claim 5, wherein the second portion comprises two TβSR-EDs.
7. The polypeptide construct according to claims 1-6, wherein the TβSR-ED is a TGF-β receptor type II ectodomain (TβR-II-ED).
8. The polypeptide construct of claims 1-6, wherein the TβSR-ED comprises a sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto.
9. The polypeptide construct of claims 1-8, wherein the second portion comprises a sequence selected from the group consisting of SEQ ID NO:43-SEQ ID NO:51, SEQ ID NO:61-SEQ ID NO:68, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:88, and a sequence substantially identical thereto.
10. The polypeptide construct of any one of claims 1-8, wherein the first portion further comprises a CH1, a CH1 and VH, or CH1 and scFv.
11. The polypeptide construct of any one of claims 1-10, wherein the antibody heavy chain is of human origin.
12. The polypeptide construct of any one of claims 1-11, wherein the antibody heavy chain is selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain.
13. The polypeptide construct of any one of claims 1-12, wherein the antibody heavy chain is a human IgG1.
14. The polypeptide construct of claim 4, wherein the polypeptide construct shows longer in vivo half-life compared to the half-life of the second portion alone.
15. The polypeptide construct of any one of claims 1-14, wherein the polypeptide construct is a single chain polypeptide.
16. The polypeptide construct of any one of claims 1-15, wherein the polypeptide construct forms a dimeric polypeptide.
17. The polypeptide construct of claims 1-16, wherein the polypeptide construct is heterodimeric.
18. A polypeptide construct selected from the group consisting of any one of SEQ ID NO:91 to SEQ ID NO:120, and a sequence substantially identical thereto.
19. A polypeptide construct according to claims 1-16, wherein the construct comprises an antibody, antigen binding fragment thereof, or a targeting moiety.
20. A polypeptide construct according to claim 19, comprising the antibody, antigen binding fragment, or targeting moiety at the N-terminus of the first portion.
21. A polypeptide construct according to claim 19, wherein the antigen binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb.
22. A polypeptide construct according to claim 19, wherein the antigen binding fragment binds to an antigen that is not PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.
23. A polypeptide construct according to claim 19, wherein the antibody is selected from the group consisting of Cetuximab, Avastin, Herceptin, Synagis, and FC5.
24. A polypeptide construct according to claim 23, wherein the antibody is Cetuximab.
25. A polypeptide construct according to claim 19, wherein the targeting moiety comprises a poly-aspartate sequence motif for bone targeting.
26. A polypeptide construct according to claim 25, wherein the targeting moiety comprises D10.
27. A polypeptide construct according to any preceding claim wherein the construct is a dimeric polypeptide.
28. A polypeptide construct according to claim 27, wherein the dimeric polypeptide comprises:
a first single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and third constant domain (CH3) of an antibody heavy chain, and a heavy chain variable region of a given antibody;
a second portion comprising one or more TGF-β superfamily receptor ectodomains (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and
a second single chain polypeptide comprising a first portion comprising the second constant domain (CH2) and third constant domain (CH3) of an antibody heavy chain, and a light chain variable region of said given antibody;
a second portion comprising one or more TGF-β superfamily receptor ectodomain (TβSR-ED) which is the same or different from the ectodomain(s) in the first polypeptide, wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.
29. A nucleic acid molecule encoding the polypeptide construct of any preceding claim.
30. A vector comprising the nucleic acid molecule of claim 29.
31. A composition comprising one or more than one independently selected polypeptide construct of any one of claims 1 to 30 and a pharmaceutically-acceptable carrier, diluent, or excipient.
32. A transgenic cellular host comprising the nucleic acid molecule of claim 29 or a vector of claim 30.
33. The transgenic cellular host of claim 32, further comprising a second nucleic acid molecule or a second vector encoding a second polypeptide construct different from the first polypeptide construct.
34. The use of a polypeptide construct according to any one of claims 1-28, for treatment of a medical condition, disease or disorder.
35. The use according to claim 34, wherein the medical condition, disease or disorder comprises cancer, ocular diseases, fibrotic diseases, or genetic disorders of connective tissue.
US15/755,595 2015-08-31 2016-08-31 Tgf-b-receptor ectodomain fusion molecules and uses thereof Abandoned US20200231652A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/755,595 US20200231652A1 (en) 2015-08-31 2016-08-31 Tgf-b-receptor ectodomain fusion molecules and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212058P 2015-08-31 2015-08-31
US15/755,595 US20200231652A1 (en) 2015-08-31 2016-08-31 Tgf-b-receptor ectodomain fusion molecules and uses thereof
PCT/IB2016/055204 WO2017037634A1 (en) 2015-08-31 2016-08-31 Tgf-β-receptor ectodomain fusion molecules and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055204 A-371-Of-International WO2017037634A1 (en) 2015-08-31 2016-08-31 Tgf-β-receptor ectodomain fusion molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/523,602 Continuation US20220169702A1 (en) 2015-08-31 2021-11-10 Tgf-b-receptor ectodomain fusion molecules and uses thereof

Publications (1)

Publication Number Publication Date
US20200231652A1 true US20200231652A1 (en) 2020-07-23

Family

ID=58186979

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/755,595 Abandoned US20200231652A1 (en) 2015-08-31 2016-08-31 Tgf-b-receptor ectodomain fusion molecules and uses thereof
US17/523,602 Pending US20220169702A1 (en) 2015-08-31 2021-11-10 Tgf-b-receptor ectodomain fusion molecules and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/523,602 Pending US20220169702A1 (en) 2015-08-31 2021-11-10 Tgf-b-receptor ectodomain fusion molecules and uses thereof

Country Status (4)

Country Link
US (2) US20200231652A1 (en)
EP (1) EP3344660A4 (en)
CA (1) CA2996996A1 (en)
WO (1) WO2017037634A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226069A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
US11692042B2 (en) 2018-03-09 2023-07-04 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
US11866481B2 (en) 2017-03-02 2024-01-09 National Research Council Of Canada TGF-β-receptor ectodomain fusion molecules and uses thereof

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116655801A (en) 2013-08-22 2023-08-29 阿塞勒隆制药公司 TGF-beta receptor type II variants and uses thereof
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
PL3280727T3 (en) 2015-04-06 2021-07-19 Acceleron Pharma Inc. Single-arm type i and type ii receptor fusion proteins and uses thereof
AU2016246708B2 (en) 2015-04-06 2020-12-24 Acceleron Pharma Inc. ALK7:actRIIB heteromultimers and uses thereof
EP3878857A1 (en) 2015-04-22 2021-09-15 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
AU2017310344A1 (en) * 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
CN110546168B (en) * 2016-09-27 2024-03-15 埃皮辛特瑞柯斯公司 Immunomodulatory fusion proteins
US11267865B2 (en) 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
BR112019006993A2 (en) 2016-10-05 2019-09-03 Acceleron Pharma Inc alk4 heteromultimers: actriib and uses thereof
AR110755A1 (en) * 2017-01-20 2019-05-02 Genzyme Corp BONE DIRECTED ANTIBODIES
TW202313678A (en) 2017-01-20 2023-04-01 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
US11702466B2 (en) * 2017-01-30 2023-07-18 National Research Council Of Canada Fusion protein comprising a blood-brain barrier (BBB)-crossing single domain antibody Fc5, an immunoglobulin Fc fragment and a beta-amyloid binding polypeptide (ABP)
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EA202090838A1 (en) 2017-09-27 2020-08-28 Эписентарикс, Инк. IMMUNOMODULATING FUSION PROTEINS
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2020006511A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
TWI829799B (en) * 2018-11-09 2024-01-21 大陸商江蘇恆瑞醫藥股份有限公司 A PHARMACEUTICAL COMPOSITION COMPRISING TGF-β RECEPTOR FUSION PROTEIN AND THE USE THEREOF
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114127111A (en) 2019-02-21 2022-03-01 马伦戈治疗公司 Antibody molecules that bind NKP30 and uses thereof
CN112239507A (en) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 Fusion protein of ETA antibody and TGF-beta Trap, and pharmaceutical composition and application thereof
WO2021078123A1 (en) * 2019-10-21 2021-04-29 Nanjing Leads Biolabs Co., Ltd. RECOMBINANT PROTEIN TARGETING PD-1 AND TGFβ
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
JP2023523011A (en) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof
CN116761818A (en) 2020-08-26 2023-09-15 马伦戈治疗公司 Method for detecting TRBC1 or TRBC2
CN116249718A (en) 2020-08-26 2023-06-09 马伦戈治疗公司 Multifunctional molecules binding to calreticulin and uses thereof
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
KR20240025533A (en) * 2021-06-24 2024-02-27 브리스톨-마이어스 스큅 컴퍼니 Transforming growth factor-beta ligand trap for disease treatment
WO2023141724A1 (en) 2022-01-28 2023-08-03 35Pharma Inc. Activin receptor type iib variants and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA199900947A1 (en) * 1997-04-18 2000-04-24 Байоджен, Инк. HYBRID PROTEINS TGF-BETA II TYPE / CONSTANT AREA OF IMMUNOGLOBULIN
PL3404102T3 (en) * 2004-04-21 2021-12-13 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
EP2578684B1 (en) * 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8658135B2 (en) * 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
CA3083324A1 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2819187A1 (en) * 2010-11-29 2012-06-07 National Research Council Of Canada Covalently dimerized bivalent binding agents
HUE033008T2 (en) * 2011-04-13 2017-11-28 Bristol Myers Squibb Co Fc fusion proteins comprising novel linkers or arrangements
US20140227719A1 (en) * 2011-09-23 2014-08-14 Merck Sharp & Dohme Corp Mdl-1 ligand
RU2698975C2 (en) * 2013-03-12 2019-09-02 Биокон Лтд. Fused immunomodulatory proteins and methods for production thereof
CN116655801A (en) * 2013-08-22 2023-08-29 阿塞勒隆制药公司 TGF-beta receptor type II variants and uses thereof
JP6640083B2 (en) * 2013-11-21 2020-02-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Compositions and methods for treating pulmonary hypertension

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866481B2 (en) 2017-03-02 2024-01-09 National Research Council Of Canada TGF-β-receptor ectodomain fusion molecules and uses thereof
US11692042B2 (en) 2018-03-09 2023-07-04 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
WO2022226069A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Also Published As

Publication number Publication date
EP3344660A1 (en) 2018-07-11
WO2017037634A1 (en) 2017-03-09
US20220169702A1 (en) 2022-06-02
CA2996996A1 (en) 2017-03-09
EP3344660A4 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
US20220169702A1 (en) Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP7036860B2 (en) Multispecific antibodies, multispecific activateable antibodies, and how to use them
US11518808B2 (en) Anti-PD-1 antibodies and methods of treatment
JP6764474B2 (en) Anti-TIGIT antibody and usage
TWI762484B (en) Anti-pd1 antibody molecules, the manufacture process, and use thereof for cancer treatment
US20210095038A1 (en) Binding molecules for the treatment of cancer
JP6560341B2 (en) Treatment of progressive ossifying fibrodysplasia
JP2022536898A (en) NOVEL IL-15 PRODRUGS AND METHODS OF USE THEREOF
BR112019022751A2 (en) pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
BR112021002032A2 (en) antibody constructs for cldn18.2 and cd3
CN108137699A (en) To the bispecific antibody of PD1 and TIM3 specificity
JP2018506964A (en) Anti-CD47 antibodies and uses thereof
KR20190089949A (en) Antibodies and methods for their use
KR102455680B1 (en) Novel anti-human tie-2 antibody
KR102478433B1 (en) Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
CN111699200A (en) Single domain antibodies to PD-1 and variants thereof
CN113150147A (en) anti-MET antibodies and methods of use thereof
JP2022505923A (en) How to administer anti-TIM-3 antibody
JP2022541022A (en) Anti-TIGIT antibody and its application
JP2018533620A (en) High titer monoclonal antibody against angiogenic factors
US20210347895A1 (en) Exosome-targeting bispecific antibodies
CA3208455A1 (en) Novel anti-gremlin1 antibodies
US20220098310A1 (en) Anti-alk2 antibodies and uses thereof
US20210214435A1 (en) Antibodies targeting glycoprotein vi
RU2652880C2 (en) Epidermal growth factor receptor antibody

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION